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Pancreatic cancer is often referred to as the “silent killer“ due to the asymptomatic 
nature of the disease in the early stages and the extremely poor prognosis overall. 
The average one-year survival rate for PDAC patients is 24% (American Cancer 
Society, facts and figures, 2010), decreasing to 5%-6% over 5 years (WHO report, 
Pancreatic cancer, 2010). Only 20% of patients are suitable for surgical resection at 
the time of diagnosis and treatment options available to PDAC patients have not 
improved significantly over the past few decades. Thus novel therapeutic approaches 
are essential to treat this disease. Our experimental, clinical and pre-clinical data 
suggest integrin αvβ6 may be a suitable target.  
 
Bioinformatics studies using the Pancreatic Expression Database revealed that the 
β6 gene (ITGB6) was highly up regulated in pancreatic ductal carcinoma (PDAC) 
compared with normal pancreas. Further analysis carried out showed that there was 
a significant correlation between ITGB6 expression at the mRNA level and survival in 
a cohort of 292 PDAC patients. Immunohistochemistry analysis on two separate 
patient cohorts (n=118 and n=147) showed that normal pancreas lacked αvβ6 
expression whereas 91% of PDAC tissues expressed αvβ6 at the protein level. 
There was no significant correlation between αvβ6 expression and survival at the 
protein level in both cohorts of patients tested.  
 
Flow cytometry and Western blotting analyses on a panel of PDAC cell lines 
confirmed expression of αvβ6 in PDAC cell lines. This study investigated the 
functional role of αvβ6 in PDAC cell lines. Antibody mediated function blockade of 
αvβ6 significantly inhibited proliferation in a dose dependent manner, specifically in 
αvβ6 positive PDAC cell lines. A significant reduction in migration and invasion was 
also observed in a panel of αvβ6 positive PDAC cell lines when treated with an αvβ6 
function-blocking antibody. αvβ6 targeted antibody mediated therapy in combination 
with gemcitabine significantly inhibited tumour growth in a physiologically relevant 
pre-clinical subcutaneous xenograft model of PDAC.  
 
These data reaffirms that αvβ6 is a potential novel therapeutic target and an αvβ6 
specific function-blocking antibody can be used as a novel agent to treat pancreatic 
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1. Introduction  
1.1 Cancer 
 
Cancer is a name given to a broad collection of almost 200 different diseases. It is 
usually characterised by uncontrolled growth of cells in a specific area of the body. 
The cells that become “cancerous” harbour molecular changes within their genomes, 
also known as mutations, which are passed onto the next generation of cells when 
they divide [1]. Cellular proliferation in normal tissue is a carefully controlled process 
regulated by signalling pathways that enable the entry and progression of cells 
through the cell cycle, with multiple check-points, including tumour suppressor genes 
(e.g. p53 gene, retinoblastoma (Rb) gene), to ensure any abnormal cells (mutated) 
are not allowed to replicate and forced to undergo apoptosis (programmed cell 
death) [2]. Mutation of key genes means cancer cells can deregulate these pathways 
and are able to form a mass of tissue commonly referred to as a tumour. In many 
cancers, this abnormal mass of tissue has the ability to grow at a very rapid rate and 
invade into the surrounding extra cellular matrix (ECM). These malignant cancer cells 
have the ability to up regulate the production of various matrix-remodelling enzymes, 
such as matrix metalloproteases (MMPs), which favour invasion into the surrounding 
stroma. Thus, cancer arising from one specific part of the body can invade to other 
parts of the body through the vasculo-lymphatic network and grow at a distant site; 
this process is referred to as metastasis. Cancer cells can also secrete factors that 
modify (activate) the local stromal cells, which in turn can secrete growth factors that 
are essential for the growth/survival of cancer cells (paracrine effect). This cross talk 
between the tumour cells and the surrounding stromal cells plays an important role in 
the progression of cancer, especially in pancreatic cancer, where sometimes up to 
70%-80% of the tumour is composed of the stroma [3].  
 
Detection and diagnosis of cancer at an early stage is extremely crucial for better 
prognosis. Current chemotherapy remains fairly ineffective in curing patients that 
already possess metastatic disease. Thus, in many cancers, early diagnosis and 
treatment leads to a significant improvement in the clinical outcome. Targeting 
cancer cells specifically is yet another major challenge, as many of the current 
chemotherapeutic drugs available to patients in the clinic are generic and do not 
delineate between normal and cancer cells. Rather, they often target replication non-
specifically; a characteristic frequently manifested by non-transformed cells. There 
are several studies focusing on targeting integrins, a molecule expressed on the cell 
surface of most cells, that integrate the extracellular matrix to the cytoplasm, to treat 
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cancer [4]. Finding the ideal target to image and treat cancer is critical in order to 
manage this disease. This study will focus on one such integrin, αvβ6, which is 
epithelial cell specific, expressed by many solid cancers and completely absent in the 
normal adult tissue in humans [5].  
 
Despite better strategies to prevent cancer related deaths through introduction of 
screening programmes and improving therapeutic interventions, this figure is 
expected to rise over the next decade or so and one in three people in developed 
countries will develop cancer before the age of 75 (Cancer Research UK, 2012). 
Cancer is a leading cause of death worldwide and in 2009 alone, 320,500 people 
were diagnosed with cancer (excluding non-melanoma skin cancer) in the United 
Kingdom (UK) (Cancer Research UK, 2012). A direct comparison between cancer 
incidence in 1979-1981 and 2007-2009, shows that there has been a 25% increase 
in cancer in the UK, 14% for men and 32% for women (Cancer Research UK, 2012). 
Even though there are so many different types of cancers, only some of them, such 
as breast, lung, bowel and prostate account for over half of the new cases that are 
diagnosed (Cancer Research UK, 2012). In 2006, it was estimated that about 1.2 
million people in the UK were alive having received a diagnosis of cancer [6]. 
Metastasis of cancer cells is often recognised as the most frequent cause of death in 
patients with cancer. The diagnosis of malignancy usually involves clinical 
examinations including blood test, biopsy, histology and, in recent years, advanced 
contrast imaging.  
 
According to the national cancer statistics (Cancer Research UK, 2012), lung cancer 
accounts for the largest number of cancer related deaths but breast cancer remains 
the cancer that has the greatest incidence rates. Pancreatic ductal adenocarcinoma 
(PDAC), sometimes referred to as pancreatic cancer, has a relatively low incidence 
rate compared with many other cancers. Despite the low incidence rates, mortality 
rates are very high, and it is 5th in the list of 20 most common cancer related deaths 
in people in the UK. It is worth mentioning that the incidence rates of pancreatic 
cancer almost mirror the mortality rates, with five-year survival rates of PDAC 
patients ranging between 5%-6% from the time of diagnosis, making this one of the 

























Figure 1: Cancer related mortality in the UK in 2010. Modified from Cancer 
Research UK, 2012. http://info.cancerresearchuk.org/cancerstats. 
 
This study will focus on Pancreatic ductal adenocarcinoma (PDAC) or pancreatic 
cancer [7]. Incidence rates are relatively low (8364 in 2010, Cancer Research UK, 
2012) compared to other cancers (Breast cancer – 48,788 in 2010, lung cancer -
41,428 in 2010, Cancer Research UK, 2012) but mortality rates are extremely high 
(7901 in 2010, Cancer Research UK, 2012) and are usually very similar to the 
incidence rates. Research conducted to date has improved the understanding of the 
molecular biology of this disease as well as staging and diagnosis. This disease is 
usually not detected at an early stage and treatment options available to patients 
have not improved significantly over the last two decades. This study will be aiming 
to understand the functional role of integrin αvβ6 in PDAC and its use as a potential 




1.2.1 Structure and function 
 
The pancreas is a dual function organ located in the upper abdomen behind the 
stomach. It is divided into three parts: the head, the body, and the tail. In humans it is 
approximately 18cm long and 4cm wide (Figure 3). The pancreas is both an exocrine 
and an endocrine gland with two major physiological roles: it aids digestion by 
producing pancreatic juice comprising various digestive enzymes (exocrine function) 
and regulates glucose metabolism by producing the hormones insulin and glucagon 
(endocrine function) [8].  
 
The exocrine pancreas comprises small glands formed by pyramidal-shaped acinar 
cells (acini), which drain into small ducts, composed of cuboidal epithelium, which 
gradually become tall columnar mucus-secreting epithelial cells, in the larger ducts. 
These ducts ultimately drain via the main pancreatic duct into the duodenum and 
together form the pancreatic ductal system (Figure 2). The acinar cells contain 
zymogen granules in the apical areas and the basilar cytoplasm is basophilic. It 
produces an alkaline “juice” containing various pro-enzymes such as trypsinogen, 
lipase, amylase, pro-elastase within membrane bound zymogen granules, which are 
secreted into the pancreatic ductal system upon stimulation. The alkaline nature of 
the pancreatic juice is due to a high concentration of bicarbonate ions and the 
pancreatic juice is essential for digestion of acidic food, proteins and vitamins [8]. 
 
Scattered throughout the exocrine pancreas are clusters of endocrine cells called 
islets of Langerhans, which constitute about 1%-2% of the pancreas (Figure 2). They 
are round, highly vascularised and comprised of four different cell types [9]. The α 
cells secrete glucagon (resulting in an increase of glucose in the blood), β cells 
secrete insulin (decreases glucose in the blood), δ cells secrete somatostatin, (which 
regulates the function of α and β cells) and PP cells (pancreatic polypeptide 
secreting cells), which secrete pancreatic polypeptide, which helps in regulating the 
secretory function of both exocrine (pancreatic digestive enzymes) and endocrine 











































Figure 2: H&E picture of the normal pancreas showing pancreatic ducts, blood 
vessel, acini (exocrine pancreas) and the Islets of Langerhans (endocrine) cells 
(top). Higher magnification H&E image (inset black square in top picture) of 
normal pancreas showing the endocrine islet cells and the exocrine acinar 

































Figure 3: Location of the pancreas in the human body. The location of the 
pancreas in the human body is illustrated in the cartoon.  
Image reference: location of pancreas in human body modified from University 
of Colorado at Boulder, 
(http://bodymindspiritintegration.com/wpcontent/uploads/2010/01/pancreas.jpg).  
  
Head Body Tail 
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1.3 Classification of pancreatic neoplasms 
 
Neoplasms of the pancreas are classified on the basis of cellular differentiation of the 
three main epithelial cell types (epithelial cells that line the pancreatic duct, acinar 
and endocrine cells) and also on the tumour type (solid, cystic or intra-ductal) [10].  In 
most cases, the term pancreatic cancer refers to pancreatic adenocarcinoma 
(PDAC), which represents >80% of pancreatic neoplasms. This cellular classification 
may not reflect the true origin of the PDACs. There are reports showing PDAC to be 
derived from either the ductal epithelium or the centro-acinar (cells present at the 
junction between acinus and duct) epithelium [11]. Some studies have linked the 
development of PDAC with cancer stem cells, which are defined as cells within a 
tumour that can self-renew and drive tumour progression. Recent studies have 
shown the existence of cancer stem cells in solid tumours including colon, breast and 
pancreas, which could also give rise to carcinomas [9, 12, 13]. 
 
Cancer stem cells have been identified in immunocompromised murine models of 
pancreatic cancer on the basis of expression of various cell surface markers 
including CD44, CD24 and epithelial surface antigen (ESA) and also by their ability to 
initiate tumours [14]. These cells were shown to be more resistant to the routinely 
used chemotherapeutic drug in the clinic, gemcitabine [15]. These cells also 
demonstrated an increased migratory and invasive potential [16]. However the origin 
of these pancreas stem cells still remains largely unknown with no clear study 
implicating their presence in the normal pancreas. Genetic changes in the progenitor 
cell population or lineage-committed cells that may have re-acquired stem cell 
characteristics may be an explanation [15]. However KRAS mutations in adult acinar 
or endocrine lineages only result in tumour formation in the presence of inflammation 
[17], suggesting that genetic changes in certain cell populations are not solely 
responsible for the development of pancreatic cancer. Recent advances in 
transgenic studies using mouse models are starting to help widen our understanding 




1.4 Pancreatic cancer 
 
Due to the high mortality rate and its asymptomatic nature, pancreatic cancer, is 
often referred to as a ‘silent killer’. It is the fourth leading cause of cancer-related 
death in the UK and five-year survival rates are less than 6% and have not improved 
over the last 40 years [18]. Surgery seldom is curative, as the tumour usually has 
metastasised by the time of diagnosis. Therapeutic options to target pancreatic 
cancer are limited to chemotherapy and surgery, the latter being suitable for only 
about 20% of patients who are diagnosed. In the UK, 5-year survival rates have 
improved marginally for patients with localised resectable disease. 
 
The head of the pancreas accounts for nearly 65% of PDACs that are diagnosed, 15 
% occur in the body, 10% occur in the tail and the remaining 10% are multi focal. The 
cancer usually breaches the basement membrane and invades into the surrounding 
normal tissue, including nerves and lymphatics. Perineural and lympho-vascular 
invasion are observed in about 40% - 75% of primary lesions, which are usually less 
than 2 centimetres, indicative of the aggressive nature of the cancer. Most patients 
that are diagnosed present with distant metastasis, usually in the liver and peritoneal 




People diagnosed with pancreatic cancer usually have a poor prognosis. There are a 
variety of factors that contribute to this poor prognosis such as the complete absence 
of a specific symptom, which in turn leads to the late presentation of the disease. 
8,085 new cases of pancreatic cancer were diagnosed in the UK in 2008 (Table 1). 
(Cancer Research UK, 2012). The lifetime risk of developing pancreatic cancer is 1 







































Table 1: Number of new cases, crude and European age-standardised (AS) 
incidence rates per 100,000 people in the UK. Office for National Statistics. 
Cancer Statistics: Registrations Series MB1. Modified from Cancer research 
UK, 2012.  http://www.statistics.gov.uk/statbase/Product.asp?vlnk=8843. 
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Figure 4: Average number of new cases per year and age-specific incidence 
rates of pancreatic cancer, UK, 2006-2008.  
Office for National Statistics. Cancer Statistics: Registrations Series MB1. 
http://www.statistics.gov.uk/statbase/Product.asp?vlnk=8843. 
 
Due to the late stage presentation and the aggressive nature of pancreatic cancers, 
surgery is possible only in a minority of patients (~20%) as the tumour usually has 
metastasised due to aggressive tumour behaviour and late presentation [18]. 
However in the cases where surgical resection is possible, together with adjuvant 
chemotherapy, five-year survival rates improve dramatically up to about 21% [20].  
 
1.6 Pancreatic cancer: risks and causes 
 
Although the precise events that result in development of pancreatic cancer are 
unknown, studying the biology of pancreatic cancer in large population based 
studies/meta analyses may provide a better understanding of the development of the 
disease. Pancreatic cancer is rare in people under 40, with a peak incidence in men 
between the age group of 70 - 80 and 75 - 85 for women [18]. Smoking, and thus 
presumably the carcinogens in cigarette smoke, is a major risk factor with a meta 
analysis of 82 studies between 1950 and 2007 showing smokers to have a 1.7 fold 
increased chance of developing pancreatic cancer [21] [22].  
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Various other factors including, a diet rich in meat and fat, obesity [23], alcohol intake 
[24] and people with diabetes mellitus [25] may have a slightly increased risk of 
developing pancreatic cancer. Long-term inflammation of the pancreas i.e. chronic 
pancreatitis [26] is a major factor increasing risk of pancreatic cancer. The risk of 
pancreatic cancer also increases in those who have a genetic predisposition. This is 
defined as having at least two first degree relatives with pancreatic cancer in the 
absence of other inherited cancer syndromes such as Peutz-Jeghers syndrome 
(mutation in STK11/LKB1 gene) or Hereditary pancreatitis (mutations in PRSS1 
gene), familial atypical multiple mole melanoma (FAMMM) syndrome (caused by 
mutations in the INK4A gene), hereditary nonpolyposis colorectal cancer syndrome 
(caused by mutations in the hMLH1 or hMSH2 gene) [27] [28] [29]. The more first-
degree relatives affected, the higher the risk, which might be due to an autosomal 
dominant inheritance of a rare allele. Interestingly, a mutation of BRCA2 is found in 
about 20% of all familial pancreatic cancer [27] with three or more cases of 
pancreatic cancer.  
 
1.7 Pathology of pancreatic cancer 
1.7.1 Non-invasive pancreatic neoplasia 
 
Research over the years has shed some light on the molecular and histological 
events that are associated with pancreatic carcinogenesis. Pancreatic intra epithelial 
neoplasia (PanIN), Mucinous Cystic Neoplasms (MCN) and intraductal papillary 
mucinous neoplasms (IPMN) are the three different forms of precursor non-invasive 
pancreatic neoplasia [30].  
1.7.2 Pancreatic intra epithelial neoplasia (PanIN) 
 
PanINs are neoplastic epithelial proliferations in the small pancreatic ducts and are 
usually seen as microscopic precursor lesions (<5mm). PanINs are sub-classified 
based on their differentiation into three grades, PanIN 1, PanIN 2, PanIN 3.  
 
PanIN 1 is further subdivided into PanIn 1-A, characterised by lesions that are flat 
and cells with increased levels of mucin (arrow) (Figure 5) have basally located small 
oval nuclei while PanIN 1-B are papillary lesions with basal nuclei and appear to 
have pseudo-stratified tissue architecture (Figure 5-arrow,). They maintain cell 
polarity, have high levels of supra nuclear mucin with no nuclear atypia (Figure 5). 
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PanIN 2 lesions (Figure 5) are predominantly papillary with nuclear abnormalities. 
Mitotic bodies can also be observed (non luminal and not atypical) [30].   
 
PanIN 3 lesions lose nuclear polarity, exhibit nuclear atypia and show abnormal 
mitosis. PanIN 3 (Figure 5) lesions have a marked similarity to Pancreatic Ductal 
Adenocarcinoma (PDAC) but cells do not breach the basement membrane 
(carcinoma in situ) [30]. Studies have reported patients with PanINs to develop 
invasive pancreatic cancer. When comparing the normal pancreas to PDACs, there 
is a progressive increase in the number and grade of PanINs [31]. Present imaging 
techniques available to patients cannot detect PanINs but can image larger 



























Figure 5: Histological images of haematoxylin stained human PanIN sections 
showing the different sub-classification. (arrow points to increased secretion 
of mucin). Figures courtesy of Mr. Hemant Kocher, Barts Cancer Institute, 
Queen Mary University of London. 
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1.7.3 Mucinous cystic neoplasms (MCN) 
 
With a characteristic “ovarian type” stroma, MCNs are mucin-producing epithelial 
neoplasms which mostly affect women [31]. Arising in the tail of the pancreas these 
are columnar cells with varying degrees of differentiation (Figure 6). They are sub 
classified into mucinous cystadenomas (uniform nuclei, no significant atypia), border 
line MCNs (minimal cytological and architectural atypia), MCNs with carcinoma in 
situ (high grade dysplasia) and invasive mucinous cystadenocarcinoma [33]. About a 
third of all MCNs are associated with a ductal type of adenocarcinoma of the 























Figure 6: Haematoxylin stained section of mucinous cystic neoplasm (MCN). 
(10X magnification) Figure courtesy of Mr. Hemant Kocher, Barts Cancer 
Institute, Queen Mary University of London. 
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1.7.4 Intraductal papillary mucinous neoplasm (IPMN) 
 
Intraductal papillary mucinous neoplasms (IPMNs) are usually detected more easily 
in the head of the pancreas using magnetic resonance cholangiopancreatography, 
and these cells secrete the mucin MUC 2 (most PanINs express MUC 1) [35]. IPMNs 
are composed of columnar cells and are classified into two broad groups – those that 
are, and those that are not associated with invasive cancer; the latter having an 
excellent prognosis after surgery. IPMNs arising in the branch ducts (Figure 7) are 
less likely to progress to invasive carcinoma compared with main duct IPMNs [34]. 
Tubular/ductal invasive adenocarcinoma or the colloid or muconodular types of 


























Figure 7: Haematoxylin stained section of intraductal papillary mucinous cystic 
neoplasm (IPMN) (5X magnification). Figures courtesy of Mr. Hemant Kocher, 
Barts Cancer Institute, Queen Mary University of London. 
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All the above-mentioned precursor lesions have their own characteristic 
morphological features (Table 2) and genetic alterations that have an impact on the 
prognosis of these lesions. It has been well established now that these precursors 































Table 2: Features of precursor lesions of PDAC and their presenting 
symptoms. Modified from Maitra et al. Adv Anat Oathol, 2005 MCN – Mucinous 
Cystic Neoplasm, IPMN – Intraductal Papillary Mucinous Neoplasm, PanIN – 
Pancreatic Intraepithelial Neoplasia, PDAC – Pancreatic Ductal 
Adenocarcinoma.  
  
MCN IPMN PanIN 
Age at diagnosis Non invasive, 55 
years. 
Invasive, 65 years. 
Non invasive, 63 
years. Invasive, 
68 years 
Increasing with age 
Gender 90% F 40% F 50% F 
Location in pancreas Tail Head Head 
Growth within larger 
pancreatic ducts 
No Yes No 
Manifests clinically Yes Yes No 
Grossly visible Yes Yes No 
Mucin oozing from ampula No Yes No 
Ovarian type stroma Yes No No 
Extra-pancreatic neoplasms No Yes No 









1.8 Progression into pancreatic ductal adenocarcinoma 
 
PDAC is the deadliest and most frequently occurring form of pancreatic cancer 
among the multiple histological subtypes of this disease. With a dismal five year 
survival rate of <5%, there is an urgent need for a thorough understanding of the 
molecular changes of this disease to allow early diagnosis and therapeutic 
intervention.  
 
Macroscopically the tumours appear as a white-yellow firm mass and microscopic 
observations show that the infiltrating glands comprise low columnar mucin-
containing cells [36]. The area surrounding the cancer is highly desmoplastic and the 
cancer cell nuclei often show loss of polarity, pleomorphism, and prominent nucleoli 
[36]. More than 80% of patients with PDACs show metastasis to distant organs, the 
most common sites being the liver (80%), peritoneum (60%), lung, pleura (50%-70%) 
and adrenal gland (25%) [37]. The cancer invades the vasculature, lymphatic and 
perineural tissue surrounding the pancreas with approximately 80% of resected 
organs showing disease in the regional lymph nodes [36].  
 
1.8.1 Genetic changes leading to PDAC 
 
The aggressive nature of pancreatic cancer is a result of multiple heterogeneous 
genetic changes, which is a hallmark of pancreatic cancer. Variations in copy 
number, micro-satellite instability (e.g. mutations in LMLH1), epigenetic silencing 
(e.g. hyper methylation of promoter CpG islands in ppENK) are some of the common 
genetic abnormalities observed [38]. There are many common genetic aberrations 
between PanINs and PDACs, which might be an indication that PanINs could be a 
precursor to PDACs. Some of the genetic mutations tend to accumulate as the 
disease progresses from a pre-invasive neoplastic stage to an invasive and 
aggressive ductal adenocarcinoma [31].  
 
The GTPase KRAS protein is part of the RAS superfamily of proteins and plays a 
role in many vital cellular functions including proliferation, differentiation and survival. 
Mutations in the KRAS oncogene are observed in about 90% of PDACs and these 
are widely believed to be an initiating event, which drives tumour progression. KRAS 
mutations occur more frequently, the more advanced the lesions are; thus PanIN 1 
has about 10% - 30%, PanIN 2 has about 45% and PanIN 3 has about 85% of 
activating KRAS mutations [39]. The most common mutations observed is the point 
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mutation at codon 12 from GGT to GAT or GTT and more rarely from GGT into CGT 
[40], which results in a substitution of a single amino acid, glycine with aspartic acid 
(G12D), or with valine (G12V) or with alanine (G12A) with the latter more commonly 
observed in colorectal carcinomas [41]. These mutations often lead to a constitutively 
activated form of KRAS. Once activated, KRAS can activate many downstream 
signalling pathways including the RAF-Mitogen Activated Protein Kinase (MAPK) and 
the Phosphoinositide-3-Kinase (PI3K) pathway, which are shown to be involved in 




















Figure 8: Down stream signalling as a result of KRAS activation either by 
growth factor receptor mediated activation or presence of activating mutations 
in the KRAS gene as described above.  
 
In addition to mutations in KRAS about 80%-95% of PDACs also have loss of 
function mutations of a tumour suppressor gene, p16/CDKN2A/INK4A and these 
mutations are usually observed in the later stages of pancreatic cancer [35]. Tumour 
suppressor gene INK4A/p16 inhibits phosphorylation of the retinoblastoma (Rb) gene 
mediated by cyclin dependent kinases (CDK4/6) and prevents cell cycle progression 
at the S phase [43]. During the development of PDACs, this gene is usually mutated 
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through deletion or promoter methylation. Alternative reading frame (ARF/p19) is 
another tumour suppressor gene transcribed from an alternate reading frame of the 
CDKN2A (INK4A or p16) gene with distinct first exons and alternative reading frames 
in the shared downstream exons [44]. ARF usually inhibits tumour progression 
through stabilising the p53 gene by inhibiting Mdm2 mediated degradation of p53 
[43]. It is not yet fully understood if loss of function mutations of ARF alone can affect 
p53 function in PDAC progression because both ARF and p53 deletions coexist in 
about 40% of human PDAC [45]. There are studies which suggest that the loss of 
function of ARF/p19 could simply be due to the loss of function mutations in the 
INK4A/p16 gene [43]. Mutations in the KRAS gene can activate the INK4A and ARF 
tumour suppressor genes, which in turn can induce cell death (senescence), thus 
acting as a defence mechanism against oncogene activation [46]. Studies on 
pancreatic mouse models with mutations in the KRAS gene have shown that early 
lesions in the pancreas (PanINs) do express INK4A but expression was lost almost 
completely when lesions progressed to invasive cancer [47] suggesting that 
activating mutations of KRAS followed by changes in growth factor signalling can 
lead to loss of function mutations in the INK4A and ARF genes as the lesions 
progress from PanINs to PDAC (Figure 9) [43].  
 
PDAC is often comprised of profound aneuploidy and intra-tumoural heterogeneity 
and this has been widely attributed to the loss of function mutations of the p53 gene 
[43]. Almost 50%-75% of PDAC patients have missense alterations (point mutation) 
in the DNA-binding domain of the p53 gene (Figure 9) [48]. Similar to the other 
tumour suppressor genes, including INK4A and ARF, p53 mutations are more 
common as the early pancreatic lesions progress to PDAC. The fact that p53 is only 
mutated and not deleted in PDAC could result in a gain of function of the mutant p53, 
which could in fact promote tumour growth. In fact, mutant p53 has been shown to 
play a key role in overcoming senescence (growth arrest) induced as a result of 
activating mutations of the Kras gene and promote PDAC tumour growth in a mouse 
model for PDAC [49]. Further studies have also revealed that mice with accumulated 
mutant p53 are more prone to developing metastatic osteosarcomas and 
carcinomas, including PDAC, compared to p53 null mice where no metastasis was 
observed [49, 50].  
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TGFβ belongs to a superfamily of secreted proteins and these are secreted as 
inactive complexes with a pro-peptide, latency-associated peptide (LAP) of TGFβ 
[51]. TGFβ signalling in cancer is extremely complex and there are contradictory 
reports published describing its functional role in cancer, both as a tumour 
suppressor and as a tumour promoter. Upon binding to its receptor, TGFβ 
downstream signalling is mainly carried out by the SMAD family of proteins (SMAD1-
8). One of the signalling routes described is through the phosphorylation and 
activation of SMAD 2 and 3, which in turn bind to the transcription factor, SMAD4, 
which is translocated into the nucleus where it acts to regulate gene expression [52]. 
TGFβ signalling is very important in pancreatic cancer progression as about 50% of 
PDAC patients in the late stages have a mutational deletion of SMAD4 or DPC4 
(deleted in pancreatic cancer, locus 4) a key component in the TGFβ signalling 
cascade, being a transcriptional regulator [53] (Figure 9). In PDAC, SMAD4 deletions 
are associated with the interaction between the tumour and its microenvironment and 
restoring SMAD4 expression had a major impact on angiogenesis and matrix 
remodelling in xenograft mouse models [54]. Loss of heterozygosity (LOH) of the 
SMAD4 gene in PDAC means that the epithelial growth inhibitory effects promoted 
by TGFβ are lost and in fact in some cases, it has been shown to provide PDAC 
tumour cells with a survival advantage [52].  
 
Mutations are also observed in the DNA repair genes like BRCA2, Fanconi anaemia 
(FANC) gene, and the mis-match repair genes, hMLH1 and hMSH2 [35] [55]. Apart 
from PDACs, there are other tumours that arise in the pancreas including primary 
non-endocrine tumours, adenosquamous carcinoma, acinar cell carcinoma, giant cell 
carcinoma, which have been observed in recent years. These tumours are not as 
deadly as PDAC and most of them are treatable with good clinical outcomes [8] The 
exact roles of tumour suppressor genes and oncogenes implicated in these events 
remain unclear but continued efforts to elucidate the genetic and molecular causes 


























Figure 9: Genetic progression model for pancreatic cancer. Early stages of 
pancreatic cancer involve the shortening of telomeres and mutations in the 
KRAS oncogene. As the disease progresses the cells accumulate more 
mutations in the INK4A/ARF19 tumour suppressor gene leading to an 
accelerated progress into PDAC where further inactivating mutations of TP53 
and SMAD4 are observed. The changes observed in the epithelial cells are 
accompanied by alterations in the tumour microenvironment. Figure adapted 
from Morris et al, 2010 [56].  
 
 
1.9 Pancreatic cancer – the role of the microenvironment 
 
There have been many studies which have examined the molecular mechanisms of 
carcinogenesis but it has become widely accepted that tumour progression actually 
is a consequence of the dynamic interaction between the transformed cancer cells 
and the cellular and the neighbouring non-cellular components that surround them, 
the stroma [57].  
 
1.9.1 Tumour stroma 
 
Tumour stroma is composed of a mixture of various extracellular matrix (ECM) 
proteins containing cellular components including fibroblasts, immune and 
inflammatory cells and blood vessels. Previously thought to be a passive milieu 
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through which cancer cells invaded, it is now evident that there is an active exchange 
of signals between cancer cells and the stromal environment, which influences and 
determines the behaviour of the tumour [57]. The cancer cells themselves can modify 
the stroma, often referred to as “activated” stroma, and, depending on the degree of 
activation, a desmoplastic (fibrotic) stroma provides a permissive milieu for tumour 
progression [58]. A large amount of intense fibrous or desmoplastic stroma is a 
characteristic feature of pancreatic cancer and it accounts for a large proportion 































Figure 10: Histology of pancreatic cancer showing the intense stromal 
response. H&E section shows staining of pancreatic cancer and below is the 
schematic representation, which shows the area of desmoplasia in yellow. 
Figure reference:[59]. 
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Indirect immunofluorescence studies carried out on 12 PDACs showed that the main 
components that made up the stroma were collagen type 1, type 5 and fibronectin. 
Studies have reported a three-fold increase in the average collagen content in 
pancreatic cancer compared to normal pancreas [60, 61]. Even though PDAC cells 
can secrete various ECM proteins such as collagen, fibronectin and laminin, there is 
increasing evidence that myofibroblasts (activated or transformed fibroblasts) and 
activated pancreatic stellate cells play a major role in modifying the ECM [62]. In 
normal pancreas, there are stromal cells (fibroblasts and pancreatic stellate cells) 
which have a controlled level of proliferation and secrete growth factors required to 
maintain tissue homeostasis. In PDACs, where the cells breach the basement 
membrane in to the surrounding stroma, the stromal cells rapidly proliferate and 
secrete more growth factors and collagen much like a wound healing response. The 
difference being, in cancer, the stromal activation does not revert back into the 
quiescent state [62].  
 
1.9.2 Cancer cells modify their stromal environment 
 
Cancer cells can modify their adjacent environment directly by producing enzymes 
that modify stromal proteins and indirectly by activating stromal cells to modify the 
ECM. Thus tumour cells often secrete matrix metalloproteinases (MMPs), which are 
proteolytic enzymes that can degrade ECM proteins [63]. They also secrete a variety 
of growth factors, including epidermal growth factor (EGF) and transforming growth 
factor-β (TGF-β), which can act in a paracrine fashion to modify the surrounding 
stroma [64]. These secreted factors activate the stromal cells, which in turn start to 
proliferate more and secrete more growth factors, which then will aid in tumour 
progression.  
 
1.9.3 Tumour associated fibroblasts 
 
The idea of a cross-talk between cancer cells and their microenvironment was 
suggested as early as 1889 by Steven Paget in his “seed and soil hypothesis” [65]. 
According to this hypothesis, an active tumour-stroma interaction is required for the 
cancer cells (seeds) to metastasise into a secondary microenvironment (soil) and 
grow [66].  Genetic changes in epithelial cells initiate release of cytokines and growth 
factors, which activate the stromal fibroblasts. Once activated, these cells are often 
referred to as tumour-associated fibroblasts or cancer associated fibroblasts (CAFs) 
or myofibroblasts. Due to their mesenchymal origin, myofibroblasts have similarity 
 44 
with the muscle cells, including the expression of α-smooth muscle actin (α-SMA), 
expression of which is used as a marker for the myofibroblastic phenotype [67]. The 
tumour cells secrete growth factors including TGF-β, basic fibroblast growth factor 
(bFGF), vascular endothelial growth factor (VEGF), which can activate the fibroblasts 
and in turn upregulate various growth factors such as hepatocyte growth factor 
(HGF), which has a paracrine effect on the tumour cells by binding to its receptor c-
Met, expressed on epithelial cells and thereby leads to increased proliferation, 
migration, invasion and matrix remodelling. This process is cyclical and leads to the 
formation of a stroma, which supports tumour growth and invasive behaviour [68-70].  
 
TGFβ is one of the most important factors that induce desmoplasia [71]. It does this 
principally by causing the trans-differentiation of pancreatic stellate cells and 
fibroblasts into the activated state, which is characterised by α-SMA expression and 
increased collagen secretion. In addition to this, resistance of tumour cells to growth 
inhibition by TGFβ is usually accompanied by an increased expression of TGF-β. In 
PDAC this is usually due to a mutation of the SMAD4 gene (DPC4) allowing cells to 
escape the growth inhibitory function of TGF-β [68] [72]. Other growth factors, 
including platelet derived growth factor (PDGF) or fibroblast growth factor (FGF), also 
have been shown to induce myofibroblast differentiation and promote desmoplasia 
[73]. A study which looked into the invasive ability of pancreatic cancer cells co-
cultured with pancreatic specific fibroblasts showed more invasion in the presence of 
fibroblasts than in their absence [74]. This could possibly be due to increased 
expression of HGF by the fibroblasts [74]. This study will focus on pancreatic stellate 
cells, the major cellular components in PDAC stroma and their role in PDAC 
progression.  
 
1.9.4 Pancreatic stellate cells 
 
With fibroblast-like morphology, pancreatic stellate cells (PSC) are localised in areas 
of the pancreas that have an exocrine function. These cells can be identified by 
accumulation of vitamin A (retinol) in intracellular fat droplets and were first identified 
in mouse and human pancreas in 1982 and 1990 respectively [75, 76]. Vitamin A is 
auto fluorescent and under ultraviolet (UV) light emits a rapidly fading blue green 
fluorescence, which is a characteristic feature of cells which store vitamin A. Due to 
their close resemblance to the hepatic stellate cells, these cells were characterised 
by two independent laboratories and subsequently called pancreatic stellate cells 
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[77, 78]. A gene-expression microarray analysis revealed that only 29 genes of the 
20,000 studied were differentially expressed in pancreatic stellate cells compared 
with hepatic stellate cells [79]. This might suggest a common stellate precursor with a 
few organ specific adaptations. More recently, immunohistochemical analysis on 
tissues revealed the presence of stellate cells in other organs including kidney, lung 
and heart [80].  
 
In normal pancreas, stellate cells are primarily located in the peri-acinar and 
interlobular space and constitute only about 4% of all pancreatic cells. In addition to 
storing vitamin A, these cells express a set of specific markers, which include glial 
fibrillary acidic protein (GFAP), nestin, desmin and vimentin [81] [77, 78]. Similar to 
the fibroblasts, pancreatic stellate cells can be activated into a myofibroblast-like 
phenotype. When this happens, they lose their vitamin A fat droplets and start 
secreting various ECM proteins including collagen type 1, fibronectin, laminin [78] 
[81]. They also begin to express the myofibroblastic marker, α-SMA. Co-culture of 
pancreatic stellate cells and cancer cells compared with cancer cells alone in vivo 
(subcutaneous xenografts or orthotopic injections in nude mice models) show that 
the introduction of stellate cells markedly increased the desmoplastic response 
observed [82-84]. Sections from tumours isolated from co-cultured in vivo 
experiments showed remarkable similarity to human pancreatic cancer and alcohol- 
induced chronic pancreatitis [85]. Immunohistochemical analysis of these tumours 
showed strong positive staining for desmin, GFAP and α-SMA in the stroma. Co-
localisation of α-SMA-positive cells with mRNA encoding procollagen α1 suggests 
that activated pancreatic stellate cells contribute significantly to the desmoplastic 
reaction observed in pancreatic cancer [86].    
 
Cancer cell proliferation and invasion increased when these transformed cells were 
co-cultured with pancreatic stellate cells in an orthotopic mouse model [83]. The 
authors of this publication also observed a significant increase in tumour incidence, 
growth and metastasis when a higher proportion of pancreatic stellate cells were co-
injected with the cancer cells (1:5 cancer cell : stellate cell ratio). Very recently, in 
vitro observations in our laboratory showed that cancer cell invasion into a 3D matrix 
using the organotypic co-culture model was dependent on the number of stellate 
cells in the system. Maximum invasion and growth was observed at a ratio of 1:2 




















Figure 11: Pancreatic stellate cell. Various factors that are secreted by the 
stellate cell, which in turn have a paracrine or autocrine effect and contribute 
to the modulation of the ECM [81].  
 
TGFβ plays an important role in the activation of pancreatic stellate cells via several 
direct and indirect mechanisms. It is one of the growth factors known to increase the 
migratory potential of stellate cells [87]. Activin A (member of the TGFβ family) has 
been shown to activate pancreatic stellate cells, thereby increasing collagen 
deposition and secretion of other growth factors, which in turn have an autocrine 
effect to keep them in an activated state [88]. Activated stellate cells also secrete 
factors that have a paracrine effect on the cancer cells and help in tumour 
progression. Cancer cells can secrete tumour necrosis factor α (TNFα), FGF2, 
interleukin (IL) 1, 6 and 8, all of which have been implicated in the activation of 
pancreatic stellate cells. Activated PSCs are known to stimulate various intra-cellular 
signalling pathways including the mitogen activated protein kinase pathway (MAPK), 
phosphatidyl inositol 3 (PI3) kinase pathway, Rho-Rho (ROCK) and TGFβ / SMAD4 
pathway (Figure 11) [89].  
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The role of pancreatic stellate cells, both in the quiescent and activated state, is far 
from completely understood. There are many recent studies that show a very strong 
cross talk between the pancreatic cancer cells and pancreatic stellate cells. Thus 
increased understanding of pancreatic stellate cells is essential for studying 
pancreatic cancer progression.  
 
1.9.5 Three dimensional (3D) in vitro models of pancreatic 
cancer 
 
Over the years, in vitro 2D cell culture has contributed to vast amounts of data 
relating to various genetic, biochemical and cell biological processes. However, cells 
grown as a monolayer in 2D on tissue culture plates differ in their morphology, cell-
cell and cell-matrix interactions compared with 3D cell cultures. 3D models are 
increasingly used to study cell-cell and cell-matrix interactions because they can be 
used as a preliminary screen to examine specific genetic, biochemical or cellular 
questions more easily than in complex animal models. While they cannot replace 
animal models, they offer a significant advantage over 2D systems because they act 
as physiological mimetics.   
 
Studying cellular behaviour in 3D is extremely important to understand the various 
biochemical pathways that are involved in cancer progression. Tissues are very 
heterogeneous and contain multiple cell types, like epithelial cells, mesenchymal 
cells (fibroblasts, stellate cells), vascular cells (endothelial cells, pericytes), 
inflammatory or immune cells (macrophages, lymphocytes). Co-culturing multiple cell 
types in vitro in a single organotypic model is a very complex process but it 
recapitulates better the in vivo condition. There are very few 3D co-culture models 
that are established for pancreatic cancer to date. Froeling F.E et al; 2010 [59] in our 
laboratory adapted the organotypic co-culture model, used for studying skin cancer 
[90], to study pancreatic cancer. The pancreatic cancer cells were co-cultured with 
pancreatic stellate cells embedded in a matrix of collagen type 1 and Matrigel™ in a 
1:1 ratio and grown at an air-liquid interface. These co-cultures offered a three 
dimensional matrix for the cancer cells to interact with the stellate cells and also 
provided a matrix for them to grow on and invade into. This model can be used for a 
variety of in vitro experiments and can be set up for using genetically manipulated 
cells (siRNA treated) or testing new therapeutic agents (antibodies or small molecule 
inhibitors) to target the epithelial or stromal, or both, cell types in a more 
physiologically relevant environment. The same co-culture model has been used to 
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target the pancreatic stellate cells (stromal compartment) specifically using all trans 
retinoic acid (ATRA). The ATRA rendered the activated stellate cells quiescent, 
leading to a decreased proliferation and increased apoptosis of the surrounding 
pancreatic cancer cells (epithelial compartment) [91]. This clearly highlights the 
importance of tumour-stroma cross talk and the need for these three dimensional 
models to study biological functions. These organotypic co-culture models provide a 
system, which can be manipulated to address specific questions, and serve as useful 
tools before using in vivo models.  
 
1.9.6 In vivo mouse models of pancreatic cancer 
 
In vivo mouse models for pancreatic cancer are crucial for our understanding of the 
complex nature of this disease.  A pre-clinical animal tumour model is essential for 
obtaining data on development, progression, signalling pathways, mechanism of 
action and therapeutic efficacy of new anti-cancer agents, which are clinically 
relevant. Selecting the right animal tumour model, its design and use is entirely 
dependent on the questions to be answered and a successful pre-clinical animal 
tumour model should be reliable, reproducible and affordable. It should also allow the 
user to determine an objective and quantitative end point [92]. Various types of in 
vivo mouse models for pancreatic cancer have been developed over the years.  
 
One such model is where immunocompromised mice are inoculated (ectopic 
injection), with human cancer cells alone or a combination of human cancer cells and 
pancreatic stellate cells, subcutaneously [82]. The main advantages of using this 
model are the ease of design compared with other animal models, extreme 
reproducibility, minimal labour, easily quantifiable data, varying treatment plans 
according to tumour burden and the fact that it is cheaper compared with other 
animal models. The major drawback is the absence of metastasis, absence of 
relevant host infiltrate and also the presence of an inappropriate tumour 
microenvironment.  
 
Another model, widely considered to be better than the subcutaneous model, 
because of its physiological relevance is the orthotopic (site/organ specific) injection 
into immunocompromised mice [83].  The main advantage of using this model is that 
the cells are injected into the relevant site so there occurs an interaction between the 
host organ and tumour cells. This method aids both local and distant metastasis. Any 
therapy given, thus will be site directed to affect the specific relevant organ and 
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clinical situations can be recreated to a certain extent by removing the primary 
tumour and treating the secondary metastasis. The main disadvantage is that it is 
very labour intensive. Injecting into the mouse pancreas requires anaesthesia and 
surgery for each mouse, which can be technically difficult, and with Home Office 
restrictions in place, only one injection per animal can be performed, thus even the 
slightest mistake can result in the animal being removed from the group and culled. It 
is more expensive compared to the subcutaneous model because more animals are 
required per experiment due to complications that could arise due to the surgery and 
also due to a lack of a 100% uptake of tumours. Also it is more difficult to monitor 
tumour growth, compared with the subcutaneous tumours, although this is being 
overcome by use of ultrasound machines (which are expensive) [93].  
 
Although both the above-mentioned models are an advance on the 3D in vitro 
models, there is wide spread criticism over injecting human cells into 
immunocompromised mice. A genetically engineered mouse model, which can give 
rise to spontaneous pancreatic cancer, is considered to be the gold standard model. 
It provides valuable insights and closely resembles the pathophysiological and 
molecular features of human pancreatic cancer. It also allows the user to study the 
early events during the development of cancer, study the genetic background of the 
disease, study metastatic patterns that are more relevant to human disease and 
might help to design strategies to prevent cancer initiation.  
 
Like most gastrointestinal (GI) organs, the pancreas develops from the endoderm 
during gastrulation. Many key embryonic signalling pathways, including hedgehog 
signalling, notch signalling and retinoic acid signalling determine the lineage of the 
pancreas [94]. The development of the pancreas is controlled by transcription 
factors, which regulate gene expression. One of the earliest transcription factors 
essential for the development of pancreas is the homeodomain transcription factor 
pdx1 (pancreas duodenum homeobox 1). Pdx1 was initially considered to be an 
exocrine transcription factor but more recent studies have revealed that it is 
necessary for both the exocrine and endocrine differentiation [95]. Lineage tracing 
studies were possible in animal models using the Cre-Lox technology. This 
technology is currently in use for generating animal models with specific deletions 
(knock out) and insertions (knock in) of genes. Cre gene and lox p sites have to be 
introduced into mice using transgenic technology and the majority of the cre-lox 
strains generated can be grouped into four categories [96]. Cre expressing strains 
have a transgene controlled by a promoter (which can be tissue specific). Inducible 
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Cre expressing strains have a transgene, which becomes functional only upon the 
addition of an inducing agent (e.g. doxycycline, tetracycline). Lox p flanked (floxed) 
strains have the gene of interest flanked by lox p sites, which are recognised by the 
cre-recombinase and this technology is used mainly for gene deletion (knock out 
models). Cre reporter strains combines a marker (fluorescent or lac z) together with 
the lox p sites so that the recombination or alterations in gene expression can be 
monitored [97].  
 
Transgenic mice with a mutation in the oncogenic KrasG12D allele controlled by Cre-
mediated recombination and driven by Pdx1 (a specific promoter) were created and 
the pancreata of these mice spontaneously developed tumours similar to PanINs 
observed in humans [98]. In the pancreas of many of these mutant mice, an intense 
stromal response with inflammatory cells, fibroblasts and collagen deposition was 
observed. When these mice were crossed with conditional knockout mice of the 
Ink4a/Arf locus (eliminates p16INK4A and p19ARF proteins) or mice with a single G to A 
nucleotide substitution in the endogenous TP53 gene, they developed invasive and 
metastatic pancreatic tumours [99, 100]. KrasG12D mice crossed with Ink4a knockout 
mice developed poorly differentiated tumours whereas KrasG12D mice crossed with 
mutated TP53 showed a higher prevalence of well or moderately differentiated 
adenocarcinomas [101]. The loss of tumour suppressor genes along with activated 
Kras can influence the type of lesions formed and in turn affect the differentiation 
state and progression of tumour. Activated Kras gene is essential for initiation and 
development of pancreatic tumours. Loss of function of tumour suppressor genes 
(TP53, Ink4a/Arf) alone did not give rise to any tumours, suggesting Kras mutations 
drive tumorigenesis as well as determining cellular differentiation [101]. It has to be 
mentioned that in the PdxCre;Kras G12D mice, which have a mutant allele of Kras in all 
three lineages (endocrine, exocrine and acinar), the only neoplastic feature that is 
observed are PanIN lesions and PDAC; endocrine and acinar tumours are not 
observed. In addition to the above-mentioned models, which are based on 
conditional expression under the control of Pdx1 transcription factor, there are many 
transgenic mouse models, which have been developed employing various promoters 
to drive mutagenic expression. These models are currently used to study various 
deregulated signalling pathways and pathogenetic changes that lead to invasive 
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Table 3: Mouse models of pancreatic cancer. LSL – Lox-Stop-Lox, Pdx – 
pancreas duodenum homeobox 1, Ela – elastase, Mist1 – muscle intestine and 
stomach 1. 
 
Despite the number of transgenic models that are in use to study pancreatic cancer 
the long latency periods involved make these models very expensive to maintain and 
non-amenable to rapid experimental manipulation. Orthotopic transplantation is not 
an ideal model to screen new anti cancer targets because it is labour intensive and is 
difficult to monitor tumour growth on a daily basis. Ectopic models on the other hand 
are easier to maintain and make a good and easier model for screening of new 
agents to target cancer. This study uses a new ectopic model of PDAC that 
addresses some of the criticisms of this model. 
 
In this study we have identified the epithelial specific integrin, αvβ6, expressed on the 
surface of pancreatic cancer cells. This integrin is absent in normal tissue including 
pancreas, making it a promising therapeutic target. Integrins and more specifically 
integrin αvβ6 will be introduced before describing its role in PDAC cell biology in 
detail.   
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1.10 The integrin super family 
 
Tamkun et al, first coined the term “integrin” in 1986 to describe a structurally and 
functionally related set of heterodimeric cell surface receptors, which “integrated” the 
ECM with the intra-cellular cytoskeleton [102]. Integrins belong to a superfamily of 
heterodimeric, transmembrane cell adhesion glycoproteins. Integrins are composed 
of an evolutionarily conserved series of α and β subunits, which heterodimerise to 
give rise to the functionally active integrin. Many studies have shown that integrins 
play a key role in various intra-cellular signalling pathways, which affect diverse 
cellular functions including differentiation, proliferation adhesion, migration and 
invasion [103].  
 
In humans, there are eighteen α subunits (α1-α11; αIIb, αD, αE, αL, αM, αV, αX) 
and eight β (β1 - β8) subunits (Figure 12). The different α and β subunits can 
dimerise in various, but specific, combinations to give rise to twenty-four different 
functional integrins, each with distinct functions and tissue distribution. Integrins 
recognise various ligands and the heterodimer composition determines their ligand 
binding specificity [103]. Differential splicing and other post-translational 
modifications also give rise to integrin variants [104]. Integrins bind to specific ligands 
through recognition of short peptide motifs. The most common integrin binding motif 
is the arginine-glycine-aspartic acid (RGD) motif found in many ECM ligands 
including fibronectin, vitronectin, fibrinogen, Von Willebrand factor (VWF) and 
osteopontin [103]. Eight different integrins recognise the RGD (Arg-Gly-Asp) motif, 
αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, αIIbβ3 [105]. Several integrins, α1β1, 
α2β1, α10β1, α11β1 bind to the different collagens present in the ECM. Integrin 
expression can be tissue specific, e.g. β2 integrins are expressed only in leukocytes 
whereas α6β4 is expressed only in epithelial cells [106]. Figure 12 shows the 
different α and β subunits present in humans along with the possible combinations 
































Figure 12: The integrin family with the 18α  subunits and 8β  subunits. The 
known combination of the α  and β  subunits are divided into RGD receptors in 
blue, collagen receptors in shaded grey, laminin receptors in purple and 
leukocyte specific receptors in yellow. α4 and α9 in green are restricted to 
chordates. (Picture modified from Hynes et al, 2002).  
 
1.10.1 Structure and function of integrins 
 
The α and β subunits are membrane glycoproteins expressed on the plasma 
membrane with a long extra-cellular domain, a trans-membrane domain and, usually, 
a short cytoplasmic domain (30-50 amino acids) with the exception of β4, which has 
a cytoplasmic tail of over 1000 amino acids. The extracellular domain has a globular 
head, which binds to the target ligands whereas the cytoplasmic tail interacts with a 
variety of signalling and structural molecules, which will be discussed later. The α 
and β subunit dimerisation occurs in the extra-cellular region and this is where the 
ligands bind to integrins (Figure 13) [107]. Although integrins can bind to a wide 
variety of ligands, both ECM proteins and some cellular proteins (Table 4), their 


































Figure 13: Schematic diagram of the general structure of integrins 
demonstrating that they can physically connect extracellular ligands to the 
intracellular architecture of cells. 
 
It has been shown for the integrin αvβ3 that integrins can exist in different structural 
conformations [109]. Figure 14 A shows αvβ3 in the “bent” inactive form and upon 
activation, the two extra cellular “legs” are straightened resulting in the high affinity 
conformation with an “open” head domain (Figure 14 B) [109, 110]. Recent electron 
microscopic studies have shown that there is also a “closed” head domain, with the 
“legs” extended, which is a transitional conformation; hence this form is believed to 
have an “intermediate” affinity for ligands. There is compelling evidence showing that 
the cytoplasmic domain of the β subunit directs most downstream signalling of 
integrins. Cytoplasmic-tail truncation mutants of αIIb and β3 subunits transfected into 
CHO cells showed that only the β3 subunit cytoplasmic tail was essential for integrins 
to bind to focal adhesions [111]. Studies were carried out to determine the exact 
cytoplasmic residues that were essential for proper location of β1 integrins to the 
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focal adhesions [112]. A series of mutant chicken β1 cytoplasmic tail constructs with 
a single or double non-conservative substitution of every residue was expressed in 
NIH3T3 fibroblasts and their ability to locate to focal adhesions was determined 
[112]. Mutations in nine specific residues resulted in a reduced ability to locate to 
focal adhesions and comparison of sequences revealed that eight out of the nine 
residues were highly conserved in human β1, β2, β3, β5, β6, and β7 subunits [112]. 
These studies highlight the importance of the β subunit cytoplasmic tail and its role in 































Figure 14: Schematic picture of x-ray crystal structure of αvβ3 integrin. (A) 
shows the inactive structure and (B) shows the active form. (Picture modified 
from Xiong, JP et al, 2001).  
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The above figure shows the crystal structure of the αvβ3 extracellular region shown 
as a ribbon diagram (Figure 14) [109]. The inactive integrin is bent at a ‘genu’, or 
knee (arrow) in (A) compared with the active straightened model with the 12 domains 
individually labelled in (B).  The αv subunit consists of a 7-bladed β-propeller, a 
‘thigh’ domain and two ‘calf’ domains.  The β3 subunit consists of a βA domain, a 
‘hybrid’ domain, a PSI (for plexins, semaphorins and integrins) domain, four 
epidermal growth factor (EGF) domains and a β-tail domain (βTD).  ‘n’ and ‘c’ 
represent N- and C-termini.  Ligand binding occurs at the interface between the β-
propeller (αv subunit) and the βA-domain (β3 subunit). It is believed that all integrins 
exhibit these stereochemical changes. As mentioned before, the cytoplasmic tail acts 
as a link between the ECM and the cytoplasm [113]. This is often referred to as 
“outside-in” signalling (to be discussed later). However, in some cases the 
cytoplasmic tail is able to regulate signalling proteins, which in turn have a functional 
effect on the behaviour of the cell. This is often referred to as “inside-out” signalling 
(to be discussed later). A classic example for “inside-out” signalling is the ability of 
the binding of the highly conserved KXGFFKR motif, in the cytoplasmic domain of 
the α subunit, to calreticulin (regulator of the calcium transmembrane channel influx) 
for stabilising the “active” conformation of the integrin which in turn is crucial for 
integrin-mediated cell adhesion [114, 115].  
 
1.10.2  Ligand binding to integrins 
 
One of the principal functions of integrins, as the name suggests, is to integrate the 
ECM with the intracellular cytoskeleton. This is turn initiates a variety of downstream 
signalling pathways which affect cell proliferation, survival, adhesion, migration [116]. 
Integrins normally recognise short peptide motifs in their target ligands. Arginine-
Glycine-Aspartic Acid (RGD) tri-peptide was the first motif to be identified in 
fibronectin [117, 118]. Some integrins have the ability to recognise multiple ligands 
(Table 4) e.g. αvβ3 ligands include fibrinogen, laminin, thrombospondin, fibronectin, 
vitronectin and osteopontin. In some cases one ligand can be recognised by multiple 
integrins (e.g. fibronectin can be bound by αvβ1, αvβ3, αvβ6, α5β1, α4β1, α8β1) 
while others may be recognised by only one integrin (e.g. E-cadherin is recognised 
by αEβ7 [119]). Integrins also bind to cell surface ligands, thus all β2 integrins bind to 
immunoglobulin super family molecules including intracellular adhesion molecules 
(ICAM 1,2,3) [120]. Integrins also bind to some bacteria (bacterial invasin is an 
integrin ligand) and some viruses are internalised through binding of their cell surface 
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proteins to specific integrins (e.g. foot and mouth disease virus (FMDV) and 
coxsackie virus 9 (CAV) gain entry to cells that express αvβ6) [121]. Although some 
integrins recognise multiple ligands, their affinity for different ligands can vary widely. 
Thus the integrin αvβ6 can recognise fibronectin and the latency associated peptide 
(LAP) of TGFβ1 and 3 [122]. It was reported that binding to LAP was much stronger 
than binding to fibronectin [123]. Subsequent studies showed optimal ligands for 
αvβ6 have RGD at the tip of a hairpin bend in the protein followed by an adjacent α-
helix. This helix forms a second binding site on the integrin, therefore increasing the 
affinity [124].  
 
The α and β heterodimers cross the cell membrane with two short cytoplasmic 
domains. The extracellular domain of integrins binds to glycoproteins in the 
extracellular matrix (ECM) (through the short peptide motif e.g. RGD) and activate 
various downstream signalling processes (Figure 13). The signals generated can 
vary between different integrins, even when they bind to the same ligand e.g. both 
α5β1 and αvβ6 bind to fibronectin but only binding of αvβ6 to fibronectin induces 
squamous cell carcinomas to secrete MMP-9 [125]. The conformation of the ligand is 
important because that determines the exposure of its “integrin activation sequence”. 
Based on the motifs recognised, integrins can be divided into two classes: those with 
an αA domain (e.g. α2), which recognises glutamic acid based motifs (e.g. the ASP-
GLY-GLU-ALA (DGEA) tetrapeptide sequence is essential for the binding of α2β1 
mediated adhesion to platelets [126]) and those without an αA domain (e.g. αvβ3), 
which recognise aspartic acid based motifs (e.g. GLY-ARG-ASP-SER-PRO 
(GRDSP) tetrapeptide sequence. In both cases, the motifs form a complex with a 
metal ion bound within the integrin, referred to as metal-ion dependent adhesion site, 
(MIDAS), and this is essential for ligand binding to integrins [107, 109, 121]. The 
responses of different cell lines from various lineages, both transformed and non-
transformed, to the surrounding microenvironment can vary depending on the 
repertoire of integrin heterodimers expressed on their cell surfaces. Thus even within 
the same ECM, different cells may interact with different components of the 
substrate, thereby resulting in divergent biological responses.  
 
As mentioned earlier, integrins can bind to different types of ligands present in the 
ECM. Table 4 below details some of the major extracellular ligands, which bind to 






































































Fibrinogen !5"1, !M"2, !v"3, !x"2, !IIb"3 
HIV Tat protein !v"3, !v"5 
iC3b !M"2, !x"2 Ligand Integrin 
ICAM-1 !L"2, !M"2 
ICAM-2,3,4,5 !L"2 
Invasin !3"1, !4"1, !5"1, !6"1 
Laminin !1"1, !2"1, !3"1, !6"1, !7"1, 
!6"4, !v"3 
LAP-TGF" 1, 3 !v"6 
MAdCAM-1 !4"7 
Matrix metalloproteinase-2 !v"3 
Neutrophil inhibitory factor !M"2 
Osteopontin !v"3 
Plasminogen !IIb"3 
Prothrombin !v"3, !IIb"3 
Sperm fertilin !6"1 
Thrombospondin !3"1, !v"3, !IIb"3 
VCAM-1 !4"1, !4"7 
Vitronectin !v"1, !v"3, !v"5, !IIb"3 






















Table 4: ECM ligands and integrins to which they bind. Adapted from Plow, EF 
et. al, 2000.  
 
1.11 Signal transduction 
 
Sometimes integrin activity needs to be regulated rapidly and this means there needs 
to be a rapid “on” “off” mechanism. E.g. αIIbβ3, expressed by platelets, has to be 
activated rapidly for blood clots to be formed during bleeding. αIIbβ3 recognises the 
H-H-L-G-G-G-A-K-Q-A-G-D-V sequence in the fibrinogen gamma chain leading to 
rapid platelet aggregation, which acts as a plug to prevent bleeding. In other cases, 
integrin signalling has to be turned off so that cells can detach (e.g. during mitosis or 
during physiological migration) [127]. Integrin signalling has to be extremely dynamic 
so that it can switch between the active and inactive states quickly. Integrins usually 
are in the inactive state and in this state they cannot bind to any ligands. The switch 
from an inactive to active form correlates with their ability to bind ligands and requires 
a conformational change in the integrin. The structural changes occurring were 
confirmed by electron microscopy in recombinant integrins treated with calcium (does 
not support ligand binding); treatment with this element showed more “bent 
structures” (inactive) whereas when treated with manganese (supports ligand 
binding), the integrins showed more “extended structures” (active) [128].  Ligand 
induced (antibody) binding site (LIBS) epitopes, which were first described in αIIbβ3 
in response to ligand mimetic binding [129], are concealed epitopes exposed upon 
activation. Sometimes intracellular signals lead to these epitopes being exposed and 
Ligand Integrin 
ICAM-1 !L"2, !M"2 
ICAM-2,3,4,5 !L"2 
Invasin !3"1, !4"1, !5"1, !6"1 
Laminin !1"1, !2"1, !3"1, !6"1, !7"1, 
!6"4, !v"3 
LAP-TGF" 1, 3 !v"6 
MAdCAM-1 !4"7 
Matrix metalloproteinase-2 !v"3 
Neutrophil inhibitory factor !M"2 
Osteopontin !v"3 
Plasminogen !IIb"3 
Prothrombin !v"3, !IIb"3 
Sperm fertilin !6"1 
Thrombospondin !3"1, !v"3, !IIb"3 
VCAM-1 !4"1, !4"7 
Vitronectin !v"1, !v"3, !v"5, !IIb"3 
von Willebrand factor !v"3, !IIb"3 
Ligand Integrin 
ICAM-1 !L"2, !M"2 
ICAM-2,3,4,5 !L"2 
Invasin !3"1, !4"1, !5"1, !6"1 




Matrix metalloproteinase-2 !v"3 
Neutrophil inhibitory factor !M"2 
Osteopontin !v"3 
Plasminogen !IIb"3 
Prothrombin !v"3, !IIb"3 
Sperm fertilin !6"1 
Thrombospondin !3"1, !v"3, !IIb"3 
VCAM-1 !4"1, !4"7 
Vitronectin !v"1, !v"3, !v"5, !IIb"3 
von Willebrand factor !v"3, !IIb"3 
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therefore they are also known as activation-dependent binding sites [128]. Several 
monoclonal antibodies have been characterised, which can identify and bind to these 
epitopes. They have been valuable in monitoring the activation of integrins during 
biological processes, e.g. addition of 12G10 monoclonal antibody to cells stimulated 
cell adhesion and spreading in an α5β1 dependent manner [130].  
 
Integrins are key regulators of many important cellular functions. They do this by 
transducing signals across the cell membrane subsequent to ligand binding. Integrins 
have the ability to transmit signals in both directions (bi-directional signalling).  
Expression of an integrin by a cell does not imply that it has a functional role. For 
example, αIIbβ3 is expressed by platelets but cannot bind to its ligands in the 
absence of platelet activators such as thrombin or collagen. If αIIbβ3 was activated at 
a site other than the site of tissue damage, it could lead to generalised thrombosis 
[131]. Therefore, regulation of integrin activation is essential for maintaining tissue 
homeostasis.  In vitro, integrins can be activated using different techniques such as 
addition of an agonist to simulate a natural ligand [131], binding of specific antibodies 
to induce the “active” state, addition of manganese salts to cells [132] and also by 
addition of phorbol esters [133].  
 
Once activated, integrins cluster at the cell membrane bringing them in close 
proximity to other integrins and signalling molecules that are associated with the 
cytoplasmic tail. This increased proximity allows signalling molecules to generate 
intracellular signals. This clustering of integrins with the cytoplasmic associated 
proteins occurs at adhesive structures called focal adhesions. Studies have shown 
that these integrin clusters specifically recruit talin and this is important for formation 
of focal adhesions, acting as a link between the integrin and actin cytoskeleton [134]. 
It has also been demonstrated that the interaction of phosphoinositol-4-5-
biphosphate (PI4,5P2) with talin is crucial for clustering of integrins. PI4,5P2 reveals 
the integrin binding site on talin by inducing a conformational change upon its binding 
[135]. The focal adhesions help the cells to anchor to the surrounding ECM serving 
as an adhesion site and also help in the downstream signalling, which controls many 
cellular functions including cell spreading and cell movement (Figure 15). Normal 
cells, with the exception of leukocytes, require anchorage to a suitable matrix in order 
to survive and thus these cells are often called “anchorage dependent” [136]. Such 
cells usually undergo apoptosis when they do not have a suitable matrix to adhere to 
and this type of cell death is termed “anoikis” [137]. Integrins play a key role in 
controlling anchorage dependence. In many cancers, the transformed cells 
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overcome the integrin mediated cell death signals and continue to survive and 
proliferate. This is a characteristic feature of neoplastic transformation. Thus these 
adhesive interactions translate into cellular signals that result in processes such as 














Figure 15: Schematic diagram showing integrin activation and clustering of 
integrins. PI4,5P2 binds to talin and exposes the integrin binding site. Talin 
binds to the cytoplasmic tail of the integrin, thus activating it to form the pre-
adhesion complex (inside-out signalling). Integrins can also bind to its ligands 
(RGD) in the ECM and become activated. The integrin-talin complex clusters 
together to form focal adhesions, which are essential for cellular functions 
[139]. 
 
1.11.1  Inside-out signalling of integrins 
 
When a cell receives signals from other receptors, it can activate downstream 
signalling pathways. These signals can in turn interact with the cytoplasmic tail of the 
integrins and convert the integrin to its activated form. (e.g. c-Met binding to HGF can 
affect α6β4 activity [140]). The structural changes that cause the integrin to be 
activated alter the way the integrin interacts with the ECM [141]. This activation is 
crucial to modulate the affinity of integrins towards the ECM and the cell can regulate 
integrin adhesiveness to its ligand (affinity modulation). Receptor clustering can also 
be controlled by intracellular signalling, where the cell can remodel its cytoskeletal 
integrin complexes or change its receptor diffusion rates, which can also regulate the 
ability of the integrins to bind to its ligand (avidity modulation) [142]. The adhesive 
ability of integrins to bind to the ECM is regulated by altering its affinity for its ligands 
RGD 
Inactive form of integrin Activated form  of integrin Integrin clustering to form 
 focal adhesions 
Talin molecule 
PI4,5P2 




or its avidity (Figure 16). For example, R-RAS activation in cells can lead to 
increased affinity for binding to the ECM while H-RAS activation can have the 
opposite effect. Similarly, small GTP binding proteins Rac and Cdc42 can activate 
integrin clustering, thereby increasing integrin avidity [143]. Therefore, integrin 
activity is tightly regulated by affinity and avidity modulation through which cells 
control their ability to adhere, migrate or invade [144, 145].  
 
Some studies in the past have shown that “inside-out” signalling is initiated by the 
disruption of the non-covalent clasp or “salt-bridge” between the membrane proximal 
regions of the α and β cytoplasmic tails [103]. Point mutations in these cytoplasmic 
tails, in either one of the α and β subunits, can lead to constitutive activation of the 
receptor [146]. Springer and colleagues used leukocyte specific αLβ2 integrin to 
show that replacing the cytoplasmic transmembrane region between the tails 
inactivated the receptor, whereas breakage of the clasp activated the receptor [110]. 
The affinity and avidity modulation of integrins prevents excessive integrin-mediated 
signalling which, if left unchecked, could lead to profound pathological conditions. For 
example, constitutive activation of αIIbβ3 integrins could lead to spontaneous clot 
formation and thrombosis. Therefore a rigorous regulation of integrin mediated signal 











Figure 16: Schematic diagram of inside out signalling of integrins. Small GTP-
binding proteins play an important role in the regulation of “inside-out” 
integrin signalling. There is an increase in integrin affinity for its ECM upon 
activation of RRAS and the converse holds true when HRAS is activated. 
Integrin avidity is increased as a result of enhanced clustering due to 
activation of RAC, CDC42 and protein kinase C (PKC), which play an important 
role in cell migration. Figure from Hood, JD et al, 2002 [143]. 
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1.11.2  Outside-in signalling of integrins 
 
“Outside-in” signalling is considered to be a more ‘classical’ form of signal 
transduction and is initiated by ligand binding to the extracellular domain of the 
integrin (Figure 17). It can be divided into two broad categories – “direct signalling” 
and “collaborative signalling”. When a ligand binds to an integrin resulting in 
clustering of integrins, and if this is the only extracellular stimulus, it is often referred 
to as direct signalling. This can activate multiple cytoplasmic tyrosine kinases 
including focal adhesion kinase (FAK), serine threonine kinases like mitogen 
activated protein kinase (MAPK), small GTPases and induce lipid metabolism [147]. 
When the downstream signalling pathways that are activated as a result of ligand 
binding to integrins are modulated by other signalling events initiated through other 
receptors such as receptor tyrosine kinase, it is termed as collaborative signalling 
[147]. For example, α6β4 binding to laminin leads to an increased activation of 
human epidermal growth factor receptor 2 (HER2). Transformed epithelial cells, 
which express both α6β4 and HER2, have a proliferative and invasive edge 
suggesting that there might be an interaction between α6β4 and HER2 in carcinoma 
progression [148].  
 
When integrins binds to a ligand in the ECM they usually activate FAK, allowing 
activated SRC to bind, which then phosphorylates several tyrosines on FAK. These 
act as docking sites for other signalling molecules. For example, growth factor 
receptor bound protein 2 (Grb2) can bind to Y925 tyrosine residue on FAK, recruit 
SOS-1 and thereby activate RAS [149]. When FAK is activated it can also promote 
Src-dependent phosphorylation of Shc, which in turn can drive Grb2 to activate RAS 
[150]. RAS can activate MEK, ERK and PI3 kinase, as a result of FAK being 
activated due to integrin binding to its ligand. PI3 kinase can activate Rac and 
activated Rac together with Cdc42 regulates numerous biochemical pathways 
including those regulating the actin cytoskeleton. Together with activated ERK, the 
signalling leads to changes in the transcriptional activity, which ultimately can lead to 
regulation of cellular behaviour including differentiation, survival, migration and 
invasion (Figure 17) [143].  
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Figure 17: Schematic diagram showing outside-in integrin signalling in cells. 
When integrins bind to their ligand, it can phosphorylate FAK (activated), 
which in turn can activate growth factor receptor bound protein (GRB2). GRB2 
can activate RAS. FAK can also activate RAS in a SRC dependent manner, 
which can then recruit mitogen activated protein kinase (MEK) and 
extracellular signal regulated kinase (ERK). Activation of ERK leads to 
transcriptional activity and also affects the myosin light chain kinase (MLCK) 
activity. RAS can also activate PI3K and RAF pathways. Activated SRC 
phosphorylates CRK associated substrate (CAS), which allows it to bind to 
CRK and dedicator of cytokines 180 (DOCK180). RAC can be activated as a 
consequence, which together with activated cdc42 can regulate various 
cellular functions.  Picture from Hood, JD et al, 2002 [143].  
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1.12 Integrins and cancer 
 
Given that integrins bind cells to the ECM and can modulate cell growth, survival, 
migration and invasion, it would be expected that they are involved in cancer 
development and spread. Cancer cells often disseminate from their site of origin and 
move to a secondary location, a complex process known as metastasis. Thus the 
cells have to detach from their neighbouring cells and possibly the basement 
membrane, invade through a basement membrane, reorganise the ECM through 
which they migrate, often travel in the blood vessels or lymphatics, extravasate and 
proliferate once they reach the secondary site (Figure 18). For cancer cells to do this, 
the first step is to alter the expression or activity of their adhesion molecules, 
including their integrins that they express. For example, carcinoma cells reduce or 
lose expression of E-cadherin, thereby reducing cell-cell cohesion [151]. By up 
regulation of certain integrins binding to ECM ligands, cells can activate downstream 
signals, which will cause cancer cells to secrete proteases such as matrix 
metalloproteases (MMPs). For example, MMP9 secretion is up regulated by oral 
cancer cell ligation of the integrin αvβ6 [125]. This can aid invasion through the 
basement membrane and the stroma.  
 
Once cells have intravasated, they may bind to platelets via integrins [152]. This can 
help in their arrest in distant capillary beds and their survival. Some cancers express 
integrins that recognise endothelial cell markers. Thus melanomas express α4β1, 
which can bind to vascular cell adhesion molecule 1 (VCAM-1) on activated 
endothelial cells [153]. Once the tumour cells have arrested they may grow in the 
capillary and eventually burst it or they may extravasate and invade into the new 
stroma. The integrin-mediated adhesion contributes to growth, signalling and survival 



































Figure 18: Metastasis of cancer cells from primary tumour to a secondary site. 
Integrins are involved in almost all the stages of metastasis from the 
detachment of the cells from the basement membrane in the primary tumour, 
migration/invasion of the cells through the surrounding stroma, intravasation 
into the vasculolymphatic system, association with leukocytes and platelets in 
the blood/lymph vessels, extravasation and invasion into the new ECM 
(secondary site). Thus integrins are crucial for the cells to be able to 
metastasise. Picture taken from Michael, A and Bendas, G, 2011. 
 
1.12.1  Survival 
 
Normal adherent cells are programmed to undergo anoikis, which is apoptosis 
caused by the absence of adhesion, in the absence of a suitable ECM to bind to. 
Anoikis is caspase-dependent and is tightly regulated by integrin-mediated 
interactions with the ECM. The first step in anoikis is the inactivation of FAK/Src 
signalling, leading to a “switching off” of the RAS/PI3kinase/ERK pathway, which 
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usually provides the cell with pro-survival signals [154]. Once anoikis sets in, there is 
disassembly of the focal adhesions, which destabilises the cytoskeleton, leading to 
the activation of Bim and Bax (pro-apoptotic factors) [154]. This is soon followed by 
activation of “pro-apoptotic” proteins including pro-caspase 8. This begins the 
caspase cascade resulting in activation of executioner caspases (caspase 3) that 
can lead to degradation of DNA [155]. 
 
Cancer cells have survival mechanisms to ensure they can continue to proliferate by 
evading anoikis [156]. Cancer cells are not dependent on adherence to the ECM for 
their survival. Thus cancer cells often have activating mutations in growth factor 
signalling pathways that remove the need for cooperative adhesion signalling from 
integrins. Sometimes this anchorage independence may be a result of the 
interactions between integrins and other receptor tyrosine kinases. For example, 
α6β4 and c-Met are known to interact with each other in cancer cells to form a 
complex, shown by immunoprecipitation. Upon HGF stimulation, c-Met provides the 
additional signalling platform to activate FAK and RAS, regardless of the fact that 
α6β4 was not binding to laminin [140]. This study showed that cancer cells have the 
ability to turn integrins from adhesive proteins to non-adhesive integrators with other 
receptor tyrosine kinases to promote oncogenic signalling and survival. It was also 
reported that the downregulation of αvβ5, through upregulation of αvβ6, might protect 
SCCs from anoikis by activating the AKT survival signalling pathway [157].  
 
1.12.2  Proliferation 
 
Various pathways and multiple environmental factors including interaction of the cell 
with the ECM regulate normal cell proliferation. Most normal cells are anchored to 
the ECM and this is critical for cell proliferation. Loss of adhesion usually leads to a 
G1 phase cell cycle arrest and cell death [158]. Cancer cells, in contrast, often 
proliferate at a rapid rate, as this is crucial for formation of tumours and their spread 
to a secondary site. This is dependent on the ability of the cancer cells to detach 
from the ECM and still be able to survive. Together with various growth factors, 
integrins use multiple cytoplasmic signalling pathways, which are highly interwoven 
into complex networks, to regulate cell proliferation (Figure 19). It has to be noted 
that integrin signalling occurs via defined points of focal contacts as opposed to 
stimulation of pathways through soluble factors, which affect the entire cell. Integrins 
bind to their ligands and can activate various receptor tyrosine kinases, which in turn 
activate the ERK signalling pathway at multiple points [159]. Integrins can also 
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activate Rac and Cdc42 both directly and indirectly thereby affecting cell proliferation 
[160]. Integrins can also activate the PI3 kinase pathway mediated via FAK and 
Cdc42 [161] and also aid in actin polymerisation and organisation. These generate 
tension/mechanical force, which contribute to G1 cell cycle phase progression [162]. 
Cyclin D1 regulation through the ERK pathway modulation by integrins is one of the 


































Figure 19: Role of integrins in regulating cell proliferation. Note: activation of 
the Raf/MEK/ERK pathways happens at the cell membrane. Shown in the 
cytoplasm to avoid overcrowding. Picture from Schwartz et al, 2001. 
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1.12.3  Migration 
 
Migration involves the movement of cells along a gradient. In normal adults, cell 
migration is crucial for wound healing and maintaining immunity. However, 
uncontrolled migration can result in serious pathological situations like metastasis of 
cancer cells. Cell migration is a complex process, which occurs as a result of 
changes in the cytoskeleton, cell-substrate adhesion and ECM components. The 
Rho family of GTPases have been shown to play an important role in migration and 
there occurs a significant cross talk between the Rho family of GTPases and RAS. 
Integrins can activate RAS, which in turn can lead to the activation of Rho leading to 
the assembly of contractile actin myosin filaments (stress fibres) and associated focal 
adhesion complexes [163]. Rac, another member of the Rho family of proteins, also 
plays a role in the assembly of the actin filaments at the cell periphery, which aids in 
the formation of lamellipodia and membrane ruffles [163]. Filopodia (actin rich 
surface protrusions) formation has been shown to be induced by the activation of 
cdc42, also a member of the Rho GTPase family of proteins. Thus, the Rho family of 
proteins together with RAS activated by integrins plays an important role in cell 
migration.  
 
Cell migration can essentially be divided into five distinct steps (Figure 20). Extension 
of the lamellipodia at the leading edge is often the initiating step, which is followed by 
formation of new focal adhesion complexes. Several integrins have been shown to 
play a key role at this step, e.g. αvβ3 has been shown to be involved in migration and 
invasion of melanoma cells [164]. This is followed by secretion of proteolytic 
enzymes (MMPs), which modify the ECM and helps in the movement of cells through 
the ECM. The cell body contracts through the formation of the actin-myosin 
complexes (Rho-Rac-cdc42 activity) and moves forward towards a gradient (e.g. the 
surrounding ECM have proteins that are recognised by integrins and in turn favour 
migration) while the tail end of the cell is detached from the ECM, which has been 
shown to be regulated by a protease, calpain, which cleaves the focal complex 





































Figure 20: Schematic diagram showing cell migration. Picture modified from 
Parri, M et al, 2010 [166].  
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1.12.4  Invasion 
 
Invasion is the migration of cells through a non cell-permeable barrier usually 
towards a gradient (ECM proteins, blood vessels). In order for (epithelial) cancer 
cells to invade, they have to detach from the primary tumour mass, breach the 
basement membrane and invade into the surrounding stroma (Figure 21). The 
basement membrane is impermeable to cells under normal physiological conditions 
and is composed predominantly of collagen type IV, laminins, fibronectin, nidogens 
and heparan sulphate proteoglycans [167]. Invasion is a multifaceted process, which 
involves the modulation of cell adhesion, survival and directed migration [168].  
 
For cancer cells to invade and metastasise, they must dissolve the basement 
membrane, which is achieved by secretion of various proteolytic enzymes such as 
matrix metalloproteinases (MMPs). Type IV collagen, a predominant basement 
membrane protein, is a substrate for a variety of MMPs (-2, 3,7,9,12 and 19). Certain 
integrins have been shown to upregulate secretion or production of MMPs, in turn 
favouring cancer cell invasion. For example, αvβ6-positive oral squamous cell 
carcinoma cells have been shown to invade in an MMP9-dependent manner [125]. 
The invasive potential of these cells is acquired through a series of changes to the 
intra and intercellular signalling pathways along with widespread remodelling of the 
ECM. Different cancers express different integrins and, in some cases, there are 
variations in integrin expression between subtypes of cells within the same tumour. 
Therefore, it is hard to judge the effect of an individual integrin because of the 
extreme complex nature and the sheer number of signalling pathways that are 
involved in cellular invasion. Looking at published data over the years, there are 
many studies which link a certain integrin to certain cancers. For example, α2β1 has 
been linked to tumour progression and metastasis in melanoma [169], prostate [170] 
and gastric carcinoma [171] while the same integrin is expressed by normal breast 
epithelium and down regulated in breast cancer [172]. The fact that the same integrin 
is expressed by both normal and cancer cells shows that it has varied functions 
depending on the phenotype of the cell. It may have been downregulated during 
transformation of the breast epithelium because it supports a normal phenotype or 
inhibits cell growth but in transformed cells it plays an active role in tumour 
progression. There are several studies showing expression of a particular integrin 
correlating with cancer progression. For example, high expression of αvβ3 in 

















Figure 21: Schematic figure of cancer cells invading through the basement 
membrane into the surrounding ECM. Figure modified from Guo, W et al, 2004 
[116]. 
 
1.13 Integrin αvβ6 
 
Of the 24 different integrin heterodimers in humans, this study will focus on the 
epithelial specific integrin, αvβ6. This integrin is not constitutively expressed in 
healthy epithelia but is expressed de novo by many epithelia undergoing tissue 
remodelling processes such as wound healing, chronic inflammatory responses and 
carcinogenesis [175]. The αv subunit is coded at chromosome 2q31-q32. The β6 
subunit dimerises only with the αv subunit as a heterodimer and is located at 
chromosome 2q24-q31. Under reducing conditions the β6 subunit migrates on SDS-
PAGE gels at about 100-110kDa, whereas the αv subunit migrates at 130kDa [176]. 
As discussed later, the β6 subunit retains conserved domains that enable it to 
promote cytoplasmic signalling processes of αvβ6 [146, 177].  
 
1.13.1  Transcriptional regulation of αvβ6 
 
Not many studies have focused on transcriptional regulation of αvβ6. Ets-1 has been 
described as a transcription factor for the β6 gene ITGB6 and four potential Ets-1 
binding sites were identified in the first 1kb of the β6 promoter in humans [173]. Gel 
shift assays and site-directed mutagenesis showed Ets-1 bound strongly to site one, 
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αvβ6 is strongly expressed in wild type keratinocyte cells. Scott and colleagues 
showed that TNFα knock out mice had significantly lower expression of αvβ6 
expression in keratinocytes, compared with the wild type mice [178]. They went on to 
show that addition of recombinant TNFα to the TNF knock out mice resulted in an up 
regulation of expression of αvβ6 in keratinocytes in a dose dependent manner. Bates 
et al also suggested that TGFβ works together with TNFα to up regulate expression 
of αvβ6 [173]. Both the above-mentioned cytokines are known to work via the Ets-1 







Figure 22: Schematic diagram for β6 promoter. TSS is the transcription start 
site and translation starts at the ATG site. Site 1-4 shows the potential Ets-1 
binding site and its location. Consensus DNA binding sites, GGAA, are shown 
in bold. Figure taken from Bates et al, 2005 [173].   
 
Another potential transcriptional regulator for β6 is STAT 3 [179]. Several STAT 3 
binding sites have been discovered in the β6 promoter and these were confirmed 
using cross-linking immunoprecipitation assays [179]. The same authors also 
observed that increased expression of αvβ6 led to an increase in cell migration and 
anchorage-independent growth, characteristic features in cancer cells. It is also 
known that STAT 3 regulates expression of fibronectin and tenascin C, both of which 
are ligands of αvβ6 [179].    
 
1.13.2  Ligands for αvβ6 
 
The integrin αvβ6 is one of eight integrins that binds arginine-glycine-aspartic acid 
RGD motif in its target ligands. The principal ligand for αvβ6 is the pro-peptide of 
TGFβ-1 and TGFβ-3, called latency associated peptide (LAP). αvβ6 binds to the 
sequence RGDLXXI, found in LAP, but also to the closely related RGDLXXL found in 
the viral capsid proteins of FMDV and coxsackievirus A9 (CAV9) [51, 180]. αvβ6 also 
binds to fibronectin, vitronectin and tenascin-C [180]. The table below shows some of 





























Table 5: Main ligands of αvβ6 and the type of protein 
 
1.13.1  Sequence of the cytoplasmic tail of β6 
 
Most integrin β subunits have three highly conserved cytoplasmic domains, 
cytodomains -1, -2, and -3 as shown in Figure 23. These conserved regions are 
involved in recruitment of integrins to focal adhesions and play an important role in 
integrin affinity [112]. In addition there is an unique eleven amino acid C-terminal 
extension (EKQKVDLSTDC) specific to β6. 
  
Ligand Type of 
protein 
Reference  
Fibronectin ECM protein 
 
Busk et al, 1992  
Tenascin-C ECM protein Prieto et al, 1993 
Vitronectin ECM protein Huang et al, 1998 
LAP of TGF!-1 Cytokine Munger et al, 1999 
LAP of TGF!-3 
 
Cytokine Annes et al, 2002 










Williams et al, 
2004 
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Figure 23: Integrin β  subunit homology in cytoplasmic tails 
 
The cytoplasmic tail amino acid sequences of β1, β3, β6 subunits are compared 
using the single letter method for naming amino acids. The highly conserved 
(cytodomain 1, 2, 3) areas are highlighted in red and the unique C-terminal 11 amino 
acid extension for β6 is highlighted in green. This sequence has been reported as 
critical for several β6 dependent functions (Figure 23). The table below lists a few of 


























Table 6: Table showing reported functions of the β6 C terminal 11 amino acid 
tail.  
  
Function Cell type Reference 
Enhances cell proliferative 
capacity 
Colon carcinoma Agrez et, 1994 
Dixit et al, 1996 
Promote PKC-dependent 
MMP 9 secretion 
Colon carcinoma Niu et al, 1998 
Necessary for foot and 
mouth disease virus 
(FMDV) infection 
Colon carcinoma Miller et al, 
2001 
Essential for cell density 
dependent increase in 
beta 6 expression 
Colon carcinoma Niu et al, 2002 
Required for decrease in 
urokinase receptor 
expression and function 
Oral SCC Dalvi et al, 
2004 
Required for promotion of 
invasion through up 
regulation of MMPs 
Oral SCC Morgan et al, 
2004 
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1.13.2  αvβ6 signalling 
 
There are very few studies detailing the signalling pathways associated with ligation 
of the αvβ6 integrin. As with many other integrin studies, recent investigations on 
interaction of αvβ6 with other proteins have begun to shed more light on its effects on 
cellular functions. As discussed below, ERK-2 and Fyn are the only two ‘classical’ 
signalling molecules, which have been shown to bind directly to αvβ6 and, as a 
consequence, evoke a functional response down stream.   
 
1.13.2.1 Extracellular signal related kinases (ERK) 
 
A sub-family of mitogen activated proteins (MAPs), called ERKs are activated by 
phosphorylation of their tyrosine and threonine residues through signalling cascades 
originating from the plasma membrane [181, 182]. ERK 1 (p44) and ERK 2 (p42) are 
the most widely studied members of this sub-family of MAP kinases. Ahmed and 
colleagues performed an in vitro assay in colon carcinoma cells, where they 
observed an interaction between the last 130 amino acids of ERK2 (generated from 
a clone) and the β6 cytoplasmic domain (presented as a biotinylated peptide) using 
co-immunoprecipitation from soluble lysates. They also showed that deletion of the 
ERK 2 binding site (RSKAKWQTGTNPLYR) on the cytoplasmic tail of the β6 subunit 
reduced proliferation of cells compared to the control cells, suggesting that there 
might be a direct interaction between these two molecules. Moreover p42/p44 
signalling has been shown to be upregulated in cells expressing high levels of αvβ6 
[181, 183]. These authors also showed that binding of ERK 2 to the β6 subunit 
increased MMP 9 secretion, which is a proteolytic enzyme thought to be necessary 
for tumour progression [183]. This pathway can thus regulate the malignant potential 
of cancer cells and appears to require the direct binding of ERK 2 to the cytoplasmic 
domain of β6 (Figure 24).  
1.13.2.2 Src family kinase, Fyn 
 
Integrins have been shown to interact with, and initiate signal transduction through, 
tyrosine kinase phosphorylation including members of the Src family kinases (SFKs) 
[184]. The cytoplasmic tail of the β6 subunit has been shown to interact directly with 
a member of the Src family kinase protein, Fyn, which becomes activated upon 
integrin ligation [185, 186]. Studying oral carcinoma cells, Li and colleagues 
performed in vitro kinase assays, which showed that ligation of β6 to fibronectin, 
 78 
recruited Fyn and this activation was absent when an irrelevant substrate (i.e. 
substrate not recognised by β6) was used or when β6 was blocked using function 
blocking antibodies. They went on to show that the Fyn-β6 complex induced FAK 
phosphorylation which, in turn, was recognised by various FAK associated proteins. 
Activation of Fyn by β6 is also required for activation of another adaptor protein, Shc, 
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1.13.2.3 TGFβ activation and role of αvβ6 
 
Transforming Growth Factor β belongs to a family of cytokines that regulate cellular 
behaviour, migration, proliferation as well as gene expression [53]. It has 3 isoforms 
in mammalian cells, TGF-β1, 2, 3, each encoded by distinct genes. TGF-β is 
expressed in the inactive pro-peptide form covalently linked with the corresponding 
LAP at the N-terminus from which it has to be cleaved or exposed to become 
biologically active. This acts as a safeguard against inadvertent activation of TGFβ, 
which is anchored to the ECM, where it is sequestered. Thus, the matrix acts as a 
reservoir from which TGF-β can rapidly be recruited. TGFβ is often referred to as the 
“double edged cytokine” in cancer. It has been shown to be a tumour suppressor in 
the early stages of cancer by suppressing cell growth [187]. However in late stages 
of cancer, biochemical and genetic changes alter the TGFβ signalling pathway, 
which promotes cell growth, thus making it a tumour promoter. TGFβ is secreted at 
elevated levels by cancer cells and this has been shown to activate the surrounding 
stromal cells, which in turn can upregulate factors that favour tumour progression 
[188].  
 
Several integrins are reported to bind to LAP through recognition of the RGD motif. 
αvβ6 is rapidly upregulated by injury (wound healing) or inflammation [175]. While β6 
knock out mice do not develop lung fibrosis, despite exaggerated lung inflammation 
caused by bleomycin treatment [189]. The study went on to show that αvβ6 was a 
ligand for TGFβ1 and, by knocking out β6 in mice, there was a localised deficiency of 
active TGFβ1 leading to the lack of fibrosis. They also reported that conformational 
changes in LAP, caused due to the binding of αvβ6, led to activation of TGFβ rather 
than the cleavage of LAP peptide. Colon carcinoma cell lines with a mutated β6 
cytoplasmic tail were able to bind to LAP but could not interact with the actin 
cytoskeleton, hence transfected cells lost the ability to activate TGF-β [190]. TGF-β 1 
and 3 have LAP peptides, which contain an RGD sequence, whereas TGFβ 2 does 
not and hence cannot be activated by αvβ6.  Since activated TGFβ has a growth 
inhibitory effect on epithelial cells, it may seem confusing as to how αvβ6, which can 
activate TGF-β, can promote tumourigenesis [191]. However, studies have revealed 
the complex biphasic role of TGF-β in tumour biology.  
 
Even though there is a general consensus amongst scientists that TGFβ is a tumour 
suppressor in early stages of cancer and a tumour promoter in late stages of cancer, 
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there are no verified biomarkers to accurately define when a tumour has “switched” 
from seeing TGFβ as a tumour suppressor to a tumour promoter. This makes it a 
challenge to target TGFβ therapeutically. Often cancers acquire TGFβ pathway 
mutations as they progress; perhaps the best known is the loss of SMAD4 (deleted in 
pancreatic cancer, locus 4) (DPC4) in pancreatic cancer, where over 50% of late 
stage PDAC patients acquire SMAD4 mutations [52]. In early tumourigenesis of 
breast cancer, TGFβ is capable of inhibiting cell cycle progression via G1- arrest. 
The anti-proliferative effects are mediated by suppression of c-Myc through 
mobilisation of cyclin dependent kinase inhibitors p15, p21, p27 [192].  
 
In contrast, TGFβ is known to induce epithelial to mesenchymal transition (EMT), a 
process believed to be the transitional stage of non-invasive to invasive cancer [193] 
and is known to facilitate tumour growth indirectly by modifying the tumour 
microenvironment [53]. Tumour cells up regulate TGFβ secretion and this in turn can 
activate fibroblasts into myofibroblasts (cancer associated fibroblasts), which modify 
the ECM, alter angiogenesis and promote tumour growth [194, 195]. In an ongoing 
study of 355 patients with pancreatic cancer, either with locally advanced or 
metastatic disease, there was a significant correlation between levels of TGFβ in the 
plasma and overall survival. Overall survival of patients with high levels of TGFβ in 
the plasma (>19.05ng/ml) was 27.7 weeks versus 40 weeks for patients with low 
levels of TGFβ in the plasma (Milind JM et al, 2012, data not yet published. Data 
presented at ASCO 2012, poster 201). αvβ6 was found to be expressed more at the 
invasive front in oral squamous cell carcinomas (OSCCs) consistent with the 
likelihood  that β6 binds to LAP of TGF-β, frees it for modulating the 
microenvironment, thereby promoting tumour growth [196, 197]. With its broad range 
of biological activities the TGF-β signalling pathway has become one of the major 
therapeutic targets as a strategy towards controlling cancer. Unfortunately small 
molecule inhibitors of TGF-β receptor I resulted in high toxicity, including increased 
risk of colon cancer [173]. However local blockade of TGFβ activation by blocking 
αvβ6 may be a therapeutically viable scenario to treat advanced cancers to negate 
the pro-tumourigenic effects caused by TGFβ. 
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1.13.3   Role of αvβ6 in wound healing 
 
β6 mRNA is detected in human keratinocytes at the wound edge at an early stage of 
wound healing [175]. Detection of αvβ6 at a protein level occurs at a later stage, 
usually when epithelial integrity has been restored [198]. There is also a correlation 
of αvβ6 expression and TN-C expression leading to the suggestion that the principal 
functions of αvβ6 in wound healing are modulated through its interaction with this 
particular matrix protein [199]. α9β1 is also a ligand for TN-C and is known to induce 
proliferation in cells plated on TN-C. α9β1 is upregulated during early wound healing 
and is downregulated in the later stages, which coincides with the increased 
expression of αvβ6. Haapasalmi et al, 1996 suggested that the principal role of αvβ6 
is not related to the initial cell migration but is more critical after the initial movement 
of wound keratinocytes has occurred [198, 199]. This switch between integrin 
expression during different stages of tumour progression has been described 
previously in cancers. For example, there is a reciprocal expression of αvβ5 
(expressed in stratified squamous epithelia but down regulated in SCC) and αvβ6 
(expressed in SCC but not in normal epithelia).  
 
1.13.4   Expression of αvβ6 in carcinomas 
 
Carcinogenesis has been considered a deregulated form of wound healing as both 
phenomena have many biological processes in common [200]. αvβ6 overexpression 
was first described in OSCCs but since then this integrin has been shown to be up 
regulated in various carcinomas including colon, stomach, lung, breast and ovary 
[175, 181, 190, 201, 202]. αvβ6 protein is not expressed in normal adult tissue 
barring very low expression in the basal layer of the hair follicle in skin and the base 
of the crypt in the small gut [201]. Figure 25 shows the expression of αvβ6 in 













































Figure 25: Expression of β6 in carcinomas. The normal tissue on the left is 
completely negative while the brown membranous staining on cancer tissue 
indicates strong up regulation of αvβ6. Figures courtesy of Dr. John Marshall, 








αvβ6 expression was often found to be localised to the tumour-stroma interface or 
the invasive front [203]. It should be noted that, in the studies above, αvβ6 
expression was not detected or was very weak in the corresponding normal tissues. 
In oral leukoplakia patients, expression of αvβ6 meant that the progression to 
malignant disease had occurred, suggesting that αvβ6 expression may be useful in 
predicting malignant transformation of cells [201]. However about 85% of specimens 
of lichen planus (a mucocutaneous disease associated with a low risk of malignant 
change) also expressed αvβ6 suggesting that the mere expression of the integrin is 
not enough to drive malignant progression in some diseases [201].  
 
Since the initial observation in OSCCs, numerous studies of different carcinomas 
have correlated poor prognosis with αvβ6 expression. Elayadi et al, 2007 showed 
that 54% of lung cancer patients significantly up regulated expression of αvβ6 in the 
lung epithelium out of the 311 lung cancer patients in the study. They went on to 
show that αvβ6 can be used a prognostic marker for non small cell lung cancer 
(NSCLC) with the high expressers showing lower survival rates [204]. Similarly, 
Hazelbag et al, 2007 reported high to moderate expression of αvβ6 in 58% of 
cervical cancer patients out of a total of 85 patients studied. The authors reported 
that patients negative for αvβ6 had a 91% 5 year survival compared with 76% for 
moderate expressers and dropping to 54% in the strong expressers of αvβ6. In 
ovarian cancer, higher levels of αvβ6 have been correlated with progression of 
tumour grade [181] and in gastric cancer, it has been shown to correlate with lymph 
node metastasis [205]. Bates et al, 2005 showed that expression of αvβ6 correlated 
inversely with patient survival. Median survival of colorectal cancer patients with nil or 
very low expression of αvβ6 was up to 16.5 years compared with 5 years for high 
expressers of αvβ6 [173]. These data confirm that the persistent presence of αvβ6 


















































Table 7: Published data for expression of αvβ6 in carcinomas. ISH – In situ 
hybridisation; TN-C – Tenascin-C; LN-met – lymph node metastasis; NSCLC – 
non small cell lung carcinoma, IHC – immunohistochemistry; WB- western 
blotting; RT-PCR – Real time PCR.   
  
Gastric Kawashima et 
al, 2003 
38 47 IHC, RT-
PCR 
94% of positive 
carcinomas had 
LN mets 
NSCLC Smythe et al, 
1995 
51 50 IHC Good prognostic 
marker? 
Breast Arihiro et al, 
2000 
90 18 IHC, WB No grade 1 
tumours beta 6 
positive 
Ovary Ahmed et al, 
2002 






NSLC Elayadi et al, 
2007 
311 54 IHC Poor prognostic 
marker 









Breuss et al, 
1995 
30 90 ISH Normal tissue 
negative 
Jones et al, 1997 17 100 IHC 
Hamidi et al, 
2000 
5 80 IHC 41% expression 
in oral 
leukoplakia  
Impola et al, 
2004 
11 100 ISH Expression 
maintained in 
lymph mets 
Regezi et al, 
2002 
40 100 IHC Colocalised with 
TN-C 
Colon Bates et al, 2005 488 37 IHC Poor prognostic 
marker 




















1.13.1   Role of αvβ6 in tumour progression 
 
Expression of integrins by cancer cells often differs compared with their non-
transformed normal counterparts. Several integrins are reported as down regulated 
in neoplastic tissues. For example, αvβ5 expression is reduced in melanoma [164] 
and oral SCC, whereas α2β1 and α3β1 are reduced in colon and breast cancer 
[206].  In contrast, αvβ3 is upregulated in melanoma and glioblastoma and αvβ6 is 
up regulated in many carcinomas (Table 7). It is perhaps worth noting that in general 
the down-regulated integrins are associated with more static behaviour, whereas the 
upregulated integrins, e.g. αvβ3 and αvβ6, are associated with proliferation, 
migration and invasion.  
 
1.13.1.1 Role of αvβ6 in proliferation and survival 
 
Very little is known about the role of αvβ6 in modulation of cell proliferation. One 
study has shown that αvβ6 enhances proliferative capacity of tumour cells. Thus, 
SW480, an αvβ6-negative colon carcinoma cell line, when transfected with the gene 
for wild type β6 showed a remarkable increase in proliferation in 3D culture 
compared with identical cells transfected with a control plasmid [190]. These authors 
went on to show that the proliferative enhancement specifically was due to the 
presence of the unique 11 amino acid sequence of the β6 cytoplasmic tail. More 
recently, another group identified β6 as part of a “gene signature” in lung and 
pancreatic cancer cells that are dependent on mutant KRAS for their survival [207]. 
They have shown that depleting β6 in these “KRAS dependent” cell lines leads to 
apoptosis proving that β6 is crucial for cell survival in certain cancer cell types [207].  
In this latter study, results clearly highlight the role of αvβ6 in pancreatic cancer cell 
proliferation and survival (to be discussed later). This makes β6 a prime therapeutic 
target in cancers. 
 
1.13.1.2 Role of αvβ6 in migration 
 
Since αvβ6 binds to both fibronectin and vitronectin, it makes it a key player in 
cellular migration. Huang et al showed that β6 knock out keratinocytes migrated less 
readily compared to the wild type keratinocytes [208]. Transwell® migration assays 
performed to study haptotactic migration of oral squamous cell carcinoma cell lines 
showed that αvβ6 promoted migration towards fibronectin [209]. Both groups 
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performed proliferation assays in addition to migration assays to confirm that the 
difference in cell numbers observed were a true reflection of the influence of αvβ6 on 
cellular migration. There is also a study which reported that αvβ6 mediated Fyn 
activation correlated with increased migration [185].  
 
1.13.1.3  Role of αvβ6 in invasion 
 
Transwell® invasion assays were used to study a panel of oral squamous cell 
carcinoma cell lines, which express varying levels of αvβ6 [209]. Their results 
showed that, the higher the levels of αvβ6, the higher the levels of invasion through 
Matrigel™. These authors confirmed the specificity of the role of αvβ6 by using 
specific blocking antibodies to block the function of αvβ6 and showed a reduction in 
invasion compared with a control antibody [209]. In a separate study, the same 
authors demonstrated that malignant keratinocytes with high expression of αvβ6 up 
regulated secretion of type IV collagenases (pro-MMP-9 and pro-MMP-2), shown by 
zymographic examination [210]. They went on to show that blocking αvβ6 or αv 
alone significantly decreased MMP-9 activity and cell invasion. Li et al, showed that 
activation of the Fyn-FAK complex through αvβ6 leads to the activation of Shc and 
the Raf-ERK/MAPK pathways which, in turn, promoted the transcriptional activation 
of the MMP-3 gene leading to increased in vitro proliferation of OSCC cells and 
increased metastasis in animal models [185]. These data, together with other 
published literature linking αvβ6 expression in various solid cancers to poor 
prognosis and dismal survival rates, suggest strongly that αvβ6 is a major driver of 
tumour progression. 
 
1.14 αvβ6 in pancreatic ductal adenocarcinoma 
 
The last decade has seen a handful of publications linking αvβ6 and pancreatic 
cancer. As mentioned earlier, many solid cancers express αvβ6 including PDACs. In 
the initial study showing αvβ6 expression in PDACs, all 34 of the PDAC cases 
stained for αvβ6 expression were strongly positive [201]. The authors of this study 
also observed that αvβ6 was expressed at higher levels in the well differentiated 
tumours compared to the poorly differentiated tumours. They went on to check for 
some of the major known ligands of αvβ6, fibronectin and tenascin-c, in the small 
number of PDAC cases and found no correlation between their presence in the ECM 
and αvβ6 expression [201]. Their findings indicated that αvβ6 positive PDAC cell 
 87 
lines tend to form spheroids when cultured in vitro.  KRAS is a frequently mutated 
oncogene occurring in about 20% of solid cancers. Most pancreatic 
adenocarcinomas have a mutant KRAS and it is a very potent tumour initiator [207]. 
Most of the pancreatic adenocarcinoma cell lines harbour KRAS mutations, the most 
frequent being a single nucleotide mutation at codon 12. Singh et al, 2009, 
established a “gene expression signature” in a panel of PDAC cell lines by dividing 
them into two groups based on their requirement for activated KRAS for cell growth 
in vitro. Gene microarray studies revealed a sub set of genes, which included Syk, 
RON-β, MST1R and integrin β6 (ITGB6) subunit, which were also required by cell 
lines dependent on activated KRAS for cell viability. These authors went on to show 
that β6 is strongly associated with a well differentiated KRAS driven phenotype [207]. 
Efforts to develop drugs to target KRAS have been challenging due to the difficulty in 
targeting a specific down stream RAS GTPase but these signature genes, including 
β6, could have implications as a potential therapeutic targets in pharmacologically 
intractable cancers like PDACs. PDACs tend to have a very high desmoplastic 
response compared to other cancers. In some cases, almost 70%-80% of the tumour 
is comprised of stroma. Since chronic expression of αvβ6 leads to chronic activation 
of TGFβ and thus fibrosis in lung [189] and kidney [211], it is likely that αvβ6 
contributes to the desmoplasia seen in PDAC. 
 
Very recently published data using a transgenic mouse model for PDAC show that 
targeting TGFβ using a blocking antibody led to an increase in tumour growth. The 
authors also targeted αvβ6, using a αvβ6 blocking antibody, and found that it too 
induced tumour progression [212]. These data may highlight that TGFβ may 
suppress early pancreatic cancer growth. It should be noted that the murine model 
used in the above mentioned study are Kras-p53Lox+ (mutant Kras and p53 knockout) 
with homozygous deletion of Smad4 and these animals give rise to tumours from 
cystic precursors as opposed to tumours formed by progressing through PanINs 
[213]. These mice form fairly large pancreatic tumours at approximately 10 weeks, 
which is when most of their antibody treated animals were terminated. As mentioned, 
the mice were p53 null, whereas human PDAC has mutant p53. It has been shown 
that accumulation of mutant p53 can help overcome growth senescence and drive 
metastasis in another mouse model for PDAC [49]. This study highlights the 




1.15 Current treatment options available to PDAC patients 
 
Treatment options for PDAC patients depend on multiple factors including stage and 
extent of disease (mainly two factors: distant spread, involvement of local vessels 
such as portal/mesenteric vein and/or celiac/superior mesenteric artery) and also the 
general fitness of the patient. The only potentially curable option available to patients 
is surgical resection of the pancreas, which is available for only about 20% of the 
individuals who present with the disease [7]. There are different surgical options 
available to these patients who can undergo surgery. The “Kausch-Whipple 
procedure”, also known as the proximal pancreaticoduodenectomy with antrectomy, 
or the “Traverso-Longmire procedure” also known as the pylorus-preserving 
pancreaticoduodenectomy, are the most common surgical procedures used to 
remove tumours from the head of the pancreas, which may improve the quality of life 
of the patient and help increase the survival rate [214]. For tumours that arise in the 
body or the tail of the pancreas, a left pancreatectomy combined with a splenectomy 
might be appropriate [215]. Chemotherapy and radiotherapy can be used as a 
palliative treatment as well as in the adjuvant setting after surgical resection. Surgery 
can also be used for palliation, usually when endoscopic and percutaneous methods 
are unsuccessful in relieving biliary and/or duodenal obstruction.  
 
Gemcitabine-based chemotherapy is the current standard treatment option available 
to patients with locally advanced unresectable disease or those with metastasis. This 
has been shown to increase overall survival rate and quality of life of patients [216]. 
Chemoradiation and 5-fluorouracil-based chemotherapy maybe useful in some 
instances. Some patients who respond well to the above combination of drugs may 
also be treated with a gemcitabine combination and a platinum analogue 
chemotherapeutic drug like oxaliplatin or cisplatin [217]. Recent data suggest that 
FOLFIRINOX based chemotherapy [218] as well as nab-paclitaxel chemotherapy 
(von Hoff, GI ASCO 2013) may give survival advantage over gemcitabine alone 
therapy.  
 
For patients with metastatic disease, who account for 50%-55% of cases, there are 
very limited treatment possibilities and often palliation is the only option available. 
These patients have a very short survival rate, ranging from three to six months, 
depending on the tumour burden and performance status at the time of presentation 
[22]. Inserting a stent or a surgical bypass in the bile duct relieves any gastric 
obstruction and these individuals who are operated upon usually receive gemcitabine 
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monotherapy. If patients respond to this, they are given a combination of gemcitabine 
and cisplatin or oxaliplatin. Co-therapy with the EGFR inhibitor, erlotinib has been 
shown to improve survival rates marginally compared with gemcitabine alone [219].  
 
1.16 Potential novel therapies 
 
The treatment options available to pancreatic cancer patients have not shown 
significant improvement over the last forty years. The last major change in treatment 
of pancreatic cancer was in 1997, when gemcitabine in combination with fluorouracil 
was introduced and this regimen marginally increased survival rates and reduced 
associated side effects such as weight loss and pain reduction in patients who 
presented with advanced disease [220]. Poor prognosis of PDAC means any clinical 
trials where new agents are used to target the cancer, either on their own or in 
combination with gemcitabine, bring about only a modest improvement in survival. 
However, very recent data using a combination drug regimen consisting of 
oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) used in combination 
with gemcitabine have given a significant improvement in overall survival (11.1 
months) compared with gemcitabine treatment alone (6.8 months) in PDAC patients 
with metastasis [218]. In recent years, scientific research is helping to understand the 
disease at a molecular level and there are now new agents, which are developed 
particularly to target specific pathways. One such drug is the EGFR inhibitor, 
erlotinib, which is a small molecule inhibitor that binds to the ATP binding site on the 
kinase domain of EGFR and thereby preventing its downstream signalling [219]. The 
original trial was performed in patients with advanced disease and there was a 
marginal but significant increase in median survival of 6.24 months compared to 5.91 
months in the gemcitabine treated group alone (p=0.03). Since EGFR is expressed 
by a variety of cells in the body, there was a marked increase in toxicity and the drug 
has proven difficult to manage in the clinic.  
 
Other novel therapies, which are in phase III trials for people with advanced 
pancreatic disease include cetuximab, a monoclonal antibody targeting EGFR used 
as a single agent, which so far has not shown a significant difference in overall 
survival (6.3 months) of PDAC patients compared with patients treated with 
gemcitabine alone (5.9 months) [221]. Bevacizumab (Avastin), another monoclonal 
antibody targeting VEGF, when used in combination with gemcitabine did not show 
any difference in the overall survival (5.8 months) compared with 
gemcitabine/placebo control group (5.9 months) in PDAC patients in a phase III 
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clinical trial [222]. Small molecule inhibitors of the RAS pathway (tipifarnib) MMP 
inhibitors and inhibitors of the gastrin pathway are some of the other novel small 
molecule inhibitors which are in clinical trials at the moment to treat PDAC patients 
[223]. Many of the above-mentioned agents showed very promising results in vitro 
and in some cases in vivo but did not show any promising improvements in clinical 
outcome. Thus, there remains an urgent need to try and develop new agents to 
target PDAC specifically and efficiently to improve therapy of this disease. This thesis 
will be focusing on studying the role of integrin αvβ6 in PDAC and using it as a 
potential therapeutic target for the treatment of pancreatic cancer.   
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1.17  Aims 
 
This study will aim to:- 
 
Study the expression of αvβ6 in a panel of well differentiated and poorly 
differentiated PDAC cell lines.  
 
Establish the functional role of αvβ6 in PDAC cell lines with particular emphasis on 
possible roles in proliferation, adhesion, migration and invasion, which are known key 
functions modulated by αvβ6 in many carcinomas.  
 
Evaluate the expression of αvβ6 in human PDAC tissue samples and correlate 
expression levels of αvβ6 with available clinical follow up data.   
 
Generate pancreatic cancer xenograft models (subcutaneous and orthotopic), which 
are physiologically relevant and replicate the human disease, using human PDAC 
cell lines expressing αvβ6.  
 
Investigate the potential of αvβ6 as a new therapeutic target in PDAC using the novel 
xenograft models by giving a function-blocking antibody at physiologically relevant 








MATERIALS AND METHODS 
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2. Materials and methods  
 
2.1. Cell culture and cell lines 
 
All the pancreatic cancer cell lines and stromal cell lines used in this study grew as 
adherent monolayers, in 100% humidified atmosphere of 8% (volume/volume) of 
carbon dioxide (CO2) / air. Cell lines were tested routinely for, and found free of, 
Mycoplasma and were cultured in sterile tissue culture flasks (Corning life sciences, 
USA) of various sizes (T-25, T-75, T-175 cm2 of surface area as required).  
 
2.1.1 Pancreatic Cancer Cell lines 
 
All cancer cell lines were grown in Roswell Park Memorial Institute (RPMI) -1640 
medium or Dulbecco’s Modified Eagle Media (DMEM) (PAA Laboratories, E15-842; 
E15-843) supplemented with 10% foetal calf serum (FCS) (Biosera) and glutamine 


















Table 8: List of pancreatic cancer cell lines used in this study [224-232]. The 
genetic identity of each cell line was confirmed by STR-profiling (short tandem 
repeats). (Mutation and differentiation status of some cell lines were not known).   
Name Derivation Differentiation Mutations Growth 
Medium 
Reference 
AsPc1 Ascites Poor KRAS, p53, 
p16 






p53 RPMI 1640 Tan MH et al 
Capan1 Liver met Well BRCA-2 RPMI 1640 Fogh J et al 
CFPac1 Liver met Well KRAS, 
DPC4 
RPMI 1640 Schoumacher 
RA et al 
Colo357 Lymph node 
met 
Well - DMEM Morgan R et 
al 




Poor KRAS, p53 RPMI 1640 Yunis AA et al 
Panc04.03 Primary 
tumour 




Poor KRAS, p53, 
p16 











Table 8 summarises all the cell lines used in this study together with the media 
requirements, differentiation status (at the time of origin) and known associated 
mutations. The four cell lines used most regularly for in vitro experiments are detailed 
below. 
 
CFPac1 (CRL-1918 – ATCC) [227] is a well-differentiated epithelial cell line derived 
from a liver metastasis from a patient with pancreatic cancer and cystic fibrosis. It 
possesses mutations in K-Ras (G12V), p53 and methylated INK4A, along with the 
most common mutation in CFTR (CFTRΔF508).  
 
Panc04.03 (CRL-2555 – ATCC) [231] is a well differentiated epithelial cell line 
derived from a primary tumour from the head of the pancreas of a male patient. It 
harbours a K-Ras mutation (G12A). 
 
MiaPaCa2 (CRL- 1420 – ATCC) [230] is a poorly differentiated epithelial cell line with 
p53 and K-Ras mutations at codon 12 (G12C), derived from tumour tissue of the 
pancreas obtained from a male patient. 
 
Panc1 (CRL-1469 – ATCC) [232] is a poorly differentiated epithelial cell line derived 
from a primary tumour with mutated K-Ras (G12D), p53 and INK4A.  
 
2.1.2 Pancreatic Stromal cells 
 
Human pancreatic stellate cells (PSCs) were first isolated through the outgrowth 
method from fibrotic regions of the pancreas surgically resected from patients with 
chronic pancreatitis [78]. Another laboratory also identified pancreatic stellate cells at 
the same time and demonstrated that they played a crucial role in the desmoplastic 
response observed in pancreatic cancer [77] [86].   
 
In our laboratory, non-tumourigenic pancreatic stellate cells were isolated using the 
outgrowth method from an adult male human pancreas (donation for transplantation) 
donated by the UK human Tissue Bank (Ethics approval; Trent MREC 
(05/MRE04/82). The resulting cell strain, called FS1, was verified for characteristic 
markers of stellate cells, such as the presence of lipid droplets in the cytoplasm, 
expression of GFAP, desmin, vimentin and αSMA as published previously. Stellate 
cell line FS1 was immortalised using ectopic human telomerase reverse 
transcriptase (hTERT) expression by Dr.Fiona Li and Ms. Jennifer Saddle and were 
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named FS1hTERT or PS1 cells after confirmation of immortalised cell telomerase 
activity by TRAP assay and continuous passage over a period of six months without 
loss of phenotypic characteristics.   
 
PS1 cells were grown in a 1:1 mixture of DMEM (PAA, E15-843) and Ham’s F12 
(PAA Laboratories, E15-817) supplemented with 10% FCS, glutamine (4mM final 
concentration) and 1µg/ml puromycin (Sigma, P9620), as a selection agent.  
 
2.2 Routine Cell Culture 
 
The cultures were examined daily under an inverted phase contrast microscope 
(Olympus IMT-2; Olympus Opticals, Welwyn Garden City), their morphology noted, 
(e.g. dendritic-like appearance for stellate cells). This acted as a check as to how 
confluent the cells were (cell density) before being passaged and re-plated at a lower 
density. Old medium was removed and cells were washed with phosphate buffered 
saline (PBS) (CR-UK services). PBS was replaced with 0.25% (w/v) trypsin/5mM 
EDTA (PAA Laboratories, L11-003) and flasks were placed at 37ºC for 5 – 15 
minutes depending on the cell line. Once all the cells had detached (confirmed by 
microscopy) 5 – 10X volume of serum-containing growth medium was added to 
inactivate the trypsin. Cells were pipetted repeatedly to ensure a homogenous single 
cell suspension. A fraction of the cell suspension was then transferred to fresh flasks 
with fresh medium.  
 
2.2.1 Counting Cells 
 
A disposable haemocytometer (Fast Read102™, #BVS100H, Immune systems, UK) 
was used to determine cell counts. A small volume of cell suspension (10µl) was 
isolated from a diluted suspension and mixed thoroughly with trypan blue (0.04% 
final concentration) for a minimum of 2 minutes. Live cells exclude the dye and 
appear unstained while dead cells, which have permeabilised membranes, appear 
blue. The average number of cells in a square was determined.  
 
Total cells/ml = average cell count/1mm square x dilution factor x 104. 
Total cells = total cells/ml x original volume from which sample was removed. 
% Viability = Total number of live cells (unstained) x 100 / total number cells counted. 
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2.2.2 Preservation of Cells 
 
Cells detached by trypsination (trypsin/EDTA) were centrifuged (1200rpm for 3 
minutes) and resuspended to 1 – 10 x 106 per ml of freezing medium (70% DMEM, 
20% FCS, 10% DMSO) in Nunc cryotubes. Cells were cooled slowly in a freezing 
box (1 degree a minute) (Eprak Scotlab, Scotland) at -80°C to prevent ice crystal 
formation. Cells were then left at - 80°C overnight. Then cryovials were transferred to 
liquid nitrogen (-196°C) for long-term storage.  
  
When required, the frozen cryovials were transferred directly to a 37°C water bath. 
As soon as the cells thawed out, they were diluted with 10 volumes of fresh growth 
medium and centrifuged (1200 rpm for 3 minutes). The pellet was re-suspended in 


























5E8D9 !1 Mouse Chemicon NA 10µg/ml 
P1E6 !2 Mouse Chemicon NA 10µg/ml 
P1D6  !5 Mouse Chemicon 10µg/ml 10µg/ml 
62oW "6 Rat CRUK 10µg/ml NA 
62G2 "6 Mouse Biogen 5µg/ml NA 
C19 "6 Goat Santa Cruz 1:1000 NA 
23C6 !v"3 Mouse Chemicon 10µg/ml 10µg/ml 
P1F6 !v"5 Mouse Chemicon 10µg/ml 10µg/ml 
10D5 !v"6 Mouse Chemicon 10µg/ml 10µg/ml 
53a.2 !v"6 Rat CRUK 10µg/ml 10µg/ml 
264RAD !v"6 Human Astra 
Zeneca 
NA 10µg/ml 
14E5 !v"8 Mouse Collaborator NA 1:100 
Anti-!SMA !SMA Mouse Dako 1:300 NA 
Anti-GFAP GFAP Mouse Sigma 1:500 NA 
Anti-Ki67 Ki67 Rabbit Novocastra 1:200 NA 
Anti-HSC70 HSC70 Mouse Santa Cruz 1:5000 NA 
W6/32 MHC I Rat CRUK 10µg/ml NA 
Negative 
Control 


















Table 9: List of primary antibodies used for experiments 
IF – Immunofluorescence, IHC- Immunohistochemistry, WB- Western Blot, Flow – 















Table 10: List of secondary antibodies used for experiments 
IF – Immunofluorescence, IHC- Immunohistochemistry, WB- Western Blot, Flow – 









5E8D9 !1 Mouse Chemicon NA 10µg/ml 
P1E6 !2 Mouse Chemicon NA 10µg/ml 
P1D6  !5 mouse Chemicon 10µg/ml 10µg/ml 
62oW "6 rat CRUK 10µg/ml NA 
62G2 "6 mouse Biogen 5µg/ml NA 
C19 "6 goat Santa Cruz 1:1000 NA 
23C6 !v"3 mouse Chemicon 10µg/ml 10µg/ml 
P1F6 !v"5 mouse Chemicon 10µg/ml 10µg/ml 
10D5 !v"6 mouse Chemicon 10µg/ml 10µg/ml 
53a.2 !v"6 rat CRUK 10µg/ml 10µg/ml 
264RAD !v"6 humanised Aztra 
Zeneca 
NA 10µg/ml 
14E5 !v"8 mouse Collaborator NA 1:100 
Anti-!SMA !SMA Mouse Dako 1:300 NA 
Anti-GFAP GFAP Mouse Sigma 1:500 NA 
Anti-Ki67 Ki67 Rabbit Novocastra 1:200 NA 
Anti-HSC70 HSC70 Mouse Santa Cruz 1:5000 NA 
W/632 MHC I rat SantaCruz 10µg/ml NA 
Negative 
Control 





IgG mouse Dako 10µg/ml 10µg/ml 
Antibody/
Clone 




5E8D9 !1 Mouse Chemicon NA 10µg/ml 
P1E6 !2 Mouse Chemicon NA 10µg/ml 
P1D6  !5 Mouse Chemicon 10µg/ml 10µg/ml 
62oW "6 Rat CRUK 10µg/ml NA 
62G2 "6 Mouse Biogen 5µg/ml NA 
C19 "6 Goat Santa Cruz 1:1000 NA 
23C6 !v"3 Mouse Chemicon 10µg/ml 10µg/ml 
P1F6 !v"5 Mouse Chemicon 10µg/ml 10µg/ml 
10D5 !v"6 Mouse Chemicon 10µg/ml 10µg/ml 
53a.2 !v"6 Rat CRUK 10µg/ml 10µg/ml 
264RAD !v"6 Human Astra 
Zeneca 
NA 10µg/ml 
14E5 !v"8  Collaborator  1:100 
Anti-!SMA !SMA  Dako 1:300 NA 
Anti-GFAP GFAP M  Sigma 1:500 NA 
Anti-Ki67 Ki 7 Rabbit Novocastra 1:200  
Anti-HSC70 HSC70 M  Santa Cruz 1:5000  
W6/32 MHC I Rat CRUK 10µg/ml  
Negative 
Control 
IgG Human Astra 
Zeneca 
NA / l 
Negative 
Control 



























Goat Dako 1:1000 NA 
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2.4 Introduction of siRNA duplexes into cells using 
Oligofectamine™  
 
Oligofectamine™ reagent (Invitrogen) is a lipid based transfection reagent, which 
interacts efficiently with oligonucleotides to form transfection complexes, and is used 
for transfecting cells. Manufacturer’s instructions were followed for transfections.   
 
Custom SMARTpool siRNA oligonucleotides targeting β6 integrin gene (ITGB6) were 
purchased from Dharmacon RNA technologies, USA (MQ-008012-01-0002) and 
were re-suspended in 1X siRNA buffer (100mM KCl, 30mM Hepes-pH 7.5, 1mM 
MgCl2 to a 20µM stock solution) and then stored at -20°C until used.  
  
Cancer cells were seeded into 6 well plates (5x104 cells/well) in growth media such 
that, after 24 hours, the cells were approximately 30%-40% confluent, which is 
optimal for transfection. For each 6 well plate, the following solutions were prepared. 
To 1188µl of Optimem™ (Invitrogen) was added 33µl of ITGB6 siRNA or control non-
targeting siRNA from the 20µM stock. The final concentration of siRNA used for the 
transfection was 100nM. In another tube (tube 2) 79.2µl of Optimem™ was added 
to19.8µl of Oligofectamine™ and mixed gently. After 10 minutes at room temperature 
the siRNA mixture was added into tube 2, mixed gently and incubated at room 
temperature for 20 minutes. Meanwhile, the medium on the cells was removed and 
washed with fresh Optimem™ (twice) before adding 800µl of Optimem™ per well. 
Finally, 200µl of the transfection mixture was added to each well and the cells were 
incubated for 4 hours at 37°C. 500µl of medium with 30% FCS was added and left at 
37°C for 48 hours before harvesting.  
 
2.4.1 Introduction of shRNA (short hairpin RNA) into cells to 
knock down αvβ6 
 
The ITGB6 shRNA targeting sequence was in a pGIPZ lentiviral vector driven by a 
CMV promoter (Figure 26). The vector also had a turbo-GFP as a read out to 
measure the levels of expression. The vector contained both puromycin and zeocin 
antibiotic selection for eukaryotic and prokaryotic selection respectively. HEK 293 FT 
cells were used to make the lentivirus, which carried the expression vector with the 












Figure 26: Schematic diagram of the vector with the shRNA sequence. (Figure 
from Open Biosystems ltd). 
CMV Promoter - RNA Polymerase II promoter 
cPPT - Central Polypurine tract, helps translocation into the nucleus of non-dividing 
cells 
WRE - Enhances the stability and translation of transcripts 
turbo GFP - Marker to track shRNAmir expression 
Puror – Puromycin - Mammalian selectable marker  
AMPr – Ampicillin - bacterial selectable marker 
5'LTR - 5' long terminal repeat 
pUC ori - High copy replication and maintenance in E.coli 
SIN-LTR - 3' Self inactivating long terminal repeat 
RRE - Rev response element 
ZEOr - Bacterial selectable marker 
 
The shRNA sequences to knock down ITGB6 (β6) were purchased from open 
biosystems (Thermo fisher, UK).  
 
1) Hairpin sequence for V3LHS_374278  (mir-30 context sense loop antisense) 
TGCTGTTGACAGTGAGCGAATGCTGAAAGATTCAATGAAATAGTGAAGCCACAG
ATGTATTTCATTGAATCTTTCAGCATCTGCCTACTGCCTCGGA 
Mature Sense for V3LHS_374278 
TGCTGAAAGATTCAATGAA 
Mature Anti sense for V3LHS_374278 
TTCATTGAATCTTTCAGCA 
 
2) Hairpin sequence for V3LHS_374274 (mir-30 context sense loop antisense) 
TGCTGTTGACAGTGAGCGAAAGCTGCTGTGTGTAAGGAAATAGTGAAGCCACA
GATGTATTTCCTTACACACAGCAGCTTGTGCCTACTGCCTCGGA 
Mature Sense for V3LHS_374274 
AGCTGCTGTGTGTAAGGAA 




3) Hairpin sequence for V3LHS_374276 (mir-30 context sense loop antisense) 
TGCTGTTGACAGTGAGCGCCTGGTACAAAACAACGTGTTATAGTGAAGCCACAG
ATGTATAACACGTTGTTTTGTACCAGTTGCCTACTGCCTCGGA 
Mature Sense for V3LHS_374276 
TGGTACAAAACAACGTGTT 
Mature Antisense for V3LHS_374276 
AACACGTTGTTTTGTACCA 
 
The lentivirus containing the shRNA sequence was generated over a period of four 
days.  
DAY1: HEK293T cells were seeded at one million cells per well 24 hours prior to 
transfection in a T75. (Cells should be sub-confluent at the time of transfection and 
numbers may need to be adjusted according to the cell line used). 
 
DAY2: Transfection: The shRNA sequences were diluted in a total volume of 15ml 
with TE buffer (pH 8.0) at a final concentration of 1.5µg. 200µl of Optimem™ was 
added to 10µl Fugene and mixed carefully with the packaging vector and target 
sequences. The mixture was left at room temperature for 15 minutes and 
Optimem™/fugene/shRNA mix was added to the cells carefully and the plates were 
incubated overnight at 37°C.   
DAY3: 24 hours following transfection, the medium in the plates was replaced with 
8ml of fresh growth media.  
DAY4-6: virus collection: The supernatants from the plates were collected on days 
4, 5, 6 and stored at -80°C. Fresh growth medium was added to the plates following 
the collection of each supernatant. 
 
Infection with lentivirus: 
The supernatant containing the lentivirus with the shRNA targeting ITGB6 was used 
to knock down β6 expression in β6 positive PDAC cell lines.   
DAY1: Target cells were seeded into a T25 flask, which were sub-confluent the next 
day.  
DAY2: Infection: The growth medium was replaced with 2ml of fresh growth 
medium containing the shRNA encoding lentiviral particles + 2µl (1:1000) of 
polybrene and incubated at 37°C for 4 h following which an additional 2 ml of fresh 
growth medium was added and left overnight. 
DAY3: 24 hours later, the medium was replaced with 4ml of fresh growth medium 
containing 1.25µg/µl puromycin, a selection marker for the transfected cells.   
Cells were later analysed using flow cytometry for levels of GFP and αvβ6 
expression. 
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2.5 Polymerase Chain Reaction (PCR) 
 
2.5.1 Isolation of RNA and cDNA synthesis 
 
A Qiagen RNA extraction kit (Qiagen#74106) was used for lysing cells to extract 
RNA. Cells were trypsinised, counted and re-suspended to the required 
concentration. Cells were pelleted and lysed using the lysis buffer (RLT buffer) 
provided with the kit. One volume of 70% ethanol was added to the homogenised 
lysate and mixed well. The suspension was then transferred to a RNEasy spin 
column, provided with the kit, which then was centrifuged at 8000g for 15 seconds. 
The flow through was discarded. The spin column membrane containing the 
homogenised lysates were then washed in RW1 buffer, provided with the kit, to get 
rid of any DNA contamination. This was followed by a wash in RPE buffer, provided 
with the kit, by centrifugation for 2 minutes at 8000g. The last step was to add 
RNAase free water to the spin column with a new collection tube and this was spun 
at 8000g for 1 minute to elute the RNA. The quality and quantity of RNA was 
measured using a NanoDrop spectrophotometer (OD 260/280 ratio > 1.80) as well as 
run on an agarose gel to control for contamination with genomic DNA. For detailed 
protocol, see manufacturer’s guide (Qiagen). cDNA was synthesised from extracted 
RNA, using Superscript III First Strand Synthesis kit using random hexamers, 
according to manufacturer’s instructions (Invitrogen, #18080-051).  
 
2.5.2 Quantitative Real Time PCR 
 
The SensiFAST™ Probe Hi-ROX One-step kit (Bioline BIO-77005) was used for first-
strand c-DNA synthesis followed by real time PCR in a single tube. The kit has been 
optimised for use with the ABI7900HT (Invitrogen) real time instrument. Primers were 
designed using the primer design tool, (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/) NCBI. Care was taken to make sure that the primers had a melting 
temperature (TM) of about 60°C and were intron-spanning to avoid any possible 
amplification from genomic DNA. The primers were used at a final concentration of 
400nM. 100ng of RNA was used per 20µl reaction. The master mix was prepared 
following instructions provided with the kit. Cycle times were optimised, one cycle at 
45°C for 10 minutes (reverse transcription), one cycle at 95°C for 2 minutes to 
activate polymerase and 40 cycles of 95°C for 5 seconds (denaturation) followed by 
60°C for 20 seconds (annealing/extension). For each gene, the first cycle when 
exponential amplification could be detected, Ct values were normalised to the 
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endogenous expression of the house-keeping gene 18s. For detailed protocol, see 
manufacturer’s protocol (Bioline BIO-77005).  
 
Primer sequences used in this study were ordered from Sigma Aldrich, UK. 
 
1) CAPG primer sequence: 
Forward primer: GGGCGTCTTCTTCTCGGGGGA 
Reverse primer: CCCGGGATGACTGCTGGCCTAT 
 
2) ITGA2 primer sequence: 
Forward primer: CCGAGGTGACCAGATTGGCTCC 
Reverse primer: GGTGCACCTACCAAGAGCACGT 
 
3) MMP11 primer sequence: 
Forward primer: TTGCACCGCTGGAGCCAGAC 
Reverse primer: TCGGATGGTGGAGACCGCGT 
 
4) ITGB6 primer sequence: 
Forward primer: CGTACAAGGTGGCTGTGCCCTG 
Reverse primer: GCACACCAGGCACACTGAGGTC 
 
5) 18S (house keeping gene) primer sequence: 
Forward primer: CACGGGAAACCTCACCCGGC 
Reverse primer: AACGGCCATGCACCACCACC 
 
2.6 Immunohistochemistry (IHC) 
 
All archived patient samples were obtained with prior Research Ethics Committee 
approval (East London & the City REC3 07/H0705/87). Pancreatic cancer and 
Ampullary cancer Tissue Microarrays (TMAs) were received from collaborators 
(Beatson Institute, Glasgow, UK and University of Verona, Verona, Italy) and stained 
for αvβ6.  
2.6.1 General immunohistochemistry protocol 
 
Harvested organotypic co-cultures, organs and tumours from mice were fixed in 
formal saline containing 4% formaldehyde (Fisher Scientific) for 24 hours before 
transfer to 70% ethanol. Samples were then embedded in paraffin by the 
histopathology department (Barts Cancer Institute) and 5µm sections were cut. The 
sections were de-waxed in xylene for 5 minutes (x2) and taken through a series of 
graded ethanol (100%, 95%, 50% v/v in water) solutions, each twice, for 2 minutes. 
Endogenous peroxidase was blocked with a 0.45% solution of H2O2 in methanol for 
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15 minutes. An Immedge™ Pen (Vector laboratories) was used to delineate the 
specimen edge on the slide, surrounding it with a hydrophobic barrier in order to 
minimise the volume of reagents required to coat the sample. The slides were then 
subjected to antigen retrieval. This step is critical and varies for different primary 
antibodies. Antigen retrieval protocols used in this study are detailed below.  
  
Heat retrieval (citrate buffer) 
1.47g Tri-sodium citrate was dissolved in 500ml of distilled water and pH adjusted to 
6. The slides were transferred into boiling citrate buffer and microwaved for 10mins 
to 12mins. Slides were allowed to cool for 30mins at room temperature in the citrate 
buffer before carrying on with the next step. 
 
Pepsin retrieval 
Pepsin Solution Digest all (Invitrogen 003009) was warmed to 37°C before use. The 
pepsin was added directly onto the sections and incubated for 5 minutes at 37°C in a 
humid incubator. 
 
The sections were then washed twice in PBS for 2 minutes and then incubated for 10 
minutes each at room temperature with avidin and biotin blocking solutions 
respectively (Vector laboratories SP-2001). After washing twice in PBS, the sections 
were incubated with a blocking buffer (normal horse serum, Vector ELITE ABC Kit, 
Vector laboratories) for 30 – 45 minutes at room temperature. Primary antibody was 
added to the sections at required final concentrations as specified in the data sheet 
and left overnight at 4°C. An isotype IgG antibody was also used as a negative 
control in parallel.  
 
The following day, sections were washed in PBS and then incubated with HRP 
conjugated secondary antibody for 45 minutes at room temperature. The sections 
were then washed again and incubated with the avidin-biotin enzyme complex (ABC) 
Vectastain Elite ABC kit (Vector Laboratories) for 30 minutes at room temperature. 
Following washes, DAB (Dako, K3467) was added for about 2-5 minutes and excess 
DAB was washed off. Sections were counterstained with Mayer’s haematoxylin 
(Dako, S3309) for one minute and excess stain washed away. The sections were 
dehydrated in reverse through the different grades of alcohol, cleared in xylene and 
mounted in DPX (VWR #360294H). Digital images of samples were recorded using a 
light microscope (Zeiss Axioplan, Welwyn, Garden City, UK).  
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TMA samples labelled for αvβ6 expression were scored out of four (0: negative; 1: 
background staining; 2: weak; 3: moderate; 4: strong), and the proportion of epithelial 
cells staining positively was scored out of four (1: <25%; 2: 25-50%; 3: 51-75%; 4: 
76-100%). The combined score gave a score in the range of 0 to 8 and grouped as - 
(score = 0), + (score = 1-3), ++ (score = 4-5), or +++ (score = 6-8). Three 
independent observers carried out blind scoring of all samples. The scores were 
averaged and used to perform statistical analyses.  
 
2.6.2 Immunofluorescence (IF) 
 
Cells (1x104 - 1x105) were plated in a 24 well plate on coverslips as a monolayer, 
dependent on the time of fixation. Cells were fixed with 3.7% formaldehyde for 10 
minutes, permeabilised with 0.1% Triton-X 100 for 5 minutes, blocked with 
DMEM/0.1% BSA for 10 minutes and incubated with primary antibody for 1 hour at 
room temperature. Coverslips were washed three times with blocking buffer and 
incubated with appropriate secondary antibodies for 1 hour at room temperature 
(Invitrogen, alexa fluor). The nuclei were stained with 4’,6-diamidino-2-phenylindole 
(DAPI) (1:5000 of stock at 5mg/ml) for 15 minutes at room temperature. Isotype 
specific immunoglobulins were used at matching concentrations as negative controls. 
Coverslips were mounted onto slides with Mowiol (mountant with anti-fade #AF1, 
Citifluor Ltd). Cells were viewed using a confocal laser-scanning microscope (LSM 
510 META, Carl Zeiss, Inc., Germany) with a 63x/1.4 NA Plan-Apochromat oil 
immersion objective. A diode 405nm laser, 488nm argon laser and helium neon 
543nm laser were used to excite DAPI, GFP and Cy3 respectively. This allowed high 
quality images (12 bit, 1024 pixels) to be reconstructed using the LSM 5 software, 
version 3.2.  
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2.7 Flow Cytometry Analysis 
 
2.7.1 Analysis of integrin expression using flow cytometry 
 
Cells to be labelled with different anti-integrin antibodies were trypsinised from tissue 
culture flasks, washed twice in chilled 0.1/0.1 DMEM (0.1% BSA / 0.1% sodium azide 
(w/v) in DMEM). Cells were then re-suspended to 4x106/ml in 0.1/0.1 DMEM and 
50µl transferred into Falcon 2054 centrifuge tubes to give a final cell number of 2x105 
cells per sample on ice.  A final concentration of 10µg/ml of the antibody was added 
to the cells in suspension and was incubated for 45 minutes on ice. A class matched 
IgG was used as a negative control. After the incubation, the cells were pelleted by 
centrifugation (1200rpm for 3 minutes), washed in 0.1/0.1 DMEM three times and the 
appropriate alexafluor 488 secondary antibody added at a final concentration of 
1:250 and incubated for 30 minutes at 4°C. The cells were washed in 0.1/0.1 DMEM 
by centrifugation three times and after the final wash, re-suspended in approximately 
300µl of 0.1/0.1 DMEM.  
 
Flow cytometry was performed on a FACS Calibur cytometer (BD Biosciences) using 
the Cell Quest Pro software version 4.0.2. Ten thousand events were collected within 
a gated population on the forward scatter (FSC) versus side scatter (SSC). A marker 
was set to include less than 1% of control labelled cells. The percentage of positive 
cells was quantified on a histogram of green fluorescence, detected by the FL-1 
channel against the cell count. As the data obtained were not normally distributed, a 
geometric mean was plotted using the Cell Quest Pro software.  
 
2.7.2 Cell cycle analysis 
 
Cells were seeded at a density of 2x105 cells per well of a 6 well plate and the 
following day treated with αvβ6 blocking antibody or a control isotype antibody at a 
final concentration of 10µg/ml. After 96 hours post-treatment, samples were 
harvested by collecting both supernatant and attached cells by trypsinisation. 
Following neutralisation of trypsin and three washes in PBS, cells were pelleted by 
centrifugation and re-suspended in ice cold 70% ethanol whilst vortexing before 
fixing for a minimum of 24 hours at 4°C. The DNA content of the cells was analysed 
by washing the fixed cells with PBS (to remove the ethanol) and incubating with 
RNase A (Invitrogen) and 100µg of propidium iodide (PI) (Sigma Aldrich, UK), a DNA 
binding dye, in a total volume of 300µl of PBS for 30 minutes at 37°C in the dark.  
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Ten thousand events were acquired by flow cytometry on a FACS Calibur cytometer 
(BD Biosciences) with Cell Quest Pro software version 4.0.2. A primary gate on 
forward scatter (FSC) versus side scatter (SSC) was set to exclude debris and a 
second gate to exclude doublets on a dot plot of width (FL2-W) versus pulse area 
(FL2-A). PI fluorescence (FL3-H) was then plotted against cell counts on a linear 
scale to distinguish between the different phases of cell cycle. The G1 maximum 
peak was set by adjusting FL-3 H so that the first peak was at a value of 200 mean 
fluorescent intensity (MFI). Next, a G2/M marker was set at the second peak at the 
4N DNA content. The S phase marker included all cells between these two peaks. A 
sub-G1 marker counted cells with <2N DNA and a fifth marker was also set to 
quantify cells with >4N DNA.  
 
2.8 Western Blotting 
  
2.8.1 Preparation of whole cell lysates 
 
Cells nearing confluency in tissue culture flasks were washed with PBS and 
trypsinised to collect the cell pellet. Cell pellets were washed with PBS and lysed for 
20 minutes on ice in RIPA buffer (50mM Tris HCl pH 8.0, 150mM NaCl, 1 mM EDTA, 
1% Igepal CA-630 (NP-40), 0.1% SDS) containing a 1:100 dilution of protease 
inhibitor cocktail 1 stock (Calbiochem). After centrifugation at 13000rpm for 10 
minutes, supernatant was transferred to clean 1.5ml centrifuge tubes and protein 
concentration determined using Bio-Rad DC Protein Assay (Bio-Rad Laboratories) 
according to manufacturer’s instructions. Bovine serum albumin (BSA) (Sigma 
Aldrich, UK) standards (0-2000µg/ml) were prepared in distilled water. 5µl of either 
standard or sample added per well of a 96 well plate in duplicate. 25µl of activated 
solution A (1000µl of reagent A+ 20µl of reagent S (BioRad DC assay kit)) was 
added per well, followed by 200µl of Reagent B and incubated at room temperature 
for 15 minutes and absorbance was measured at 550nm using a spectrophotometer 
(SLT Lab instruments). A standard curve of absorbance vs concentration was 
constructed for the different concentrations of BSA and the protein concentration in 




2.8.2 Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). 
 
Lysates were diluted, to either 10µg/µl or 20µg/µl, in RIPA buffer and an appropriate 
volume of 2x sample loading buffer (Sigma Aldrich, UK) (0.5M Tris, 0.2M NaH2PO4 
[pH 7.8], 5% β-mercaptoethanol, 50% Glycerol, a few grains of bromophenol blue in 
distilled water) added to give a final concentration of 1X. Samples were heated at 
100°C for 5 minutes. Samples were run on either a NuPAGE 4-12% Bis-Tris pre-cast 
gel (Invitrogen) or a 10% or 15% polyacrylamide gel. Resolving gels were made by 
mixing 3.8ml of 1.5M Tris-HCl (pH 8.8), 5ml of 30% polyacrylamide solution (National 
Diagnostics #EC890), 150µl of 10% SDS (National Diagnostics, #EC-874), 150µl of 
10% ammonium persulphate (APS), 6µl TEMED (Sigma Aldrich UK, #T7024) in 
5.9ml of distilled water and allowed to set. Stacking gel was prepared by mixing 
670µl of 30% polyacrylamide solution, 500µl of 1M Tris-HCl (pH 6.8), 40µl of 10% 
SDS, 40µl of APS to 2.7ml of distilled water and added to the top of the resolving gel 
before inserting a comb and was allowed to set at room temperature. 10µg - 20µg of 
sample protein was loaded per well along with 5µl of PageRuler Pre-stained protein 
ladder (Fermentas UK, York, UK) for separation by electrophoresis at 120V for 90 
minutes using Tris-Glycine SDS PAGE Running buffer (Invitrogen) for cast 
polyacrylamide gels, or 1X MOPS Buffer (Invitrogen) for precast gels.  
 
2.8.3 Western blotting 
 
Proteins were transferred onto Hybond nitrocellulose membranes (GE Healthcare, 
Buckinghamshire, UK) using a wet transfer Cell (Invitrogen). Briefly, nitrocellulose 
membrane along with the blotting paper and gel were soaked in transfer buffer (2.9g 
Tris, 14.5g Glycine, 200ml methanol in distilled water to a total volume of 1 litre) for a 
few seconds. A “sandwich” of blotting paper, gel, nitrocellulose membrane, blotting 
paper was placed in the holder inside the blotting cell. Electro-transfer of proteins 
was done at 30V for 90 minutes with nitrocellulose closest to the anode.  
 
The membrane was blocked in 5% (w/v) non-fat milk and 1% Tween-20 in TBS 
(TBS-T) for a minimum of 20 minutes at room temperature. It was then rinsed with 
TBS-T before the addition of primary antibody in 5% milk overnight at 4°C with a 
gentle rocking motion. The next day, it was washed three times with TBS-T (1% 
Tween-20) for 10 minutes per wash. The appropriate HRP conjugated secondary 
antibody was added in TBS-T for 1 hour at room temperature followed by a further 
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three washes with TBS-T. Protein levels were detected using chemo-luminescent 
detection of HRP using ECL Western blotting detection reagents (GE Healthcare, 
Buckinghamshire, UK). Signal was visualised by exposure of the membrane to 
Hyperfilm ECL (GE Healthcare, Buckinghamshire, UK) and developed in a Curix 60 
Developer (Agfa, Middlesex, UK). 
 
2.9 Functional assays 
 
2.9.1 Migration assay 
 
Cell migration assays were performed using protein-coated polycarbonate filters (8 
µm pore size (Transwell®, Beckton Dickinson) (Figure 27). 200µl of the protein 
solution, fibronectin (Sigma Aldrich, UK) at 10µg/ml final concentration, or LAP at 
1µg/ml was added to the lower chamber of the Transwell® plate and incubated for 1 
hour at 37oC. The protein solution was then replaced with 200µl of migration buffer 
(a-MEM containing 0.1% BSA) for 30 minutes at 37oC. Cells were plated in the upper 
chamber of the Transwell® at a density of 5x104 in 200 µl of migration buffer for 16 
hours. In blocking experiments, the cells were incubated with blocking antibodies at a 
final concentration of 10µg/ml (or chemical inhibitors) for 30 minutes at 4oC prior to 
plating. For RNAi (100nM final concentration) experiments, cells were used 24 hours 













Figure 27: Schematic diagram of migration assay. Modified from Rochefort, H 
et. al, 1998.  
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After 16 hours, cells in the lower chamber (including those attached to the under 
surface of the membrane) were trypsinised and counted using a Casy cell counter 
(Sharfe System GmbH, Germany). Migration assays were set up in replicates of four 
and were repeated at least 3 times.  
 
2.9.2 Transwell® invasion assay 
 
Transwell® invasion assays were prepared using Matrigel™-coated polycarbonate 
filters, 8 µm pore size (Transwell®, Beckton Dickinson). 70µl of Matrigel™ (diluted 
1:2 in serum free medium) was added to the upper chamber and allowed to gel for 1 
hour at 37oC. Cancer cells were were then added to the Matrigel™ at a density of 
5x104 in 200 µl of serum free media per well. To act as a chemotactant, 500µl of 
serum containing medium was added to the lower chamber of the Transwell® plate 
(Figure 28). Samples were incubated for 72 hours at 37°C. In antibody blocking 
experiments, the cells were incubated with antibodies or chemical inhibitors at a final 
concentration of 10µg/ml for 30 minutes at 4oC prior to plating. For RNAi (100nM final 
concentration) experiments, cells were used 24 hours post transfection with siRNA. 
After 72 hours, the cells in the lower chamber (including those attached to the under 
surface of the membrane) were trypsinised and counted using a Casy cell counter 
(Sharfe System GmbH, Germany).  Relative invasion was determined from a 














Figure 28: Schematic diagram of Transwell® invasion assay. Modified from 
Rochefort, H et. al, 1998. 
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2.9.3 Organotypic invasion assay 
 
The organotypic invasion assay is a three-dimensional (3D) invasion assay that 
attempts to replicate the tumour-stroma interface. The assay requires 3 days to set 




The various materials required for setting up the organotypic co-culture gels are 
listed below. 
 
• Rat tail collagen type 1 (BD Biosciences) 
• Matrigel™ Basement Membrane Matrix (BD Biosciences, #354234) 
• 25% glutaraldehyde (Sigma-Aldrich, #G5882) 
• 10X DMEM (Media Production, Clare Hall, CR-UK) 
• RPMI 10% Serum containing medium (PAA Laboratories) 
• Fibroblasts 
• Cancer cells (Different cell types of choice) 
• Nylon Mesh (Tetko, Sefar LTD, #3-100/5) 
• Steel Grids, 2cmx2cm with 5mm feet (Mechanical Workshop, BICMS London) 
• Spatula, Forceps, Scalpel 
• 6 well/24 well plates (NUNC, Beckton-Dickinson, UK) 
• Shandon Cryomatrix (OCT), (Thermoelectron corporation, Ref: 676900) 
• Cork Disks (Ref: E7.15/CD, Raymond A Lamb-Laboratory Supplies) 
• Coverslips, (Menzel-Glaser, MNJ-380-020H) 
 
Day 1 
The gels are composed of collagen, Matrigel™, 10x DMEM, FCS and fibroblasts in 
the following ratio: 
Collagen : Matrigel™ – 3.5 volume : 3.5 volume 
10 X DMEM – 1 volume 
FCS – 1 volume 
Cell suspension (fibroblasts) – 1 volume 
Total Volume – 10 volumes 
 
The components were added together on ice. Fibroblasts were used at a final 
concentration of 5 x 105 cells/ml per gel and mixed thoroughly, to ensure even 
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distribution. The gel mix should appear pink in colour suggesting that it is in an 
optimal pH range (7.1-7.3). If the gel mix appeared as a pale yellow colour, 1M 
NaOH was added in about 100µl aliquots, till the mix attained a pink colour. 1ml of 
the gel mix was added per well of a 24 well plate placed at 37°C for an hour for the 
gels to solidify. After an hour 1ml of growth medium was added to each of the wells 
and plates returned to an incubator overnight. 
 
Day 2 
2cm squares of nylon supports were sterilised by autoclaving. Collagen gel mix was 
prepared according to the following recipe. 
Collagen – 7 volumes 
10X DMEM – 1 volume 
FCS – 1 volume 
E4 (10%FCS) – 1 volume 
Total Volume – 10 volumes 
 
The coating mix was prepared on ice and mixed thoroughly. 250µl of the above mix 
was added per nylon sheet and left at 37°C for 15-30 minutes. 1% glutaraldehyde 
solution was used to wash the nylon sheets and left at 4°C for an hour. The sheets 
were washed with PBS to remove any excess glutaraldehyde and stored in serum 
free growth medium until required. The PDAC cell lines were suspended in growth 
medium at 5x105 cells per ml and 1ml plated onto the gels prepared on day 1and left 
at 37°C overnight. 
 
Day 3 
Using a metal spatula, gels were detached from the wells and raised onto a metal 
grid placed in a well of a 6 well plate. A collagen coated-nylon square was added to 
each grid. One gel was placed onto each nylon square and medium (approximately 
5ml) added till it covered the nylon sheet (Figure 29). Medium was replaced every 
two days. After 11-14 days, the gels were removed and cut exactly in half with a 
scalpel. One half was fixed in formol saline and sent off to histopathology (BCI 
services) for paraffin embedding. The other half was frozen down in OCT and stored 





















Figure 29: Schematic picture of organotypic co-culture system.  
 
2.9.4 Cell Viability assay 
 
Cell viability assays were performed in 96 well plates over a seven-day period. 3000-
4000 cells, determined for each cell line in preliminary experiments (data not shown), 
were plated per well in 200µl of growth medium. The cells were left to adhere 
overnight and replaced with growth medium containing the antibody (53a.2 or 
264RAD) at the required final concentration. At day 3, fresh antibody containing 
medium was added and plates re-incubated till day seven, unless otherwise stated. 
On day 7, (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
(Sigma) was used to detect and quantify the number of cells that were viable after 
antibody treatment. MTT reacts with the mitochondrial dehydrogenase enzymes in 
living cells to be converted to water-insoluble formazan, which is purple in colour. 
The purple crystals are solubilised with dimethyl sulphoxide (DMSO) and the 
intensity is measured colourimetrically at 550 nm using a spectrophotometer (SLT 
Lab instruments). Absorbance values for wells with medium alone were subtracted 
from that of those containing cells (background value of MTT mixture in the absence 




2.9.5 Cytotoxicity assay 
 
A proprietary cytotoxic drug attached to the αvβ6-specific peptide A20FMDV2 [124] 
was generated by Spirogen, UK and this was tested in vitro. Initial studies using this 
drug on cytotoxic assays, even at very low concentrations, in αvβ6 positive 
pancreatic cancer cell lines showed very encouraging results.   
 
3000 cells were plated in 200µl of growth medium in quadruplicate wells of 96-well 
plates. After 24 hours in culture, the medium was removed carefully and cells were 
treated with different doses of the cytotoxic drug (20, 10, 5, 1 and 0.2µM) plus an 
untreated control in a final volume of 200µl and then incubated for 72 hours. The 
medium was removed and 100 µl of 0.2mg/ml of MTT was added to each well for 60 
minutes at 37°C. MTT binds to the living cells in the plate as described above and 
the intensity was measured colourimetrically at a wavelength of 550 nm using a 
spectrophotometer (SLT Lab instruments). 
 
2.10 In Vivo models for pancreatic cancer 
 
All in vivo experiments were carried out in the Biological Service Unit (BSU) at 
Queen Mary University of London. Animal care and treatment followed guidelines 
approved by the Home Office, United Kingdom.  
 
Mice that were pathogen-free were either purchased from Charles River or Harlan 
and housed in the BSU, at Charterhouse Square, London. All experiments were 
performed using female CD1 nu/nu unless otherwise stated. All animals were housed 
in individually ventilated cages (IVC) in groups of five. Food and water were available 
ad libitum.  
 
2.10.1 Subcutaneous models 
 
2.10.1.1 Cancer cells alone 
 
CFPac1 cells (Table 8) used for injection were harvested by trypsinisation, washed in 
growth medium and then washed three times in serum free media. Two million 
CFPac1 cells in 200µl of PBS were injected into the right flank of the mouse 
subcutaneously. Depending on the experiment, mice were maintained until the 
tumours reached a volume of 100mm3 and further treatments were carried out as 
explained in the various treatment plans (2.10.3).  
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2.10.1.2 Cancer cells plus stellate cells 
 
CFPac1 cells and PS1 (stellate cells) were harvested by trypsinisation, washed in 
growth medium and then and washed three times in serum free media.  Half a million 
CFPac1 cells were mixed with one million PS1 cells (1:2 ratio) in 200µl of PBS and 
injected into the right flank of the mouse subcutaneously. Depending on the 
experiment, mice were maintained until the tumours reached a volume of 100mm3 
and further treatments were carried out as explained in treatment plan (2.10.3).  
Following the treatment regimen, tumours were excised and fixed in formol saline for 
24 hours before transferring to 70% ethanol. Tissue was paraffin embedded and 
sections were cut (Pathology department, Barts Cancer Institute) for further 
immunochemical analysis.  
 
2.10.2 Orthotopic pancreatic cancer model 
 
All surgical procedures were carried out in a laminar airflow cabinet under sterile 
conditions. Mice were under anesthesia (inhalation of isoflurane with oxygen and 
nitrous oxide) during the procedure.  
 
The flank wall of the mouse was wiped with a sterile cloth with 70% ethanol. A 2cm 
incision was made in the abdominal wall of the mouse alongside its right ribcage. 
The spleen together with the pancreas was carefully exteriorised and laid onto the 
skin. 40µl of cell suspension (two million CFPac1 alone or 1 million CFPac1 plus two 
million PS1 cells in a 1:2 ratio) was injected into the tail of the pancreas using an 
insulin syringe (29 gauge, ½ inch) (Southern Syringe Services, Leicester, UK). The 
injection site was dabbed with a sterile cotton swab to ensure no leakage had 
occurred and the organs placed back into the abdominal cavity. Skin and muscle 
were sutured using Vicryl 4.0 (Southern Syringe Services, Leicester. UK). 
Immediately after surgery, mice were transferred to a “recovery” cage, which 
contained food and water, and maintained at a warm temperature using a heater. A 
full recovery was observed within 30 minutes post operation and mice were 
monitored daily thereafter to ensure their sutures had healed adequately and that 
they were not showing any signs of ill health. The experiment was terminated six 
weeks post injection; mice were culled and tumours were harvested and processed. 
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2.10.3 Treatment plan 
 
Tumour cells alone or tumour cells in combination with stellate cells were injected 
subcutaneously into the right flank. The tumours were measured twice weekly and 
tumour volume calculated using the formula –  
Length x (breadth)2 / 2.  
Once the tumours reached 100mm3 the mice were assigned randomly to one of the 
four treatment arms.  
 
Treatment arm 1 – β6 blocking antibody – 10mg/Kg per mouse. 
Treatment arm 2 – Gemcitabine treatment – 100mg/Kg per mouse. 
Treatment arm 3 – β6 blocking antibody (10mg/Kg) plus gemcitabine (100mg/Kg) per 
mouse. 
Treatment arm 4 – IgG control antibody in PBS – 10mg/Kg per mouse.  
 
The treatments were given intraperitoneally twice a week (200µl) (400µl for treatment 
arm 3). The antibody treatment continued for a period of 6 weeks. Mice were culled 
when the tumours reached the maximum allowed tumour size as per Home Office 
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3. Expression of αvβ6 in PDAC 
 
3.1 Preliminary clinical study 
 
A small number of clinical samples of PDAC (n= 34) and normal (n= 12) pancreas 
were stained for αvβ6 expression. Figure 30A shows typical labelling of αvβ6 in 
normal pancreas and PDAC (Figure 30B) tissue, showing strong expression on the 
cancer and none on the normal tissue. Table 11 shows that 100% of PDAC samples 
expressed αvβ6 in varying levels, with 38% expressing it strongly. This positivity was 
limited to epithelial cells with no apparent staining of stromal cells. This was in 
agreement with previously published literature where 100% of PDAC samples tested 
were positive for αvβ6 [201]. In contrast, all but 1 sample of normal pancreas 
samples were negative for αvβ6 expression. Having established expression of αvβ6 
in tissue samples, the expression and functional roles of αvβ6 on PDAC cell lines 




















Figure 30: Expression of β6 on PDAC tissue samples. The normal pancreas 
was negative for β6 (A) whereas strong membranous expression was observed 















Table 11: Expression of αvβ6 in PDAC (n=34) and normal pancreas tissue 
(n=12) samples. Expression of αvβ6 varied in PDAC samples but 100% were 
positive with 38% expressing it strongly. Only 1 case of normal pancreas 
(n=12) showed low levels of staining for β6.  
 
3.2 Flow cytometry screen of PDAC cell lines 
 
Flow cytometry was used to screen a panel of 9 pancreatic cancer cell lines for a 
subset of RGD-dependent integrins using antibodies to αvβ3 (23C6), αvβ5 (P1F6), 
αvβ8 (14E5), α5 (P1F6) and αvβ6 (10D5); mouse IgG1 isotype (DAKO) was used as 
a negative control. 
Cells in suspension were labelled with respective primary antibodies and the bound 
primary antibody detected using Alexa Fluor 488 conjugated secondary antibody 
(Figure 31). A Beckton Dickinson (BD) FACS Calibur flow cytometer machine was 
used to run the samples and results were analysed using Cell Quest Pro software to 
generate geometric mean fluorescence values (section 2.7). Flow cytometry 
experiments were performed regularly on cell lines routinely used for experiments to 
ensure that the expression profile of integrins did not vary between experiments.  
  
Cases Negative Low Moderate High 
12 (normal) 11 1 0 0 























Figure 31: Representative flow cytometry histograms analysed using Cell 
Quest Pro software. A) an αvβ6 negative cell line, MiaPaCa2, stained with an 
IgG control and 10D5, an anti-αvβ6 antibody. B) an αvβ6 positive cell line 
Panc04.03 stained with an IgG control and 10D5, an anti-αvβ6 antibody (shift to 
the right of the purple curve denotes positivity). FL1-H is the excitation of alexa 
fluor 488.  
 
Representative histograms showing αvβ6 expression in αvβ6 negative and αvβ6 
positive cells lines are shown in Figure 31. Fluorescence intensity is plotted on a 
logarithmic scale on the x-axis, with shifts to the right denoting increased 
fluorescence. As data were rarely normally distributed, the geometric mean 
fluorescence intensity (MFI) was used.  
 
Whilst MiaPaca2 cells were negative for αvβ6 expression, with a geometric mean of 
5.42 (10D5) compared with 2.69 in cells stained for isotype control antibody, 
Panc04.03 cells demonstrated very strong expression of αvβ6. Geometric mean 
increased from 3.70 in the isotype control stained cells to 89.91 in the 10D5, anti-
Marker Left, Right Events % Gated % Total Geo Mean
All     1,  9910 10178 100.00 91.93 2.69
M1     9,  9910 62 0.61 0.56 14.69
Data.001
100 101 102 103 104
FL1-H
M1
Mia PaCa IgG1 !
Marker Left, Right Events % Gated % Total Geo Mean
All     1,  9910 10205 100.00 91.68 5.42
M1     9,  9910 1353 13.26 12.16 14.72
Data.002




MiaPaCa2 IgG control 
MiaPaCa2  
Marker Left, Right Events % Gated % Total Geo Mean
All     1,  9910 9970 100.00 94.80 3.70
M1    12,  9910 440 4.41 4.18 15.14
Marker Left, Right Events % Gated % Total Geo Mean
All     1,  9910 9985 100.00 95.01 89.91
M1    12,  9910 9908 99.23 94.28 91.78
Data.004
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αvβ6 antibody, treated cells. The data also show that approximately 99.23% of the 
gated population of Panc04.03 cells were positive for αvβ6 (Figure 31). 
 
A panel of 9 pancreatic cancer cell lines (from ATCC), which originated from well 
differentiated or moderately/poorly differentiated PDAC tumours were screened for 
their integrin expression profile (Table 12). A subset of RGD-dependent integrins was 
screened together with αvβ6. α1 was expressed at low levels (geometric MFI 
between 11-20) in three out of the nine cell lines tested. The well differentiated cell 
lines tended to express more α1 compared to the poorly differentiated cell lines. In 
contrast, α2 was expressed in very high levels in all of the cell lines tested (geometric 
mean >100 in most cell lines) with the exception of MiaPaCa2 which was negative. 
α5 expression was relatively low (geometric mean between 11-20) but was 
expressed in five out of the nine cell lines tested, including MiaPaCa2. αvβ3 levels 
were also very low (geometric mean between 11-20) in the three cell lines that 
expressed it (CFPac1, BxPc3 and Panc1 stained positive). αvβ5 expression was low 
and expressed by five out of the nine cell lines tested regardless of their 
differentiation status (geometric mean between 11-20). αvβ8 expression was 
detected in three of the PDAC cell lines including CFPac1, AsPc1 and BxPc3. The 
levels of expression in these cells were very low (geometric mean between 11-20).  
αvβ6 was expressed in seven out of the nine cell lines tested in varying levels. The 
well differentiated cells expressed significantly higher levels (geometric mean 
between 21-100) compared with the moderately/poorly differentiated cell lines 






































Table 12: Integrin screen of a panel of PDAC cell lines by flow cytometry. 8 out 
of 10 cell lines expressed αvβ6 at varying levels. 
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Data shown in Table 12 represent the mean of a minimum of two experiments, each 
performed in triplicate. Geometric mean fluorescence intensity was converted to a 
‘plus’ score according to the key after subtracting the negative control (IgG score). It 
was shown that 7 out of 9 pancreatic cancer cell lines express αvβ6 endogenously in 
varying levels (Table 12). Expression levels of αvβ6 were highest in well-
differentiated cell lines (Panc04.03, CFPac1, HPAF) compared to the poorly 
differentiated cell lines (AsPc1, Panc1, MiaPaCa2). BxPc3 was a moderately 
differentiated cell line expressing αvβ6 with a geometric mean of about 40 (Figure 
32). In summary, the flow cytometry integrin analysis is consistent with the 
preliminary clinical study, since the majority of the cell lines expressed αvβ6 as did 






















Figure 32: Expression of αvβ6 in PDAC cell lines grouped based on their 
differentiation status. Mean fluorescent intensity is represented by geometric 




3.2.1 Integrin screen on pancreatic stellate cell line PS1 
 
Pancreatic stellate cells isolated and immortalised in house in the laboratory, PS1 
cells, were screened using flow cytometry for the same subset of RGD-dependent 
integrins as described previously and a few additional relevant integrins expressed 


























Figure 33: Representative histograms showing integrin expression in PS1 cells 
(pancreatic stellate cells) analysed using Cell Quest Pro software.  IgG isotype 
staining is shown in (A). (B) shows integrin subunit α1 expression at high 
levels with a geometric mean of 60.09 (histogram shifts to the right). (C) shows 
that there is no αvβ6 expression in these cells (histogram shifts back to the 
left) with a geometric mean of 4.27, which is similar to the IgG control 
expression level.  
 
Typical histograms are shown in Figure 33 and data from three separate experiments 
are summarised in Table 13. PS1 cells expressed high levels of α1 (geometric mean 
between 50-100) and α2, the latter at similar expression levels observed in the 
PDAC cell lines tested previously. PS1 cells expressed lower levels of α5 subunit 
(geometric mean between 21-50) but no α8 or α9 expression was detected. Both 
αvβ3 and αvβ5 were expressed at similar levels (geometric mean between 21-50). 
Marker Left, Right Events % Gated % Total Geo Mean
All     1,  9910 5427 100.00 87.60 3.10
M1    23,  9910 27 0.50 0.44 29.39
Marker Left, Right Events % Gated % Total Geo Mean
All     1,  9910 5291 100.00 88.91 3.56
M1    23,  9910 49 0.93 0.82 33.97
Marker Left, Right Events % Gated % Total Geo Mean
All     1,  9910 5341 100.00 88.12 3.56
M1    23,  9910 53 0.99 0.87 35.58
Marker Left, Right Events % Gated % Total Geo Mean
All     1,  9910 5345 100.00 89.79 60.08
M1    10,  9910 5155 96.45 86.59 65.98
Marker Left, Right Events % Gated % Total Geo Mean
All     1,  9910 5331 100.00 88.69 183.07




























































































Marker Left, Right Events % Gated % Total Geo Mean
All     1,  9910 5325 100.00 87.67 57.33
M1    23,  9910 4227 79.38 69.59 100.08
Marker Left, Right Events % Gated % Total Geo Mean
All     1,  9910 6049 100.00 100.00 4.33
M1    23,  9910 439 7.26 7.26 37.22
Marker Left, Right Events % Gated % Total Geo Mean
All     1,  9910 5328 100.00 86.68 6.20
M1    23,  9910 657 12.33 10.69 73.96
Marker Left, Right Events % Gated % Total Geo Mean
All     1,  9910 5308 100.00 87.48 24.31
M1    23,  9910 2788 52.52 45.95 49.88
Marker Left, Right Events  ated  Total eo ean
All     1,  9910 5313 100.00 88.56 4.27
M1    23,  9910 89 1.68 1.48 34.09
Marker Lef , Right Even s % Gated % Total Geo Mean
All     1,  9910 5345 100.00 88.39 4.67
M1    23,  9910 119 2.23 1.97 35.40
Marker Left, Right Events % Gated % Total Geo Mean
All     1,  9910 5276 100.00 89.96 23.65
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Table 13: Integrin screen of PS1 (pancreatic stellate cells) cells. Data shown in 
the table represent the mean of three experiments performed in triplicate. 
Geometric mean fluorescence intensity was converted to a ‘plus’ score 
according to the key. 
 
3.3 Western blotting to detect expression of β6 
 
After establishing expression of αvβ6 at the cell surface of PDAC cell lines by flow 
cytometry, whole cell lysates were prepared to examine total cellular expression of 
β6 using Western blotting. The data in Figure 34 show endogenous expression of 
αvβ6, consistent with flow cytometry data. The double band observed is believed to 
be due to recognition of both the smaller immature (not fully glycosylated) and larger 
mature (fully glycosylated) form of β6 (determined in house in oral cancer cell lines, 




























Figure 34: Western blotting of β6 from whole cell lysates from PDAC cell lines. 
β6 was detected using C19 polyclonal antibody (Santa Cruz Ltd) and HSC70 
antibody used to confirm equal loading of samples. Image is representative of 
two independent experiments.  
 
The genetically engineered melanoma cell lines, DX3β6, was used as a positive 
control. These cells express very high levels of αvβ6 compared with the endogenous 
levels of expression seen in PDAC cell lines. There were varying levels of expression 
of αvβ6 in the PDAC cell lines tested, and these generally were similar to the results 
observed using flow cytometry. PS1 cell line was negative for αvβ6 expression.  
 
Thus, two separate methodologies were used to confirm β6 expression in a panel of 
PDAC cell lines. Based on the data obtained, Panc04.03, CFPac1 were the two 
positive cell lines selected and MiaPaca2 and Panc1 were the two negative cell lines 
picked for all further in vitro experiments.  
  
CFPac1 Panc04.03 Colo357 Capan1 AsPc1 MiaPaCa2 Panc1 PS1 Positive control 
!6 subunit 
105 kDa   
HSC70 
70 kDa  
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3.4  Immunofluorescence labelling of αvβ6 
 
CFPac1, Panc04.03 (αvβ6 positive cell lines) and Panc1 (αvβ6 negative cell line) 
were cultured as monolayers on coverslips and labelled for αvβ6 using 53A.2, a rat 
monoclonal anti-β6 antibody, and Alexa Fluor 488 was used to detect bound 
antibody. The cells were imaged using a confocal laser-scanning microscope (LSM 
























Figure 35: Expression of αvβ6 in PDAC cell lines using indirect 
immunofluorescence. Strong expression of αvβ6 in the cell membrane was 
observed in CFPac1 and Panc04.03 (green) while Panc1 cells showed weak 
cytoplasmic staining in the cytoplasm at background levels. Nuclei were 
labelled in blue (DAPI) and imaged using a confocal microscope.  
 
αvβ6 was strongly expressed on the membrane of the two positive cell lines, 
particularly at the cell-cell junctions but was absent in the αvβ6 negative cell line 
(Figure 35), consistent with the flow cytometry and Western blotting data. Integrin 
αvβ6 was expected to be present on cells and the pattern of expression observed in 









3.5 Functional role of αvβ6 in PDAC cell lines 
 
3.5.1 Role of αvβ6 in PDAC cell proliferation 
 
Uncontrolled cancer cell proliferation is considered to be the primary cause for 
tumour formation, thus cell proliferation has been the principal target in attempts to 
reduce tumour growth.  So far there has been only one paper published where αvβ6 
has been linked with PDAC cell proliferation. This study investigated whether 
blockade of αvβ6 function could affect growth of PDAC cell lines. Singh et al showed 
that knock down of β6 in the YAPC pancreatic cancer cell line resulted in a reduction 
of cell growth by 60%-80% [207]. 
 
3.5.1.1 Antibody blockade of proliferation in PDAC cell 
lines 
 
Three different antibodies targeting αvβ6 were used for this study: 10D5 (mouse 
monoclonal antibody), 53A.2 (rat monoclonal antibody), 264RAD (human monoclonal 
antibody). All the antibodies have been established as αvβ6 function blocking 
antibodies [233] and both 53A.2 and 10D5 are available commercially.  
 
CFPac1, Panc04.03 (αvβ6 positive) and Panc1, MiaPaCa2 (αvβ6 negative) cell lines 
were used for the proliferation assay, which was performed over 7 days. Once the 
appropriate cell numbers per well were optimised (3000 per well, established prior to 
assays, data not shown) cells were plated onto 96 well plates at day -1 (prior to 
antibody treatment). On day 0, αvβ6 function-blocking antibodies were added at 
multiple concentrations ranging from 0.2µg/ml to 10µg/ml. At day 4, the antibody was 
replaced (fresh media added) and the assay left till day 7. The control wells had an 
isotype negative control antibody at the respective concentrations and a no treatment 
well with only growth media was used as an additional control. Both the αvβ6 
blocking antibodies and the control isotype antibody were prepared in 10% serum 














































Figure 36: The effect of αvβ6 blocking antibody 53A.2 on in vitro growth of 
PDAC cell lines. Cell survival was quantified by MTT assay on day 7 and 
survival normalised to that of untreated cells. Results show that there is a 
significant reduction in proliferation (***) in the two αvβ6 positive cell lines 
Panc04.03 (top) and CFPac1 (bottom) when treated with a αvβ6 function 
blocking antibody 53A.2 at varying concentration compared to the control 
isotype IgG antibody. Student’s t-test p= <0.0004 (Panc04.03) and p= <0.0008 
(CFPac1).  The graphs represent the mean and +/- standard error of mean of 














































Figure 37: The effect of αvβ6 blocking antibody 53A.2 on in vitro growth of 
PDAC cell lines. Cell survival was quantified by MTT assay on day 7 and 
survival normalised to that of untreated cells. Results show that there is no 
reduction in proliferation in the two αvβ6 negative cell lines, Panc1 (top) and 
MiaPaCa2 (bottom) when treated with the αvβ6 function blocking antibody 
53A.2 at varying concentrations compared to the control IgG isotype antibody. 
(Student’s t-test non significant). The graphs represent the mean and +/- 
standard error of mean of three experiments performed with replicates of four 
per dose in each experiment. 
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The results shown in Figure 36 demonstrated that there was a significant reduction in 
the total percentage of αvβ6 positive cells that are alive after 7 days when treated 
with the αvβ6 function blocking antibody, 53A.2. Thus at 5µg/ml there is a 44% 
reduction in growth and this increased to 67% reduction at 10µg/ml in Panc04.03 
cells. Similarly growth of CFPac1 in the presence of 10µg/ml 53A.2 was reduced by 
62% after 7 days compared to the equivalent concentration of the isotype control 
antibody. It must be noted the MTT assay used measures mitochondrial metabolic 
activity as a surrogate measure of growth but does not measure cell number. The 
results in Figure 37 showed that the same antibody when used to treat two αvβ6 
negative cell lines, Panc1 and MiaPaCa2, at the same concentrations over 7 days 
showed no significant difference in the percentage of cells that were alive. All four 
cell lines were set up for the cell survival assay at the same time under the same 
conditions. The 53A.2 used for performing the above experiments was purified from 
hybridoma supernatant by Dr. Veronika Jenei, University of Southampton, UK.  
 
To confirm that the results in Figure 36 were due to blockade of αvβ6, and were not 
an irrelevant side effect of 53A.2, the proliferation assays were repeated with the 
function-blocking antibody 264RAD from Astra Zeneca-Medimmune. 264RAD 
antibody is a human antibody and has been shown to bind specifically to β6 and 











































Figure 38: The effect of αvβ6 function blocking 
antibody 264RAD on in vitro growth of PDAC cell lines. Cell survival was 
quantified by MTT assay on day 7 and survival normalised to that of untreated 
cells. Results show that there is a significant reduction in proliferation (*/**) in 
the two αvβ6 positive cell lines Panc04.03 (top) and CFPac1 (bottom) when 
treated with a αvβ6 function blocking antibody 264RAD at varying 
concentration compared to the control isotype IgG antibody. Student’s t-test 
*p= <0.05, ** <0.005.  The graphs represent the mean and +/- standard error of 












































Figure 39: The effect of αvβ6 blocking antibody 264RAD on in vitro growth of 
PDAC cell lines. Cell survival was quantified by MTT assay on day 7 and 
survival normalised to that of untreated cells. Results show that there is no 
reduction in proliferation in the two αvβ6 negative cell lines, Panc1 (top) and 
MiaPaCa2 (bottom) when treated with the αvβ6 function blocking antibody 
264RAD at varying concentrations compared to the control IgG isotype 
antibody. (Student’s t-test non significant). The graphs represent the mean and 
+/- standard error of mean of three experiments performed with replicates of 
four per dose in each experiment. 
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264RAD was used at the same concentration range as that of 53A.2. Astra Zeneca 
also provided an isotype human IgG control antibody, which was used as the 
negative control. The graphs in Figure 38 again showed that there was a significant 
reduction in the total percentage of cells that are alive after 7 days when treated with 
the αvβ6 function blocking antibody, 264RAD at 5µg/ml, 10µg/ml and 20 µg/ml 
concentration for Panc04.03 and CFPac1 compared to the equivalent concentration 
of the isotype control antibody. There was a reduction in cell numbers up to about 
30%-40% in the treated group at varying concentrations for Panc04.03 and a 
reduction of 50%-55% in the treated group at varying concentrations for CFPac1. In 
contrast, the data in Figure 39 showed that the same antibody when used to treat 
two αvβ6 negative cells, Panc1 and MiaPaCa2, at the same concentrations over 7 
days evoked no significant difference in growth.  
 
3.5.2 A20FMDV2 Ad5 knob protein mediated blockade of αvβ6 
 
Previous studies from our laboratory have generated a recombinant adenovirus type 
5 (Ad5) fibre knob protein incorporating a peptide (A20FMDV2) that specifically binds 
to and inhibits αvβ6 [234]. This A20FMDV2 knob protein was tested for its effects on 





































Figure 40: The effect of αvβ6 blocking protein A20FMDV2 knob protein on in 
vitro growth of PDAC cell lines. Cell survival was quantified by MTT assay on 
day 7 and survival normalised to that of untreated cells. Results show that 
there is a significant reduction in proliferation in the two αvβ6 positive cell 
lines Panc04.03 (top) and CFPac1 (bottom) when treated with a αvβ6 function 
blocking A20FMDV2 knob protein at varying concentration compared to the 
control wild-type knob protein. Student’s t-test * p= <0.05, ** p= <0.001 and *** 
p=<0.0001. The graphs represent the mean and +/- standard error of mean of 









































Figure 41: The effect of αvβ6 function blocking A20FMDV2 knob protein on in 
vitro growth of PDAC cell lines. Cell survival was quantified by MTT assay on 
day 7 and survival normalised to that of untreated cells. Results show that 
there is no reduction in proliferation in the two αvβ6 negative cell lines, Panc1 
(top) and MiaPaCa2 (bottom) when treated with the αvβ6 function blocking 
A20FMDV2 knob protein at varying concentrations compared to the control 
wild type knob protein. (Student’s t-test non significant). The graphs represent 
the mean and +/- standard error of mean of three experiments performed with 
replicates of four per dose in each experiment. 
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With the assistance of Dr. Lynda Coughlan, an Ad5 knob protein and a control wild 
type knob protein (without A20FMDV2) were generated as described previously 
[234]. The data in Figure 40 showed that there was a significant reduction in the total 
percentage of PDAC cells that were alive after 7 days when treated with the αvβ6 
function blocking A20FMDV2 Ad5 knob protein at 0.2µg/ml, 1µg/ml, 5µg/ml and 
10µg/ml concentration for Panc04.03 and for CFPac1 at 1µg/ml, 5µg/ml and 10µg/ml 
compared with the equivalent concentration of the wild type knob protein. Thus, at 10 
µg/ml there was a 51% reduction in growth of Panc04.03 and a 43% reduction in 
growth of CFPac1 and these changes were significant (p=<0.0001 and p=<0.001 
respectively). Again, in contrast, the data in Figure 41 showed that the same 
A20FMDV2 Ad5 knob protein when used to treat two β6 negative cell lines, Panc1 
and MiaPaCa2, at the same concentrations over 7 days induced no significant 
difference in the percentage of cells that were alive after 7 days, relative to the same 
concentrations of wild-type knob protein.  
 
3.5.3 Attempts to knock down of β6 using siRNA to inhibit 
proliferation 
 
Since two blocking antibodies and a blocking adenoviral protein produced a similar 
reduction in proliferation in the αvβ6 positive cell lines, a genetic knock down of β6 
using siRNA was performed to observe if the effect on proliferation could be 
reproduced. Multiple attempts to achieve a significant knock down of β6 in 
Panc04.03 and CFPac1 cells proved unsuccessful. Despite various optimisation 
steps to the lipid mediated siRNA protocol a significant reduction in levels of β6 
expression was never achieved (data not shown). In order to confirm if the siRNA 
sequences were targeting the correct gene, the Capan1 cell line (another αvβ6 
positive cell line) was used together with a positive control for αvβ6 expression 
















Figure 42: Western blot to confirm knock down of β6 in Capan1 and A375β6P 
cell lines using Oligofectamine™ 5 days post transfection. HSC70 was used as 
a loading control. (NT- non-targeting).  
 
siRNA was purchased from Dharmacon Ltd (gene pool with four individual 
sequences) to target β6 specifically. A non-targeting siRNA sequence was 
purchased from the same company. 5 days post transfection; the cells were lysed 
and quantified using pico green (DNA binding dye) and read at 450nm in a 
spectrophotometer. Figure 42 confirmed that the β6 siRNA knock down technique 
was working and suggested that the two positive cell lines used in previous 
experiments happened to be difficult to transfect using the lipid mediated transfection 
techniques. Fellow colleagues in the laboratory who have used the two cell lines 
(Panc04.03 and CFPac1) for siRNA-mediated knock down of other proteins using 
lipid mediated transfection reagents have encountered similar problems, indicating 





















Figure 43: Histogram above shows a significant reduction (***) in proliferation 
of Capan1 cells over 5 days when β6 is knocked down specifically (red bars). 
The non-targeting (NT) siRNA had no effect on the cells (green bars). Control 
cells are grown without any treatment in the growth media.  Student’s t-test p= 
<0.0001 (***). The histogram above represents the mean and +/- standard error 
of mean of two experiments performed with replicates of six per treatment in 
each experiment. 
 
The data in Figure 43 showed that inhibiting β6 at the mRNA level reduced cell 
proliferation in Capan1 cells similar to the effect of αvβ6 function-blocking antibodies, 
albeit observed in different cell lines. There was a significant reduction in proliferation 
from day 3 post transfection (20% decrease) compared to the NT siRNA treated 
cells. By day 5 post transfection there was a further dip in the rate of proliferation 
(30%) compared with the NT siRNA treated cells. The control cells served as an 
additional negative control to ensure the transfection protocol alone did not affect cell 
growth. It is worth noting that the reduction in proliferation when β6 is knocked down 
is less than that observed when using the αvβ6 function-blocking antibodies (30% 
inhibition compared with >50% using 53A.2). Whilst it would have been ideal to 
directly compare the effects of blocking antibodies and β6 knock down in the same 
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cell lines, the fact that neither Panc04.03 nor CFPac1 cell lines could be transfected 
with β6 siRNA meant that an alternative cell line (Capan1) had to be utilised. 
 
3.5.4 Effect of αvβ6 blocking antibody on the growth of PS1 cells 
 
The majority of the PDAC stroma is comprised of the pancreatic stellate cells and 
pancreatic fibroblasts along with other stromal cells. Our laboratory had isolated and 
characterised pancreatic stellate cells, termed PS1. As these will be used later 
(section 2.9.4) for in vivo xenograft models, it was essential to test the effect of the 
β6 function blocking antibody 264RAD on the growth of PS1 cells. 3000 cells per well 
were plated onto 96 well plates at day -1 (prior to antibody treatment). On day 0, 
αvβ6 function blocking antibody was added at multiple concentrations ranging from 
0.2µg/ml to 10µg/ml. At day 4, the antibody was replenished (fresh media with 
antibody added) and left until day 7. The control wells had an isotype negative 
control antibody at the respective concentrations and a no treatment well with only 
growth media was used as an additional control. Both the β6 blocking antibody and 
the control isotype antibody were prepared in 10% serum containing growth medium. 
The data in Figure 44 showed that there was no significant difference in proliferation 
of the pancreatic stellate cell line PS1 when treated with αvβ6 blocking antibody 
264RAD compared with the control isotype IgG antibody used at the same 






















Figure 44: The effect of 264RAD function blocking antibody on in vitro growth 
of PS1 cell line. Cell survival was quantified by MTT assay on day 7 and 
survival normalised to that of untreated cells. Results show that there is no 
reduction in proliferation. (Student’s t-test non significant). The graphs 
represent the mean and +/- standard error of mean of two experiments 
performed with triplicates per dose in each experiment. 
 
3.6 Effect of αvβ6 blockade on cell cycle progression 
 
Blockade of αvβ6 using a function blocking antibody or αvβ6 specific protein led to a 
significant reduction in proliferation in the two αvβ6 positive cell lines tested 
(Panc04.03 and CFPac1) and had no effect on the αvβ6 negative cell lines (Panc1 
and MiaPaCa2). The antibodies had maximum effect on proliferation when used at a 
final concentration of 10µg/ml final concentration. Since the difference in proliferation 
was dramatic compared to the isotype control antibody in these cell lines a cell cycle 
analysis was performed to understand how the reduction in proliferation was 
achieved.  
 
Panc04.03, CFPac1 (αvβ6 positive cell lines) and Panc1 (αvβ6 negative cell line) 
were treated with the αvβ6 blocking (53A.2) or the control antibody at 10µg/ml for a 
period of four and seven days. Residual adherent cells were harvested and added to 
floating cells in the supernatant and treated with propidium iodide (PI), a DNA binding 
dye. PI binds to the DNA in the cells and thus the cell cycle profile was analysed by 
flow cytometry. 
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The two αvβ6 positive cell lines, Panc04.03 and CFPac1, showed a significant 
difference in their cell cycle profile when treated with the αvβ6 blocking antibody 
53A.2 at 10µg/ml over seven days compared with the control IgG antibody treated 
cells, while there was no effect on the αvβ6 negative cell line, Panc1 (Figure 45). In 
Panc04.03 cells, there was a significant increase in cells in G2/M phase (Figure 46), 
whilst in CFPac1 cells a significant increase was observed in the sub-G1 phase 
(Figure 46). In all the three cell lines tested, there were a high percentage of cells in 
the Gap1 (G1) phase of the cell cycle (Figure 45 white bar). This is typical to cells 
when left in culture for a week, although this high percentage (e.g. >80% of 
Panc04.03) could potentially have masked any subtle differences in other stages of 
the cell cycle. There was no change in the percentages of cells in the synthesis (S) 
phase, (DNA replication) or in the >4N phase (polyploid cells) in all the cell lines 
tested.  
 
In contrast, there was a significant increase in the percentage of cells arrested in the 
Gap 2/Mitosis (G2/M) phase in Panc04.03 when treated with the αvβ6 blocking 
antibody (Figure 46) compared with the untreated cells or the IgG control antibody, 
from 6.5% to 16%. CFPac1 cells treated with the αvβ6 blocking antibody showed a 
significant increase in the sub-G1 population, from 8.5% to 46%, compared with the 
untreated or IgG antibody treated cells (Figure 46). Sub-G1 population usually is an 
indicator of cell death and an increase in percentage of the sub-G1 population 
suggested that there were dying or dead cells. This could be due to the fact that the 






























Figure 45: Cell cycle analysis of Panc04.03, CFPac1 and Panc1 cells when 
treated with the αvβ6 blocking antibody 53A.2 at 10 µg/ml over 7 days. There 
was an increase in the percentage of cells in G2/M phase (blue) in the antibody 
treated Panc04.03 cells and an increase in the percentage of cells in the sub-
G1 (green) in the antibody treated CFPac1 cells. No differences in cell cycle 
profile were observed in the Panc1 (αvβ6 negative) cells when treated with the 
antibody. The data represents the mean and +/- standard error of mean of two 




















Figure 46: Histograms showed a significant increase in the percentage of cells 
in different phases of the cell cycle in the αvβ6 antibody (53A.2) treated cells. 
The G2/M phase (*) in Panc04.03 and Sub-G1 (**) (red bars) in CFPac1 cells 
were significantly higher when compared to the control isotype antibody 
(green bars). Student’s t-test p= >0.04 (*) p= >0.004 (**). The data represent the 
mean and +/- standard error of mean of two experiments performed with 




3.7 Effect of αvβ6 blockade on downstream signalling 
pathways in PDAC cell lines 
 
In order to further investigate the apparent cell cycle arrest (G2/M) and apoptosis 
observed in cells treated with the αvβ6 blocking antibody 53A.2, downstream 
signalling pathways were investigated. There are very few studies detailing the 
signalling pathways associated with ligation of the αvβ6 integrin. Investigations on 
interaction of αvβ6 with other proteins have begun to shed more light on its effects on 
cellular functions. ERK-2 and Fyn are the only two ‘classical’ signalling molecules, 
which have been reported to bind directly to αvβ6 and, as a consequence, evoke a 
functional response down stream [181, 190].  
 
Panc04.03 and CFPac1 cells were treated with the αvβ6 blocking antibody 264RAD 
or a control isotype IgG at 10µg/ml over a time period of 24 to 96 hours. Every 24 
hours, the cells and the supernatant were harvested and whole cell lysates were 
prepared. These lysates were probed for the two molecules that have been shown to 
interact with β6, ERK and Fyn, by Western blotting. Due to the significant increase of 
sub-G1 phase in the cell cycle analysis, expression levels of caspase 3 were also 
investigated.    
 
3.7.1 Expression levels of ERK in αvβ6 blocked PDAC cell lines 
 
Whole cell lysates were prepared and subjected to SDS PAGE and the membranes 
were probed for phospho ERK, stripped and probed for total ERK. HSC 70 was a 
loading control and was probed in the same blot (molecular weight 70kDa). There 
was no striking difference in the expression levels of phospho ERK or total ERK in 
the CFPac1 cells (molecular weight 41-42kDa) that were treated with the αvβ6 
function-blocking antibody compared to the control antibody over 24 to 96 hours time 
period (Figure 47). There was a slight, but reproducible, reduction in expression of 
phospho ERK in αvβ6 blocking antibody treated cells compared with the control 
antibody treated cells at 24 and 48 hours, with expression reduced by 18% and 24% 
respectively. No difference in phospho ERK expression was observed at 72 and 96 
hours. This result suggested that the effect on proliferation observed when treated 
with the αvβ6 blocking antibody may be dependent on ERK and its interaction with 
















Figure 47: Western blot probing for phospho and total ERK 1/2 in CFPac1 cells 
treated with 264RAD αvβ6 blocking antibody or control IgG isotype antibody at 
10µg/ml for 24, 48, 72 and 96 hours. HSC70 served as a loading control. The 




















Figure 48: Quantification of phospho ERK following treatment with 264RAD in 
the CFPac1 cell line. Protein expression was quantified using image J 
software. Expression of phospho ERK in each lysate was normalised to 
expression of HSC70, which served as a loading control. Phospho ERK 
expression in 264RAD treated cells was then expressed relative to that in IgG 




























3.7.2 Expression levels of Fyn in αvβ6 blocked PDAC cell lines 
 
Fyn is a member of the Src family of proteins and is located on the cytoplasmic side 
of the plasma membrane. Tyrosine phosphorylation of target proteins by Fyn 
regulates intercellular signalling pathways. Fyn has been shown to interact directly 









Figure 49: Western blot probing for expression levels of Fyn in CFPac1 cells 
treated with αvβ6 blocking antibody, 264RAD or an isotype control antibody at 
10µg/ml for 24, 48, 72 and 96 hours. Beta actin served as a loading control. The 
above image is representative of two experiments carried out under the same 
conditions. 
 
The expression level of Fyn was not affected by the antibody treatment in the 
CFPac1 cell line over a 24 – 96 hour time period. Expression of Fyn was observed to 
be higher in the αvβ6 blocking antibody treated cell lysate and control antibody 
treated cell lysate at the 96 hour time point compared to the other time points (Figure 
49). Beta actin served as a loading control in this experiment with a molecular weight 
of 43kDa. The above result suggested that the effect of proliferation observed when 
treated with the αvβ6 blocking antibody was not dependent on changes in levels of 
expression of Fyn in CFPac1 cell line.  
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3.7.3 Expression levels of caspase 3 in β6 blocked PDAC cell 
lines 
 
As blocking β6 using 53A.2 antibody resulted in a significant increase in sub-G1 DNA 
(Figure 46), which may be indicative of apoptosis, levels of caspase 3 were 
investigated in CFPac1 cells. Caspase 3 is a key executioner of apoptosis and is 
either partially or totally responsible for proteolytic cleavage of many proteins such as 
poly ADP ribose polymerase (PARP). It also interacts with other members of the 
caspase family like caspase 8 and caspase 9. Cleavage of caspase 3 is generally 
used as an indicator of apoptosis in cells and is usually detected as p17 and p12 
fragments. It should be noted that there are caspase-independent mechanisms of 












Figure 50: Western blot probing for expression levels of Caspase 3 in CFPac1 
cells treated with β6 blocking antibody 264RAD or an isotype control antibody 
at 10µg/ml for 24, 48, 72 and 96 hours. HSC70 served as a loading control. 
Blots are representative of two experiments carried out under the same 
conditions. 
 
CFPac1 cells were treated with αvβ6 blocking antibody 264RAD for 24, 48, 72 and 
96 hours. Cells were lysed and Western blotting performed to detect both pro and 
cleaved caspase 3. Despite a significant increase in sub-G1 DNA at day 7 post-
treatment with αvβ6 blocking antibody (Figure 46), from 8.5% to 46%, the expression 
level of caspase 3 was not affected by the antibody treatment in CFPac1 cell lines. 
Expression of cleaved caspase 3 was observed to be higher in the β6 blocking 
antibody treated cell lysate compared to the control antibody treated cell lysate at the 
24 hour time point, although expression of total caspase 3 was also higher 
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difference in caspase 3 expression levels at any other time points. This result 
suggested that the significant increase in sub-G1 phase that was observed during 
cell cycle analysis on CFPac1 cells treated with the αvβ6 function-blocking antibody 
in vitro (Figure 46) may not be caspase mediated. However, tumours in vivo treated 
with the αvβ6 function-blocking antibody 264RAD showed significant difference in 
levels of caspase 3 expression suggesting that there occurs a difference in activation 
of caspase 3 between cells grown in tissue culture and in vivo as discussed later 
(section 5.4.1.4).   
 
3.7.4 Expression levels of cyclin B1 in αvβ6 blocked PDAC cell 
lines 
 
Cyclin B1 is a mitosis regulatory protein expressed predominantly during the G2/M 
phase of cell cycle. Its activation is involved in early events of mitosis such as 
chromosome condensation and nuclear envelope breakdown. Cells generally 
express increased inactive cyclin B1 prior to mitosis and therefore a cell cycle block 
at the G2/M phase should result in even higher levels of cyclin B1. As an increase in 
G2/M from 6.5% to 16% was observed in Panc04.03 cells following treatment with 
53A.2 antibody (Figure 46), levels of cyclin B1 were investigated in whole cell lysates 
of cells also treated with an αvβ6 function blocking antibody.  
 
Expression of cyclin B1 was higher in the αvβ6 blocking antibody-treated cell lysate 
compared with the control antibody treated cell lysates at 24 and 48 hours with an 
increase of 16% and 21% respectively (Figure 52), suggesting a possible early 
induction of G2/M arrest. However, there was no difference observed between the 
αvβ6 blocked lysates and the control antibody-treated cells at either 72hrs or 96hrs 
post-treatment with antibody (Figure 52), indicating that a single dose of αvβ6 
blocking antibody does not lead to a sustained anti-proliferative effect, despite some 
early changes in cyclin B1 levels. Interestingly, levels of cyclin B1 also increased in 
control IgG treated cells (Figure 51) from 48hrs to 72hrs post-treatment which may 












Figure 51: Western blot probing for expression levels of cyclin B1 in Panc04.03 
cells treated with αvβ6 blocking antibody, 264RAD, or an isotype control 
antibody at 10µg/ml for 24, 48, 72 and 96 hours. HSC70 served as a loading 
control. The above blot is a representative image of three experiments carried 

















Figure 52: Quantification of cyclin B1 in Panc04.03 following treatment with 
264RAD αvβ6 function blocking antibody. Protein expression was quantified 
using image J software. Expression of cyclin B1 in each lysate was normalised 
to expression of HSC70, which served as a loading control. Cyclin B1 
expression in 264RAD treated cells was then expressed relative to that in IgG 


























It is worth noting that significant increases in cells in G2/M arrest or containing sub-
G1 DNA in Panc04.03 or CFPac1 cells respectively were observed at Day 7 
following two doses of β6 blocking antibody on day 1 and day 4 (Figure 46), whereas 
levels of both cyclin B1 and caspase 3 were investigated after a single dose of αvβ6 
blocking antibody over a 96hr time period. It was hypothesised that any changes in 
proteins associated with proliferation, and particularly induction of apoptosis, would 
be apparent prior to changes observed in cell cycle analysis. However, it may be that 
one dose of αvβ6 blocking antibody is not sufficient to lead to a sustained anti-
proliferative state and a second dose is necessary. This could be one explanation as 
to why the changes in cell cycle data were not reflected as dramatically in 
downstream signalling proteins such as Erk, Fyn, cyclin B1 and caspase 3. The other 
reason being that none of the above molecules may be affected as a result of αvβ6 
blockade.   
 
3.8 Role of αvβ6 in PDAC cell migration 
 
αvβ6 expressing oral cancer cells have been shown to have an increased migratory 
capacity and this contributes towards a more malignant phenotype [209]. In order to 
investigate the role of αvβ6 in PDAC cell migration, migration of PDAC cells towards 
the αvβ6 ligands, fibronectin and LAP of TGFβ1 were conducted. αvβ6 has a strong 
binding affinity for fibronectin, which is an important ECM protein upregulated in the 
pancreatic tumour stroma. The same subset of cell lines used for proliferation 
assays, Panc04.03, CFPac1 (αvβ6 positive cell lines) and Panc1, MiaPaCa2 (αvβ6 
negative cell lines) were used to study antibody-mediated blockade of β6 and its role 
in modulating cell migration.  
 
3.8.1 Migration of PDAC cells towards fibronectin 
 
50,000 cells were plated onto Transwell® membranes where the underside of the 
membrane, had previously been coated with fibronectin at 10µg/ml (section 2.9.1). 
Cells were incubated for 16 hours in serum free media, harvested and counted. Cells 
were incubated at 4°C with αvβ6 blocking antibody 53A.2 or a control isotype 
antibody at 10µg/ml final concentration for 60 minutes prior to plating them onto 










































Figure 53: Effect of antibody-mediated blockade of αvβ6 on migration towards 
fibronectin by the two αvβ6 positive cell lines Panc04.03 and CFPac1. Cells 
were treated with 53A.2 at 10µg/ml for 1 hour before migration towards 
fibronectin over a 16 hour period was quantified. There was a significant 
reduction in migration towards fibronectin compared to the isotype IgG control 
Student’s t-test p= <0.0001 (***). The antibody did not have any effect in 
migration of cells towards BSA, which was a negative control (Student’s t-test 
p= non significant). Histograms represent mean ± SEM of two experiments, 





























































Figure 54: Effect of antibody-mediated blockade of αvβ6 on migration towards 
fibronectin by the two αvβ6 negative cell lines Panc1 and MiaPaCa2. Cells 
were treated with 53A.2 at 10µg/ml for 1 hour before migration towards 
fibronectin over a 16 hour period was quantified. There was no significant 
reduction in migration towards fibronectin compared to the isotype IgG control 
(Student’s t-test: non significant). The antibody did not have any effect in 
migration of cells towards BSA, which was a negative control. Histograms 
represent mean ± SEM of two experiments, each performed with four replicates 



















The data in Figure 53 showed that there was a significant reduction in migration by 
59% in Panc04.03 and by 44% in CFPac1 towards fibronectin over 16 hours when 
αvβ6 was blocked using a function blocking antibody, 53A.2 (p= <0.0001). The 
untreated samples did not have any antibody and served as a control for basal levels 
of migration. Levels of migration were not increased by the addition of the IgG control 
antibody demonstrating that it did not have any non-specific effects on the cells. The 
migration towards BSA served as an additional control to highlight the fact that cells 
tend to exhibit an enhanced migratory phenotype in the presence of fibronectin and 
any reduction in this migration observed was as a direct result of inhibition of binding 
of αvβ6 to fibronectin.  
 
Furthermore, the data in Figure 54 showed that there was no difference in migration 
in Panc1 and MiaPaCa2 over 16 hours when treated with a αvβ6 function blocking 
antibody 53A.2. This demonstrates that the antibody was specific and does not have 
any off target effects in αvβ6 negative cell lines.  
 
3.8.2 Migration of PDAC towards LAP 
 
Similarly, 50,000 cells were plated onto Transwell® membranes where the underside 
of the membrane had previously been coated with LAP at 1µg/ml. Cells were 
incubated for 16 hours in serum free media, harvested and counted. Cells were 
incubated at 4°C with αvβ6 blocking antibody 53A.2 or a control isotype antibody at 
10µg/ml final concentration for 60 minutes prior to plating them onto Transwell® 













































Figure 55: Effect of antibody-mediated blockade of αvβ6 on migration towards 
LAP in the two αvβ6 positive cell lines Panc04.03 and CFPac1. Cells were 
treated with 53A.2 at 10µg/ml for 1 hour before migration towards LAP over a 
16 hour period was quantified. There was a significant reduction in migration 
towards LAP compared to the isotype IgG control (Student’s t-test p= <0.0001). 
The antibody did not have any effect in migration of cells towards BSA, which 
was a negative control (Student’s t-test: non significant). Histograms represent 































































Figure 56: Effect of antibody-mediated blockade of αvβ6 on migration towards 
LAP in the two αvβ6 negative cell lines Panc1 and MiaPaCa2. Cells were 
treated with 53A.2 at 10µg/ml for 1 hour before migration towards LAP over a 
16 hour period was quantified. There was no significant reduction in migration 
towards fibronectin compared to the isotype IgG control. The antibody did not 
have any effect in migration of cells towards BSA, which was a negative 
control (Student’s t-test: non significant). Histograms represent mean ± SEM of 



















LAP is one of the major ligands of αvβ6 since binding to LAPs on latent TGFβ 
activates TGFβ. The data in Figure 55 showed that there was a significant reduction 
in migration towards LAP of 58% in Panc04.03 and 46% in CFPac1 over 16 hours 
when αvβ6 is blocked using a function blocking antibody 53A.2 (p= <0.0001). 
Untreated samples served as a control for basal levels of migration and also showed 
that the IgG control antibody did not have any non-specific effects on the cells. The 
migration towards BSA was unaffected by treatment with either 53A.2 or IgG control. 
In contrast, the results in Figure 56 showed that there was no difference in migration 
towards LAP of TGFβ in Panc1 and MiaPaCa2 over 16 hours when treated with a 
αvβ6 function blocking antibody 53A.2. As these cells do not express αvβ6, this 
result was not surprising and demonstrates the specificity of 53A.2 in evoking this 
effect upon migration.  
 
3.9 Role of αvβ6 in PDAC invasion 
 
As migration was inhibited in PDAC cell lines by blockade of αvβ6, its role in invasion 
was next investigated. Epithelial cell invasion occurs when carcinoma cells breach 
the basement membrane, migrate into and come in contact with the stromal ECM. 
This is an extremely complicated process where the cells are required to secrete 
various factors including proteases such as MMPs, which in turn will favour invasion. 
αvβ6 expression in OSCCs has been shown to correlate with an increase in 
expression of MMP9 and MMP2 and αvβ6 has been shown to be responsible for 
increased oral cancer invasion in an MMP9-dependent manner [125]. 
 
3.9.1 Invasion assay using a β6 blocking antibody 
 
Transwell® inserts coated with Matrigel™ were prepared to test the ability of a panel 
of six αvβ6 positive pancreatic carcinoma cell lines to invade through this barrier. The 
cells were first incubated with the αvβ6 function blocking antibody 10D5 (Table 9) or 
an isotype control antibody at a final concentration of 10µg/ml at 4°C for up to 60 
minutes before plating onto Matrigel™ coated membranes (section 2.9.2). The 
Transwell® plates were harvested 72 hours later and the invaded cells in the lower 





























Figure 57: Effect of blocking αvβ6 on invasion of PDAC cells. Cells were 
treated with 10µg/ml of 10D5 αvβ6 function blocking antibody or an isotype 
control antibody for 1 hour. Cells were then plated onto matrix-coated 
membranes and invading cells were counted 72 hours later. Data show the 
mean ± SEM from a minimum of two experiments each performed with 
triplicates for each condition. Student’s t-test p= <0.0001 (****), p= <0.001 (***). 
p= <0.02 (*).   
 
The data in Figure 57 showed that 5 out of the 6 PDAC cell lines had invasive 
propensity and there was a significant reduction in invasion in four out of the five 
PDAC cell lines tested when blocked with an αvβ6 function-blocking antibody 10D5 
at 10µg/ml. There was a reduction in invasion by 69% in CFPac1, 56% in Panc04.03, 
61% in BxPC3 and 34% in Capan1 compared with the control antibody. Whilst a 21% 
reduction in invasion was also observed in the AsPc1 cell line this difference was not 
statistically significant.  
 
Although all six cell lines tested in Figure 57 expressed αvβ6, their invasive potential 
varied greatly with Panc04.03 and AsPc1 cells showing higher levels of invasion 
compared with the other cell lines. The level of αvβ6 expression did not correlate with 
increased inhibition of invasion when αvβ6 was blocked. HPAF had high levels of 







































in certain PDAC cell lines, the mere expression of αvβ6 is not in itself sufficient to 
promote invasion. 
 
In separate assays, the αvβ6 blocking antibody, 264RAD, was used on a smaller 
subset of PDAC cell lines, Panc04.03 and CFPac1 (αvβ6 positive cell lines) and 
Panc1 (αvβ6 negative cell line) to confirm that the observed reduction in invasion 
was due to specific blocking of αvβ6 in the cells and not due to any off target effect. 

















Figure 58: Effect of blocking αvβ6 on invasion of PDAC cells. Cells were 
treated with 10µg/ml of 264RAD αvβ6 function blocking antibody or an isotype 
control antibody for 1 hour. Cells were then plated onto matrix-coated 
membranes and invading cells were counted 72 hours later. Data show the 
mean ± SEM from a minimum of three experiments each performed with 
triplicates for each cohort. Student’s t-test p= <0.0001 (****), p= <0.02 (*). 
 
The results in Figure 58 showed that there was a significant reduction in invasion in 
the two αvβ6 positive cell lines, Panc04.03 and CFPac1 when blocked with the αvβ6 
function blocking antibody 264RAD at 10µg/ml whereas there was no effect on the 
β6 negative cell line Panc1. There was a reduction in invasion by about 46% in 
Panc04.03 and 43% in CFPac1 compared to the control antibody.  Proliferation 
































reduction in invasion observed was not an indirect result of reduced proliferation in 



















Figure 59: Treatment of Panc04.03 and CFPac1 cell lines with the αvβ6 
blocking antibody 264RAD over 72 hours does not inhibit proliferation. Cells 
were treated with 10µg/ml 264RAD and cell survival quantified by MTT assay 72 
hours later. Data show the mean ± SEM of three experiments performed with 
replicates of four per treatment in each experiment. Student’s t-test (p= non 
significant).  
 
Data in Figure 59 showed that there was no significant difference in proliferation of 
Panc04.03 and CFPac1 cell lines when treated with the αvβ6 blocking antibody 
264RAD at 10µg/ml over 72 hours compared with the control isotype IgG antibody. 
The proliferation assays were performed in parallel with each invasion assay 
experiment for all the cell lines tested with no significant difference in proliferation 













































3.9.2 Developing a 3D organotypic co-culture  
 
Monolayer cultures do not provide even an approximate simulation of in vivo tissue 
because monoculture in 2 dimensions (2D) lacks cell-cell, cell-ECM and cell-stromal 
interactions, which are key players in control of gene expression and behaviour of 
cells. An in vitro tissue model, which allowed us to better replicate these cell-stromal 
interactions and their effects on tumour cell growth and invasion, was essential. 
Therefore organotypic 3D co-cultures of PDAC cells and fibroblasts were developed 
to model epithelial-stromal interactions. The growth, differentiation and invasive 
behaviour of cells was observed in this assay, which was modelled on organotypic 
co-cultures as described previously [90].  
 
Briefly, collagen; Matrigel™ gels embedded with human fibroblasts were overlaid 
with PDAC cells. The structures were raised to an air-liquid interface and cultures 
maintained for 14 days, feeding every other day. The co-culture model was optimised 
so that it can be used to culture PDAC cells in a more physiologically relevant 
manner. Representative images of pancreatic cancer cell lines that have been tested 
are shown in the following two figures and these images illustrate that the different 































Figure 60: Representative H&E images of 3D organotypic co-cultures with 
PDAC cell lines CFPac1 and Capan1 co-cultured with MRC5-hTert fibroblasts 
over two weeks.  
 
Figure 60 shows H&E images of CFPac1 and Capan1 cell lines growing on 
organotypic gels. Both cell lines formed deep epithelial structures filled with luminal 
spaces, typical of adenocarcinoma. There was clear evidence that CFPac1 but not 
Capan1 or Panc04.03 (Figure 61) invaded the fibroblast rich matrix. This was in 
contrast to the 2D Transwell® invasion assay, where all three cell lines exhibited 
invasive propensity. This was a clear example demonstrating the different behaviour 
of cancer cell lines in a 3D matrix when co-cultured with stromal cells.  Since these 
gels can be treated similarly to human tissue, they were stained for αvβ6 expression 










































Figure 61: Organotypic co-cultures stained for αvβ6 and ki67. Panc04.03 and 
HPAF cells were co-cultured with MRC5-h-Tert for 14 days and then processed 
for IHC. Sections were stained for αvβ6, ki67 and with H&E.   
 
The results showed that both Panc04.03 and HPAF PDAC cell lines retained strong 
expression of αvβ6, as observed by the brown colour in the epithelial cells (Figure 
61). Ki67 staining showed that a significant fraction of the cells retained their ability to 
divide (brown dots in the nuclei of the cell) in Panc04.03 and HPAF PDAC cell lines 
(Figure 61). It should be noted that αvβ6 typically was expressed strongly on the 
membrane at the cell-cell junctions. These data may also suggest that Panc04.03 
Panc04.03 β6 staining HPAF β6 staining 
HPAF ki67 staining Panc04.03 ki67 staining 




may undergo changes in cell polarity since most ki67 positive nuclei are near, or at, 
the baso-lateral surface (shown by an arrow in Panc04.3 ki67 staining x10, (Figure 
61).  
 
Even though both PDAC cell lines formed a thick layer of epithelium on the gel with 
ductal structures, typical of PDAC tumours, and continued to grow and multiply in the 
3D cultures, only CFPac1 showed invasion in this assay out of a panel of PDAC cell 
lines that was tested. Different fibroblasts and pancreatic stellate cells were also 
used to co-culture with PDAC cell lines, with no or very little invasion (data not 
shown). This could be due to the poor invasive potential of the PDAC cell lines tested 
in this assay. Each experiment (cell line) was prepared in triplicate and was repeated 
a minimum of three times. Since blocking αvβ6 significantly reduced proliferation and 
invasion in PDAC cell lines in 2D cultures, the organotypic co-cultures were a good 
model to test the role of αvβ6 in PDAC cell line proliferation and invasion in a more 
physiologically relevant 3D setting. Since these cultures were grown for fourteen 
days, siRNA mediated knock down of β6 on cell lines was not possible. Antibody 
mediated block of αvβ6 was not considered to be an option either because of the 
technical difficulties involved in treating the cells in 3D culture. A stable knock down 
of αvβ6 in PDAC cell lines was deemed essential to test its effect on proliferation and 
invasion over this long-term assay.  
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3.10 Stable knock down of β6 in PDAC cell lines 
 
Three lentiviral shRNA sequences in pGIPZ vectors (section 2.4.1) were purchased 
from Open Biosystems to knock down β6 in pancreatic cancer cell lines. The pGIPZ 
vector also had a turbo-GFP as a read out to measure the levels of expression. The 
vector contains both puromycin and zeocin antibiotic selection. After confirming, by 
sequencing, that the plasmids did indeed target the published sequences HEK 293 
FT cells were used to make the lentivirus particles, using a three vector transfection 
method as detailed in methods (section). The PDAC cell lines CFPac1 and 
Panc04.03 were incubated with the supernatant containing the viral particles together 
with polybrene (hexadimethrine bromide) for 4 hours at 37°C. Following incubation, 
fresh 10% FCS containing growth medium was added and cells left to grow. Since 
the viruses also expressed GFP driven by an IRES promoter, up stream to the target 
shRNA sequence, infected cells would express this fluorochrome in proportion to the 
expression of the shRNA in the cell. Disappointingly two of the three plasmids failed 
to reduce αvβ6 expression (data not shown). However, the plasmid (V3LHS_374274, 
Open Biosystems), when used to infect Panc0403 and CFPac1 cells did seem to 
suppress αvβ6 expression based on flow cytometry. Post infection, the increase in 




















Figure 62: Lentiviral shRNA knockdown of αvβ6 in Panc04.03 cells. GFP and 
αvβ6 expression was determined prior to (A), (B) and post (C), (D) transfection. 
GFP was analysed as a measure of transfection and αvβ6 expression was 
determined using 10D5 antibody.  
Geometric mean 210.38 
Geometric mean 2.54 
Geometric mean 105.76 





Panc04.03 were analysed by flow cytometry before and after infection with the 
lentiviral construct V3LHS_374274. Data show that after infection GFP levels 
increased (geometric MFI 105.76 from 2.54) and αvβ6 detected by antibody 53A.2 
decreased (geometric MFI 210.38 to 89.2).  
 
Expression of αvβ6 in the infected cell population was reduced dramatically following 
lentiviral infection after three to five days in culture (geometric mean of 89.20) 
compared with the uninfected parent population of cells (geometric mean 210.38). 
Note that expression was reduced by >50% three weeks after infection when 
compared to the uninfected parental control (Figure 62). There was a dramatic 
increase in GFP positive cells following infection, which was an indicator for 
successful infection of the lentivirus into the cells (top) (geometric mean 105.26).  
 
The co-expressed fluorescent marker GFP was then used to select the most GFP-
positive cells (>90%) by FACS. Following sorting, the growth rate of cells was very 
slow until 6-8 weeks, after which their growth rate returned to normal permitting 























Figure 63: Lentiviral infected Panc04.03 cells do not stably express GFP. Six 
weeks after selection of αvβ6 high expressing cells, cells were analysed for 
both GFP and αvβ6 expression by flow cytometry.  
  
Geometric mean 16.07 
Geometric mean 312.57 
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Six weeks after sorting for high GFP expressers, cells were reanalysed by flow 
cytometry. Data showed that the cells lost expression of GFP with a geometric mean 
of 16.07 at six weeks compared with >105.76 (Figure 62) just after transfection. 
Similarly, αvβ6 expression returned to high levels, geometric mean 312.57 (Figure 
63) compared with geometric mean of 89.2 at the time of sorting (Figure 62). 
 
This loss of GFP and loss of αvβ6 suppression could be due to multiple reasons. The 
fact that the plasmid was in the cells and could be detected by flow cytometry 3-4 
days post infection showed that the infection worked, but following a positive GFP 
sort, the rate of cell growth dramatically slowed down for about 6-8 weeks; then the 
growth rate returned to the normal rate of growth. Once the growth rate returned to 
normal, enough cells could be collected to perform a flow cytometry analysis, which 
revealed that the cells had lost expression of GFP indicative of either loss of plasmid 
from cells or silencing of the lentiviral plasmid.  
 
This loss of GFP correlated with a return to high levels of αvβ6 indicating that the 
shRNA was not working. These data suggested that β6 might be crucial for the 
growth and survival of the PDAC cell lines tested, Panc04.03 and CFPac1 (data not 
shown), and any attempt to knock down αvβ6 stably is not possible as it is not 
compatible with cell growth and survival. All three shRNA sequences showed very 
similar results and it was not possible to generate a stable knock down for β6 in the 
two cell lines tested. A doxycycline (dox) inducible shRNA plasmid to knock down β6 
is currently available to purchase and it might be worth attempting to generate a 
stable dox-inducible knock down of β6 to overcome the dependence of these cells on 
αvβ6 for survival.  
  
 167 
3.11  Discussion 
 
Integrins are major contributors to the development of cancer because of their dual 
capacity to generate pro-oncogenic signals (e.g. increased secretion of proteases, 
generation of survival signals) as well as their ability to physically mediate tumour cell 
motility and invasion. The role of αvβ6 in PDAC is relatively unknown and only few 
studies have linked αvβ6 expression with pancreatic cancer [201, 207]. Sipos and 
colleagues reported αvβ6 to be overexpressed in pancreatic cancer from tissue 
samples obtained from a cohort of 34 patients. 100% of the PDAC tissue samples 
screened were positive for αvβ6. In in vitro studies, Singh et al, reported that αvβ6 
was part of a “gene signature” that was essential for mutant KRAS dependent 
pancreatic cancer cell survival [207]. The study used a panel of seven pancreatic cell 
lines; although shRNA mediated transient knock down of β6 was performed in three 
of these, a significant decrease in cell survival (60% to 80%) compared to control 
knock down was only observed in the YAPC cell line, using in vitro cell proliferation 
assays [207]. If this result with a single cell line were extrapolatable to the clinical 
situation then αvβ6 could be an ideal therapeutic target since it appears to be entirely 
absent from normal tissue. Moreover, for the same reasons, it could prove to be an 
ideal imaging target. In fact, a subcutaneous inoculum of the αvβ6 positive BxPC3 
cell line was used to image αvβ6 positive tumours specifically using a radiolabelled 
peptide [(18F)] FBA-A20FMDV2 (A20FMDV2 is a peptide that binds specifically to 
αvβ6) using positron emission tomography (PET) [235]. Current non-invasive 
imaging using radio-tracers to detect metastatic PDAC pre-operatively has limited 
success due to non-specific uptake in tissues. A radiolabelled αvβ6 specific peptide 
improves tumour uptake due to expression of αvβ6 solely in the tumour tissue and 
this could have important implications in clinical outcome. 
 
3.11.1  Characterising αvβ6 in PDAC cell lines 
  
This study aimed to determine the functions that αvβ6 expression would impart to 
PDAC cells and whether these would potentially enhance PDAC growth and 
invasion. A pilot IHC study of tissue obtained from 34 PDAC patients and 12 normal 
cases, was conducted and the tissues were analysed for αvβ6 expression. All PDAC 
cases were positive for αvβ6 with 38% expressing very high levels. In contrast, only 
1 of the 12 normal cases expressed αvβ6 at a very low level. This preliminary study 
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served to confirm findings from Sipos et al, and suggested that αvβ6 could be a 
potential therapeutic target in PDAC.  
A panel of 9 pancreatic human cell lines (Table 12) was screened to check for αvβ6 
surface expression levels using flow cytometry. αvβ6 recognises its target ligands 
using the RGD tri-peptide sequence and binds to a variety of ECM proteins including 
fibronectin, LAP, tenascin-c and vitronectin. Seven out of the nine PDAC cell lines 
tested were positive for αvβ6 expression, consistent with the high expression seen in 
PDAC tissue. Varying levels of positivity were observed, with some cell lines 
expressing αvβ6 at very high levels (CFPac1, Panc04.03), some at moderate levels 
(AsPc1, BxPC3) and some with no expression (Panc1, MiaPaCa2). Published 
literature has always associated β6 with well-differentiated tumours [201], so when 
the cell lines were grouped based on their differentiation status (at the time of origin) 
it was not surprising to observe higher levels of αvβ6 expression in the well 
differentiated cell lines (Figure 32). These early events were encouraging because 
they meant that there was now a panel of PDAC cell lines available, some 
expressing varying levels of endogenous αvβ6 and some αvβ6 negative cell lines to 
study the functional role of endogenous αvβ6 in PDAC. 
 
Having looked at the surface expression levels of αvβ6 in PDAC cell lines, whole cell 
lysates from a subset of cell lines tested were prepared to measure total levels of 
αvβ6 expression and to determine if these results matched the flow cytometry data 
(Figure 34). The levels showed a similar pattern of expression to that observed with 
flow cytometry. Thus, two separate methodologies were used to confirm αvβ6 
expression in the same panel of PDAC cell lines. Based on these data, Panc04.03 
and CFPac1 were the two high αvβ6 expressing cell lines selected and MiaPaca2 
and Panc1 were the two negative cell lines selected for further investigation.  
 
3.11.2 Functional role of αvβ6 in PDAC cell lines 
 
Studies conducted to date have not looked into the functional role of αvβ6 in 
pancreatic cancer cells. In other tumour systems αvβ6 has been shown to promote 
activities that could increase tumour progression by increasing migration, invasion, 
survival and MMP secretion [209]. Very recently, an αvβ6 blocking antibody 264RAD 
was assessed as a possible new targeted therapy to treat αvβ6 positive oral and 
breast cancer tumours in xenograft models where they showed that the αvβ6 
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function-blocking antibody significantly reduced tumour size compared to the control 
antibody treated tumours in recipient mice [233]. The authors of this study also 
showed a dose dependent decrease in expression of Ki67 in the 264RAD antibody 
treated tumours indicative of a reduction in proliferation.  
 
3.11.2.1  Role of αvβ6 in regulating cell proliferation 
 
Targeting integrins using specific antibodies has long been used as a possible 
therapeutic approach to treat various cancers. An αvβ3 function blocking antibody, 
etaracizumab, targets ovarian cancer cell lines that express αvβ3 and significantly 
reduces proliferation and invasion in a phospho AKT and phospho mTOR dependent 
manner [236]. Another study has shown that the αv blocking antibody 17E6 inhibited 
the growth of melanoma cells in nude mice, although no obvious mechanisms were 
reported [4].  
 
Blockade of αvβ6 in PDAC cell lines showed there was a significant and dose 
dependent decrease in cell survival in two αvβ6 positive cell lines (Panc04.03, 
CFPac1) when treated with either of the αvβ6 function-blocking antibodies 53A.2 or 
264RAD (Figure 36, Figure 38). The 264RAD αvβ6 function-blocking antibody has 
also been shown to bind with low affinity to αvβ8 [233]. However there are several 
reasons to believe that the effect of 264RAD in this model is predominantly due to 
interaction with αvβ6. Panc04.03 do not express αvβ8 and CFPac1 cells express 
αvβ8 at very low levels. Furthermore, two αvβ6 negative cell lines (Panc1, 
MiaPaCa2) did not show any difference in cell survival when treated with the same 
αvβ6 function-blocking antibody at similar concentrations (Figure 37, Figure 39). 
These results suggested that the anti-αvβ6 function-blocking antibody blocked αvβ6 
specifically and this led to a decrease in proliferation. It also confirmed that the 
antibody did not have any non-specific off target effects because the αvβ6 negative 
cell lines were not affected by the treatment and continued to look healthy without the 
rounding and increased nuclear size observed in the αvβ6 positive cell lines.  
 
The potential power of blocking αvβ6 function as a method for therapy was further 
confirmed using a fragment of adenovirus modified to incorporate the peptide 
A20FMDV2. A20FMDV2 is a peptide derived from the foot-and-mouth disease virus, 
with a high affinity and specificity for αvβ6 [124]. A recombinant adenovirus type 5 
(Ad5) fibre knob protein incorporating A20FMDV2 in the H1 loop was generated to 
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target αvβ6 positive tumours specifically [234]. This Ad5 knob protein was generated 
as part of an independent study on viral gene therapy performed by a colleague in 
the laboratory at the time. It was decided to test this recombinant protein on αvβ6 
dependent PDAC cell proliferation. The modified Ad5 A20FMDV2 had a similar dose-
dependent effect on Panc04.03 and CFPac1 cells, inhibiting their proliferation 
significantly (Figure 40). In contrast, the two negative cell lines were not affected by 
the treatment (Figure 41). Thus, three independent targeting agents that block αvβ6 
significantly reduced PDAC cell proliferation in αvβ6 positive, but not in αvβ6 
negative tumour cell lines. These data suggest that in PDAC cell lines, αvβ6 
signalling is an essential survival factor. In support of these conclusions, when Singh 
et al, used shRNA to knock down αvβ6 in PDAC cell lines, there was no effect on 
proliferation in the Panc1 cell line but a significant decrease in proliferation in the 
αvβ6 positive YAPC cell line [207]. They also observed similar effects on cell survival 
in the two αvβ6 positive KRAS dependent lung cancer cell lines tested (H358 and 
A549).  
 
The next step in this study was to try and knock down β6 using siRNA on the two 
αvβ6 positive cell lines to observe if there was a similar effect on cell proliferation 
seen by the blocking antibodies, an approach similar to that used by Singh et al 
[207]. Unfortunately, this proved to be not possible; a consequence perhaps of 
Panc04.03 and CFPac1 proving to be extremely difficult to transfect. Different lipid 
mediated transfection agents were used (lipofectamine, oligofectamine, interferin, 
gene juice) with no success. Electroporation was performed and although it yielded a 
70% knock down of αvβ6 expression (data not shown), many dead or dying cells 
were seen after treatment with the non-targeting siRNA as a consequence of the 
electroporation. These many attempts, over a protracted time period, were 
disappointing and frustrating and occupied a considerable amount of time. For 
whatever reason, αvβ6 expression could not be reduced in Panc04.03 or CFPac1 
cells. Accordingly Capan1, another αvβ6 positive cell line, was used instead to knock 
down β6 using oligofectamine mediated siRNA transfection. There was a significant 
difference in proliferation in the β6 siRNA treated cells compared with the non-
targeted siRNA control treated cells over 5 days (Figure 43). Note that the antibody-
mediated function blocking (2 doses) of αvβ6 over 7 days yielded better inhibition of 
proliferation compared with the siRNA-mediated inhibition of proliferation over 5 days. 
This may be due to the lack of a 100% knock down of β6 in the cells over a 5 day 
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period. It could also be that the cells where β6 was still expressed (no knock down) 
started to out grow the slow growing low β6 expressers thereby masking any 
differences in proliferation between the β6 siRNA and NT siRNA treated cells.  
 
Importantly, it was necessary to confirm that neither of the αvβ6 blocking antibodies 
had any effect on pancreatic stellate cells. Using the pancreatic stellate cell line PS1, 
it was confirmed that neither 53A.2 nor 264RAD (data not shown) had any effect on 
PS1 proliferation (Figure 44).  Thus in later in vivo studies, any effect of the antibody 
on xenograft growth is unlikely to be via a direct effect on the proliferation of stellate 
cells. 
 
3.11.2.2 Effect of αvβ6 on cell cycle progression in PDAC 
 
Although blockade of αvβ6 has been shown to reduce PDAC cell survival 
significantly, the exact mechanism by which it exerts this regulation is unknown. 
Routine microscopic observation of cells revealed phenotypic changes with cells 
appearing to be more rounded with bigger nuclei in the αvβ6 blocking antibody 
treated cells (Panc04.03, CFPac1) compared with the control cells. Other studies 
have shown that blocking integrins can have an effect on cell cycle progression. 
Knockdown of the α6 subunit and overexpression of the α5 subunit in the murine 
breast cancer cell line 4T1 showed inhibition of tumour growth in vivo. In these cells, 
there appeared to be a S phase block in the cell cycle and an increase in p27 with a 
corresponding decrease in the CyclinE/CDK2 [237]. In order to better understand the 
reduction in proliferation observed as a result of αvβ6 blockade, cell cycle analysis 
was performed on Panc04.03 and CFPac1 cells. The antibody treated Panc04.03 
cells showed a small, but significant, increase in the G2/M phase compared to the 
IgG treated cells, which meant there was a block in cell cycle progression as the cells 
prepared to enter the mitotic phase (Figure 46). The CFPac1 cells treated with the 
αvβ6 blocking antibody showed a significant increase in the sub-G1 phase compared 
to the control IgG antibody treated cells (Figure 46). An increase in G2/M phase was 
also observed at day 7 in the CFPac1 cells but was not statistically significant. It is 
also possible that the cells blocked in the G2/M phase could have died, thus showing 
an increase in the sub-G1 phase. It might be worth considering earlier time points in 
the cell cycle assay to identify if there occurs any change in the G2/M phase in 
CFPac1 cells.  
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Increase in the sub-G1 population in cell cycle analysis is often mistaken for 
apoptosis and further analysis needs to be done in order to confirm if indeed it was 
apoptosis that contributed to the increased sub-G1 population in CFPac1 cells. In a 
pilot study, detection of surface annexin V was performed on CFPac1 cells treated 
with the αvβ6 blocking antibody 53A.2 (data not shown). The results obtained were 
inconclusive, however the assay needs to be optimised further before any 
conclusions can be made. Whilst Panc04.03 and CFPac1 cells showed similar levels 
of inhibition of proliferation upon treatment with αvβ6 function blocking antibodies, 
the mechanisms behind this may be different in each of the cell lines. Understanding 
the mechanism of action of the αvβ6 function blocking antibodies are vital and 
perhaps markers for cell cycle progression such as cyclin A, cdk2, cdk6, p16, p21, 
p27 need to be tested, which might provide an answer. Preliminary experiments 
conducted to test some of the above mentioned markers did not reveal any 
significant changes (data not shown). 
 
3.11.2.3 Effect of αvβ6 on downstream signalling 
pathways 
 
It was hypothesised that blocking αvβ6 was having an effect on the downstream 
signalling pathways involved in apoptosis and proliferation. αvβ6 has been previously 
shown to bind and activate Fyn, which activates the Raf-ERK/MAPK pathway and 
promote OSCC invasion [185]. αvβ6 has also been shown to interact with the ERK 
signalling pathway directly and deletion of the ERK2 binding site from the β6 
cytoplasmic tail led to a decrease in tumour growth in colon carcinoma cell lines 
[181]. Phosphorylation of ERK leads to activation of down stream signalling, which 
induces cell proliferation and survival. When levels of phospho ERK (proliferation), 
Fyn (integrin mediated signalling), caspase 3 (cell death by caspase dependent 
apoptosis) and phospho SMAD2/3 (activation of TGFβ) were examined in the cells 
treated with the αvβ6 blocking antibody or the control IgG antibody for 5, 15, 30, 45, 
60 minutes and 24 hours, disappointingly, no differences were observed between the 
two treatment groups at any of the time points (data not shown). It was then decided 
to examine later time points as the differences in proliferation observed in the cell 
cycle was at day 7. It was hypothesised that any changes in the signalling would 
happen prior to this time point. Lysates from the αvβ6 antibody treated and control 
IgG treated cells were prepared 24, 48, 72 and 96 hours post treatment and tested. 
However, no significant differences were observed at these time points when probed 
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for phospho and total ERK, Fyn, caspase 3 and cyclin B1 (Figure 47, Figure 49, 
Figure 50, Figure 51).  
 
A slight decrease in the expression levels of phospho ERK in CFPac1 cells at 24 
hours and 48 hours in the αvβ6 blocking antibody treated cells compared with the 
IgG treated cells was seen (decrease of 18% and 24% respectively). However, I 
cannot be certain if the differences observed in cell proliferation in CFPac1 cells as a 
consequence of αvβ6 blockade can be attributed to this decrease in phospho ERK 
observed. Nevertheless, it is worth bearing in mind that ERK2 has been shown to 
interact directly with the β6 subunit cytoplasmic tail and perhaps like Ahmed and 
colleagues have shown in colon cancer cell lines [181], mutating the ERK binding 
site in the β6 subunit in CFPac1 cells and studying its downstream signalling might 
be worth pursuing in the future.  
 
Cyclin B1 is an important regulatory subunit of Cdk1, essential for mitotic exit and 
completion of cell cycle and if cells are blocked at the G2/M phase, a corresponding 
increase in levels of cyclin B1 is usually expected. An increase in cyclin B1 was 
observed in Panc04.03 cells at 24hours and 48 hours (increase of 16% and 21% 
respectively). The levels of change observed were in line with the proportion of cells 
blocked at the G2/M phase upon αvβ6 blockade. Although encouraging, this change 
was not observed at the later time points tested, which made it difficult to make any 
conclusive inferences. Perhaps a more quantitative and sensitive technique (flow 
cytometry, qPCR) might reveal any subtle differences, if any, at the later time points.  
 
Generally, caspase 3 cleavage is considered to be a marker for apoptosis and is a 
convergent point for both intrinsic and extrinsic apoptotic pathway. Since there was a 
dramatic increase in the sub-G1 population in the αvβ6 function blocking antibody 
treated CFPac1 cells, lysates prepared at 24, 48, 72 and 96 hours were tested for 
caspase 3 activation. Disappointingly, no difference was observed in caspase 3 
activation at any of the time points. However as previously mentioned, the presence 
of sub-G1 DNA in itself is not definitive of apoptosis and furthermore caspase 
independent pathways of apoptosis have been described [238]. Apoptosis inducing 
factor (AIF) is released from the mitochondria during apoptosis and contribute to 
DNA fragmentation in the nucleus [239]. Importantly, release of AIF can be triggered 
independently of the caspase cascade by cathepsin D [240] and can also proceed in 
cells derived from a caspase 3 null mice [241].  
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It was disappointing that none of the potential markers showed any significant 
changes in response to αvβ6 treatment in vitro but it has to be borne in mind that 
signalling pathways are affected by multiple factors including the environment in 
which it is grown (plastic as opposed to a 3D matrix) and the surrounding 
microenvironment. These pathways are better reflected in vivo and some of these 
markers were significantly different between the αvβ6 blocking antibody treated 
tumours and control IgG antibody treated tumours, which will be further discussed 
later.  
 
3.11.2.4 Effect of αvβ6 on migration and invasion of 
PDAC cell lines 
 
Integrin signalling has been shown to be involved in both migration and invasion 
[242]. αvβ6 overexpression in OSCC cell lines promoted greater migration and 
invasion compared with control αvβ6 negative cell lines [209]. It has also been shown 
that up regulation of αvβ6 leads to an increase in MMP9 secretion which, in turn, 
promotes cancer cell migration and invasion [210]. Thus, there has been a strong link 
between αvβ6 and its role in cancer cell invasion and migration [208]. Invasion of 
pancreatic cancer cells into the surrounding nerves (perineural invasion) and blood 
vessels (vascular invasion) have been linked with local recurrence of PDAC in 
patients [243]. 
 
This study has shown that αvβ6 function-blocking antibodies can significantly reduce 
migration of αvβ6 positive PDAC cell lines towards fibronectin and LAP, the two most 
common ligands associated with αvβ6 (Figure 53, Figure 55). No change in migration 
was observed in the αvβ6 negative cell lines (Figure 54, Figure 56). Fibronectin has 
been shown to be one of the primary ECM components in the stroma surrounding 
pancreatic cancer [82]. Binding of αvβ6 to LAP exposes the TGFβ allowing activation 
of the TGFβ signalling pathway, which in turn can promote cancer cell migration and 
invasion [51]. TGFβ can also activate stellate cells to become myofibroblast-like. 
Thus, it is perhaps not surprising that enhanced expression of TGFβ has been linked 
to poor prognosis in PDAC patients [244].  
 
A significant reduction of invasion was observed in four out of the five αvβ6 positive 
invasive cell lines treated with an αvβ6 function-blocking antibody, 10D5 (Figure 57, 
Figure 58) over 72 hours compared with control antibody. Proliferation assays were 
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set up in parallel to ensure that there were no differences in cell numbers over 72 
hours (the time period employed for the invasion assay) between the αvβ6 function 
blocking antibody treated and control IgG treated groups. Interestingly, the HPAF cell 
line did not show any invasion even though it had high levels of αvβ6 expression. 
One possible explanation for this could be that the αvβ6 expressed by HPAF is in a 
different conformational state, and thereby does not promote invasion or it may 
simply be that this cell line was not invading in an αvβ6 dependent manner.  
 
There is a strong expression of Cyclooxygenase 2 (cox 2) in pancreatic stellate cells 
present in the tumour stroma surrounding PDAC [245]. Cox 2 has also been shown 
to be expressed by tumour cells and upregulate MMP9 expression, in turn promoting 
invasion of BxPC3 cells [246]. In a separate study, Cox 2 inhibition has been shown 
to suppress αvβ6 dependent invasion in oral carcinoma cell lines in 3D invasion 
assays [247] and MMP9 has been shown to promote invasion in an αvβ6 dependent 
manner in OSCCs [125]. Given more time, it would be interesting to check for levels 
of cox2 and MMP9 expression by PDAC cell lines tested in this study. It could very 
well be that invasion of PDAC cells lines tested in this study could be driven by 
MMP9 expression in response to Cox 2 expression in an αvβ6 dependent manner.  
 
3.11.3  Development of 3D co-culture model  
 
Pancreatic cancer is associated with a very strong desmoplastic response. Cancer 
cells behave differently when co-cultured with stromal cells in a 3D matrix because of 
varied gene expression as a result of the tumour-stroma interactions. Pancreatic 
stellate cells form the major cell component of this stromal response with the 
fibroblasts, nerve cells, blood vessels and immune cells providing the remaining cells 
[81].  
 
An air-liquid interface organotypic co-culture was previously established for studying 
OSCC invasion in vitro [90] and this model was later modified for generating a 3D 
organotypic model for studying PDAC [59]. This model allowed better replication of 
the tumour-stroma interaction, more relevant to the dense stromal response 
observed in human PDACs. Data obtained so far show that the organotypic gels 
revealed some of the cellular complexity of pancreatic carcinoma growth, 
differentiation and their impact on invasive potential. Four αvβ6 positive cell lines 
were co-cultured with MRC5 h-TERT immortalised fibroblasts (neo-natal lung 
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fibroblasts). MRC5 cells were used as these are reported to express high levels of 
HGF, a chemotactic and invasive factor for carcinomas [248]. It would have been 
more relevant to use the Pancreatic stellate cells  (PS1), available in-house, in this 
co-culture model but their rate of growth was incredibly slow and attaining enough 
number of cells to set up the co-culture experiment was incredibly time consuming. 
However, considerable time and effort was spent to grow these cells in bulk in the 
later stages of this study, as they were crucial for in vivo experiments, which will be 
discussed in detail later. 
 
In the co-culture system, CFPac1 cell line was found to be the only invasive cell line 
compared with Panc04.03, Capan1 and HPAF, where no invasion was observed 
(Figure 60, Figure 61). In contrast, all four cell lines tested in a 3D organotypic co-
culture system exhibited invasive capability at varying levels in the 2D invasion 
assay. An independent study which I performed comparing OSCC invasion in 
response to a panel of fibroblasts in this co-culture model revealed that the cancer 
cell lines’ invasive propensity varied in response to fibroblasts of different origin. For 
example, VB6 (OSCC) cells showed high level of invasion when co-cultured with 
MRC5 fibroblasts but a complete absence of invasion in the presence of FSF44 
(foreskin fibroblast 44) (data not published). Therefore, it is worth investigating if the 
same holds true for the PDAC cell lines tested above and perhaps PS1 cells might 
induce a more invasive response from these cells. A further consideration for the lack 
of invasion observed (with the exception of CFPac1 cell line) would be the proximity 
of tumour cells to stromal cells in the co-culture system. In a model for squamous cell 
carcinoma, Sahai and colleagues demonstrated that in order for cancer cells to 
invade collectively, close proximity to fibroblasts is required, as these fibroblasts 
create tracks via RhoA and ROCK dependent actin-myosin activity with MMP- 
mediated proteolysis [249]. As there was no direct cancer cell-to-stromal cell contact 
in the co-culture system tested in this study, it is possible that the proteolytic activity 
by the fibroblasts is absent and thus invasion does not occur.  
 
Both Panc04.03 and HPAF retained αvβ6 expression in the 3D co-culture system 
and the cells were proliferating as confirmed by the Ki67 staining, a marker for 
proliferation. Higher magnification images revealed luminal structures that were 
formed in the epithelial layer, which were very similar to in vivo PDAC tumours. In 
fact, images from the 3D organotypic co-culture model and orthotopic xenograft 
tumours (shown in results chapter III) reveal very similar features further confirming 
that this co-culture model provides a morphologically similar pattern of cellular 
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distribution. Close examination of the Panc04.03 co-culture shows that αvβ6 
expression is more pronounced along the tumour-stroma interface, which is 
consistent with the published literature where αvβ6 expression has been shown to be 
higher in the invasive front of the tumour [250]. Strong αvβ6 expression at the 
interface with stromal cells has also been observed in other cancers such as head 
and neck cancer [203]. Other studies in our laboratory have shown that in OSCCs, 
expression of αvβ6 mRNA, detected by in situ hybridisation, was greatest at the 
tumour-stroma interface (unpublished). Perhaps a similar effect might be occurring in 
the Panc04.03 cell line tested in this model, where β6 mRNA might be 
overexpressed at the invasive front.  
 
These co-culture models were generated to study αvβ6 dependent PDAC cell 
invasion with the aim of using shRNA mediated β6 stable knock down or non-
targeted knock down cell lines (discussed later). Using an antibody to block the 
function of αvβ6 in these co-culture models was challenging due to a variety of 
factors. It was impossible to assess whether the antibody would target all the cancer 
cells, including ones in the matrix, while a large amount of antibody was required for 
this assay and there was only a limited amount of the antibody (received from Astra 
Zeneca) available for the purposes of this study. Since no invasion was observed in 
the cell lines tested, with the exception of CFPac1, in this co-culture system it was 
decided not to use the in vitro co-culture model and proceed directly to in vivo 
experiments. As the challenges of antibody delivery hold true in vivo as well in the 3D 
co-culture model tested above, it was thus necessary to generate a β6 shRNA stable 
knock down cell line for use directly in the murine models.  
 
3.11.4  Development of stable knock down cell lines 
 
It is worth noting that attempts to knock down β6 with shRNA began before the 
studies on the role of αvβ6 in proliferation and actually fuelled their development. 
Having screened and characterised many PDAC cell lines for expression of αvβ6, it 
was decided to generate β6 stable knock down cell lines using lentivirus-mediated 
transfection of β6 shRNA into Panc04.03 and CFPac1. As discussed previously, 
siRNA mediated knock down of Panc04.03 and CFPac1 proved extremely difficult 
using a lipid-mediated method of transfection. It was hypothesised that lentiviral-
mediated transfection of shRNA would help generate matched pairs of the same cell 
line with the only difference in αvβ6 expression levels. This would have proven to be 
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an extremely useful tool to study the functional role of αvβ6 in 3D co-culture models 
in vitro and also in vivo in xenograft animal models. Despite trying three different 
commercially available and verified β6 shRNA-targeted sequences, it was not 
possible to successfully generate a stable cell line for both CFPac1 and Panc04.03. 
It was possible to monitor the transfection efficiency by following the GFP 
expression, which was driven by an IRES promoter. The cells when treated with the 
lentivirus carrying the shRNA plasmid showed lower levels of αvβ6 and higher levels 
of GFP compared with the non targeted (NT) control shRNA treated cells, meaning 
the transfection had worked and αvβ6 levels were low compared to the parent control 
(Figure 62). The infected cells were then positively sorted by FACS for the top 10% 
GFP expressers (indicative of high shRNA transfection levels) and re-plated. Once 
sorted, these cells (high GFP, low αvβ6) were extremely slow growing compared to 
the NT shRNA control treated cells (high GFP, high αvβ6). It took on average 
between six to eight weeks before these cells started to grow faster allowing for 
enough cells to be collected to check for expression levels of αvβ6 and GFP using 
flow cytometry (Figure 63). The sorted cells, which were GFP positive and low 
expressers of αvβ6 at the time of plating, had lost their GFP expression, indicating 
loss of plasmid from the cell and expressed high levels of αvβ6 comparable to the 
parent control cells. The above data suggested that αvβ6 might be crucial for the 
survival of the PDAC cell lines tested (Panc04.03 and CFPac1) and any attempt to 
knock down αvβ6 stably was not possible because the plasmid was ejected from the 
host genome.  
 
This dramatic reduction in cell growth when transfected with shRNA targeting β6 has 
been observed in another study using YAPC PDAC and A549 lung cancer cell lines 
[207], which are both KRAS dependent (activating mutation in KRAS) cell lines. Both 
Panc04.03 and CFPac1 have activating KRAS mutations at codon 12 and thus these 
results correlate with my results presented in this study. Providing more time were 
available, it might be worth repeating the knock down of β6 in a PDAC cell line 
without an activating KRAS mutation using the shRNA sequences to study the effect 
on proliferation. More recently, a dox -nducible shRNA plasmid to knock down β6 has 
become available (Open Biosystems Ltd). It would be worth trying the inducible 
plasmid on the same cells to try and generate an inducible knock out model, which 
will help overcome the dependence of these cells on αvβ6 for survival.  
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So in summary, blockade of αvβ6 function in the αvβ6 positive PDAC cell lines 
significantly reduces growth, migration towards fibronectin and LAP and invasion, 
suggesting that αvβ6 might be an interesting molecule to study in human PDAC with 
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4 Human PDAC and αvβ6 
 
4.1 Bioinformatics analysis of αvβ6-associated gene 
changes in pancreatic cancer 
 
The Pancreatic expression database (PED) was developed at the Barts Cancer 
Institute, Queen Mary University of London, comprising data published by multiple 
research groups who focus on pancreatic cancer [251, 252]. It contains of 56,015 
expression measurements and 6363 DNA copy number alterations obtained from 59 
different published studies. The collected data were profiled using multiple 
transcriptomics (e.g. Affymetrix GeneChip® Human Genome arrays), proteomics 
(e.g. Matrix Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) Mass 
spectrometry), miRNAs (e.g. human miRNA Agilent array) and genomics (e.g. 
Affymetrix GeneChip® Human Mapping 100K SNP Set) platforms [252]. The PED 
interface also incorporates functional data from Ensembl Mart 56, allowing users to 
link PDAC genes to the pathways they control.  
 
4.1.1 ITGB6 expression at the mRNA level 
   
In collaboration with Dr. Claude Chelala, the pancreatic expression database (PED) 
was used to examine expression of integrin ITGB6 gene expression in pancreatic 
cancer versus normal pancreas at the mRNA transcript level. The Affymetrix 
GeneChip® Human Genome array U133 Plus 2.0 platform was used to determine 
the expression level in the dataset. The dataset had a total of 96 human PDAC cases 
and 4 normal donor pancreas (normal pancreas tissue is extremely rare to obtain, 
hence the small sample size). Interrogation of the pancreatic expression database 
revealed that the expression of the β6 gene (ITGB6) was significantly up regulated in 
PDAC tumour tissue compared to the normal tissue (Figure 64). Three different 
probes for the ITGB6 gene (Figure 65) showed similar results confirming that ITGB6 





Figure 64: Expression of ITGB6 gene in PDAC (whole tissue) versus normal 
pancreas (whole tissue).  
 
There is an overexpression of ITGB6 at the mRNA level (red) in the PDAC tumour 
tissue compared to the normal pancreas (green). Data shown above are box and 
whisker plots showing the median expression (black line) of ITGB6 with a confidence 
interval between 5% and 95%. Three different Affymetrix probes 208083_S_AT 
(probe 1), 208084_AT (probe 2) and 226535_AT (probe 3) are present in the 
Affymetrix U133 Plus 2.0 chip that recognise ITGB6. The probes and their target 
sequences in ITGB6 are shown in the table below. Integrin ITGB6 has 2397 base 
pairs with 15 exons. Each probe has at least 11 different recognition sites within the 
exons and these are shown in the figure presented below.  
  




































Figure 65: Recognition sites of Probe 1 and Probe 2 in the ITGB6 gene. 
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A list of 10,000 genes was up or down regulated in PDAC with a cut off log fold 
change of 2, including ITGB6 with a log fold change of 4.261 (p=4.59E-06). 
Potentially, expression of some of these genes may be as a result of ITGB6 
overexpression in PDAC. In an attempt to identify those genes that are likely to have 
changed due to changes in ITGB6, further analyses were conducted on the list of 
10,000 genes using a high threshold of 8 in order to obtain a set of genes that had 
maximum correlation with ITGB6 expression. 40 genes were up regulated and one 
gene (FAM107A) was down regulated. The genes and their log fold change in 


























Gene of interest Gene name Log Fold 
change 
p value 
Integrin alpha 2 ITGA2 4.5273 1.8E-10 
Capping protein (actin filament), gelsolin-
like 
CAPG 2.4702 1.09E-05 
Matrix metalloproteinase 7 MMP7 2.0468 0.00618 
Matrix metalloproteinase 11 MMP11 5.2970 5.46E-06 
Laminin gamma 2 LAMC2 4.6285 2.28E-05 
Laminin alpha 3 LAMA3 4.3512 9.66E-05 
Tumour necrosis factor receptor 
superfamily, member 21 
TNFRSF21 2.4503 5.76E-05 
S100 calcium binding protein A6 S100A6 3.5582 0.00082 
Cathepsin E CTSE 6.0343 4.66E-06 
Collagen, Type X, alpha 1 COL10A1 7.1897 5.69E-14 
Chemokine like factor CKLF 2.4139 2.90E-09 
Keratin 19 KRT19 4.3910 9.13E-05 
Claudin 18 CLDN18 5.5356 0.00315 
Bcl-2 interacting killer (apoptosis 
inducing) 
BIK 2.4062 0.00172 
EPS8-like 1 EPS8L1 2.5512 0.00940 
Family with sequence similarity 107, 
member A 





































Table 14: Top 41 genes whose expression changed at the same time as ITGB6. 
Gene of interest Gene name Log Fold 
change 
p value 
Hematological and neurological 
expressed 1 
HN1 2.4300 4.48E-04 
ADAM metallopeptidase domain 10 ADAM10 2.2388 2.06E-07 
Laminin, beta 3 LAMB3 3.7281 0.0004 
Pleckstrin homology-like domain, family 
A, member 2 
PHLDA2 3.8929 2.53E-05 
Fermitin family homolog 1 (Drosophila) FERMT1 2.5231 0.00204 
Transmembrane channel-like 5 TMC5 3.8931 0.00209 
UEV and lactate/malate dehydrogenase 
domains 
UEVLD 2.2070 7.52E-08 
GAP junction protein, beta 2, 26kDA GJB2 5.9666 4.46E-08 
Solute carrier family 44, member 4 SLC44A4 2.43909 0.0324 
CD58 molecule CD58 2.8020 5.87E-11 
Anoctamin 1, calcium activated chloride 
channel 
ANO1 4.5766 1.19E-07 
Chromose 15 open reading frame 49 C15orf48 4.0073 7.03E-06 
Sperm associated antigen 1 SPAG1 3.3445 3.32E-07 
Epithelial cell transforming sequence 2 
oncogene 
ECT2 4.7843 5.32E-09 
Rhophilin, Rho GTPase binding protein 2 RHPN2 2.0807 0.00775 
Kruppel-like factor 5 (intestinal) KLF5 4.7366 1.02E-08 
Epiplakin 1 EPPK1 3.4071 0.0001 
Chromosome 19 open reading frame 33 C19orf33 4.2576 0.0005 
Heparan sulphate (glucosamine) 3-O-
sulphotransferase 1 
HS3St1 4.8245 2.24E-06 
Calpain 8 CAPN8 4.2043 0.00130 
Spermatogeneis associated, serine-rich 
2-like 
SPATS2L 3.2409 9.25E-08 
Adhesion molecule with Ig-like domain 2 AMIGO2 3.2254 6.94E-08 
FXYD domai containing ion transport 
regulator 3 
FXYD3 3.19357 0.00186 
Transmembrane protease, serine 4 TMPRSS4 4.7028 0.00032 
ADP-ribosylation factor-like 14 ARL14 3.3263 0.010851 
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4.1.2 q-PCR analysis 
 
To determine whether the observed changes were αvβ6-dependent, Capan1 cells 
were treated with siRNA to knock down ITGB6 or a control non-targeting siRNA. 
mRNA was isolated from the treated cells and a quantitative PCR (qPCR) assay was 
set up to determine whether the expression levels of three genes that were relevant 
to cancer, integrin alpha 2 (ITGA2), capping protein (actin filament) gelsolin-like 
(CAPG) and matrix metalloproteinase 11 (MMP11) changed in response to β6 knock 
down. Ct values were normalised to the endogenous expression of the house-















Figure 66: qPCR analysis of genes selected from the gene-list that were up or 
down regulated in PDAC along with ITGB6 in Capan1 cells. RNA from siRNA 
mediated knock down of β6 in Capan1 cells (red) were analysed for changes in 
gene expression and compared with non-targeted siRNA control (green). Note 
that n=1 for this experiment.  
 
CAPG is an actin-filament capping protein and is shown to be involved in actin-
cytoskeleton regulation. Previous studies have noted its up regulation in pancreatic 
cancer [253]. Its expression was marginally reduced when β6 was knocked down in 
Capan1 cells (Figure 66). There was a marginal reduction in the expression levels of 
ITGA2 when β6 was knocked down. ITGA2 when associated with integrin subunit β1, 
forms the major collagen receptor integrin, α2β1, a most relevant molecule in a 
desmoplastic tissue [254]. MMP11 encodes for matrix metalloproteinase 11 








































[255]. There was a 50% reduction in the expression levels of MMP11 in the β6 knock 
down cells compared to the NTsiRNA. It should be noted that the Pancreatic 
Expression Database data also includes stromal cells and it is entirely possible that 
any or all of the genes in our top 40 could be stromal in origin. However preliminary 
data obtained suggest that there is a drop in MMP11 gene expression as a 
consequence of knockdown of ITGB6 and there also may be a moderate reduction in 
both CAPG and ITGA2. The results shown are for n=1 and it is necessary to repeat 
the qPCR assay before any inference can be drawn from these results.  
4.1.3 IHC analysis 
 
A pilot experiment performed on five human PDAC tissue samples and one normal 
control tissue sample by immunohistochemical staining showed expression of two 
genes that were shown to be upregulated in the bioinformatics study. FERMT1, more 
commonly known as Kindlin1 is a focal adhesion protein, belonging to the fermintin 
family homolog-1 and loss of function mutations of this gene have been associated 
with Kindler syndrome, an autosomal recessive disorder characterised by skin 
atrophy and blistering [256] and it has also been identified as part of a gene 












Figure 67: Representative image of FERMT1 (brown membranous stain, 
arrows) on PDAC tissue and its absence in normal pancreas tissue. (Scale bar 
represents 100µm).  
  
FERMT1 PDAC FERMT1 normal pancreas 
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LAMC2 or laminin gamma 2 has shown to be up regulated in oesophageal 
squamous cell carcinomas and patients with high expression are linked with poor 













Figure 68: Representative image of LAMC2 (brown cytoplasmic/membrane 
stain, arrows) on PDAC tissue and absent in normal pancreas tissue. Note: 
background staining observed in the Islet cells. (Scale bar represents 100µm). 
 
Immunohistochemical analyses revealed overexpression of FERMT1 and LAMC2 in 
the cell membrane/cytoplasm of PDAC cells in all the cases tested (Figure 67, Figure 
68). The normal pancreas tissue was negative for both the proteins. 
 
4.2 ITGB6 expression at mRNA level and survival in PDAC 
patients 
 
There are no studies looking at expression of αvβ6 and its influence on survival in 
patients with pancreatic ductal adenocarcinoma. Using bioinformatics, the expression 
of ITGB6 at the mRNA level was examined for the first time to determine if ITGB6 
overexpression in pancreatic cancer had any correlation with survival in patients. 
Kaplan-Meier (KM) survival curves of ITGB6 mRNA abundance across five publically 
available data sets [259-263] and one in-house cohort of PDAC patients (BCI) were 
plotted. A total of 292 patients were dichotomised into low expressers and high 
expressers based on expression levels of ITGB6, top 25% quartile versus the bottom 
75%. 
  




Figure 69: Kaplan-Meier survival curve of PDAC patients based on ITGB6 
expression. (n=292). Logrank test p= 6.37x10-4. Red line is ITGB6 positive (top 
25%), Black line is ITGB6 weakly positive or negative (bottom 75%). Hazard 
Ratio (HR)= 1.74.  
 
Kaplan-Meier curves are used for estimating survival as a function of various 
markers in patients and usually are represented in a series of horizontal steps of 
declining magnitude. When a large enough number of samples are analysed, it 
provides a true survival function for that group. It is a method that takes into 
consideration certain types of right censoring. E.g. it takes into account if a patient 
withdraws from a study (i.e. data is lost before the final outcome). On the curve, tiny 
vertical marks indicate any survival time that has been censored.  
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Red and black curves represent high (top quartile 25%) and low (bottom quartile 
75%) expression groups. There were 217 patients in the low ITGB6 expressing 
group and 75 in the high ITGB6 expressing group at time zero. Based on predictive 
survival only 6 patients in the high ITGB6 expressing group were alive at 30 months 
compared to 47 patients in the low ITGB6 expressing group. There is a significant 
difference in overall survival between the two groups, with those expressing high 
levels of ITGB6 tending to have lower overall survival compared to the weak 
expressers of ITGB6 (Figure 69). There is a median survival difference of 6 months 
between the two groups. At 24 months, there were only 11 patients alive in the high 
ITGB6 expressing group (3.76%) compared to the 64 patients alive in the low ITGB6 
expressing group (21.91%). At three years, there were only 4 patients alive in the 
high ITGB6 expressers (1.36%) compared with the 35 patients alive in the low ITGB6 
expressers (11.98%). Survival analysis was conducted for overall survival (OS) 
truncated at 60 months. Survival at 60 months was low for both groups, with just 3 
and no patients alive in the ITGB6 low and high expressers respectively reflecting 
poor prognosis of pancreatic cancer patients as a whole. Difference between the 
dichotomised groups was assessed using the Cox proportional hazards model and 
significance of difference was evaluated using the Log-rank test.  
4.3 Expression of αvβ6 in human PDAC tissue samples 
 
Having looked at expression of αvβ6 at the mRNA level and establishing a 
correlation between αvβ6 expression and overall survival in PDAC patients, we 
wished to investigate this on PDAC tissue samples and determine if there were 
similar observations at a protein level.   
 
Sipos et al, (2004) first showed the expression of αvβ6 in human PDAC. They had a 
small sample set of 34 PDAC cases and stained them for expression of β6 using a 
novel monoclonal antibody [201]. They found αvβ6 to be expressed in varying levels 
in all 34 PDAC tissue samples (section 2.6.1). They did not perform any further 
analysis or correlation studies presumably due to the limited number of PDAC 
samples. A large number of patient samples with follow up data were required for 
conducting a clinical analysis to identify the role of αvβ6 in PDAC progression. In 
collaboration with the Beatson Institute, Glasgow, UK and the University of Verona, 
Verona, Italy, a large number of tissue microarrays (TMA) of human pancreatic 
ductal adenocarcinoma and ampullary cancer patients were obtained. Both sets of 
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TMAs had clinical follow up data, which made it possible to carry out correlation 
studies with regards to expression of αvβ6.  





























Figure 70: Expression of αvβ6 in human PDAC tissue sample. The tumour cells 
are strongly positive (brown stain) for αvβ6 expression while the normal 
pancreas is entirely negative for αvβ6. Strong and distinct membrane staining 
can be observed on the epithelial cells with the surrounding stromal cells 
entirely negative for αvβ6.   
!v"6 staining on PDAC tissue 
Normal Pancreas 
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The above picture is a typical representation of a TMA stained for αvβ6 using 62G2 
antibody. The x10 magnification image shows a TMA core with normal pancreas and 
PDAC. The antibody 62G2 picks up αvβ6, which is expressed only by the cancer 
cells and the normal cells are all negative. The higher magnification of the image 
shows the membranous localisation of αvβ6 particularly at the cell-cell junctions. It 
should be noted that the staining is restricted to the epithelial cells and the 
surrounding stromal cells are all negative. This was the case for all the TMAs stained 
and they were scored and quantified for further analysis. 
 
4.3.2 Clinical analysis of PDAC TMAs from the Beatson 
Institute 
 
A total of 118 PDAC patients in the data set and six cores per slide represented each 
patient. Scores of all six cores were averaged to get a single score per patient. As it 
was not possible to release the clinical data associated with TMAs, the scores of 
individual cores were sent to the Beatson Institute for further clinical analysis.  
 
Kaplan-Meier (KM) survival curves were plotted based on β6 expression scores for a 
total of 118 PDAC cases (Figure 71). Based on the scores, any patient with a score 
greater than or equal to the median score of 3 was considered as positive and the 
remaining patients with a median score of less than 3 were considered negative. A 
logrank test was performed to check for significance. The Logrank test is used widely 
to compare survival distribution of two sets of data. It is a non-parametric test and 
was appropriate to be used in this particular data set because the data was not 



























Figure 71: Kaplan-Meier survival curve of PDAC patients (n= 118) based on 
αvβ6 expression (median score of 3). Logrank test p= 0.241.  
 
The pink line in the graph represents a group of 98 patients with a median score 
greater than or equal to three and the blue line represent 20 patients with a median 
score less than three (Figure 71). Despite a moderate shift in the curve to the left, 
indicative of poor prognosis in the high expressers of αvβ6, a logrank test revealed 
no significant difference between the two groups of patients (p=0.241) followed over 
a time period of 120 months from the time of surgery (Figure 71). 
 
The Beatson Institute TMA data set had a variety of clinical data in addition to the 
survival data shown in Figure 71. The grade of tumours, the stage of tumour and the 
differentiation status of the tumour at the time of surgery were some of the other 
parameters which were examined in relationship to αvβ6 expression based on the 
same scores used for survival analysis. All further analyses were done as part of a 






P = 0.241 
integrin !v"6 expression  
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4.3.2.1 Correlation of tumour grade with αvβ6 expression 
 
Patients with follow up data for the grade of pancreatic cancer at the time of 
diagnosis/surgery were divided into two groups, low and high grade PDAC, and 
these groups were correlated with expression of αvβ6 based on the TMA scores. A 
Mann-Whitney test was used to test for significance. Mann-Whitney test is a non-
parametrical test used to check if one of the two data sets of independent 
observations have a higher value than the other. It is commonly referred to as the 





















Figure 72: Correlation of αvβ6 expression with patients having low (n=84) or 
high grade (n=34) PDAC. Mann-Whitney test p= 0.419. 
 
The results in Figure 72 show that there was no significant correlation between αvβ6 
expression and the grade of pancreatic cancer in the samples analysed from this 
particular data set with a p value of 0.419 using the Mann-Whitney test. The median 
represented by the black line in the box and whisker plot suggested that the level of 
expression of αvβ6 in the low grade tumours (blue) and high grade tumours (pink) 
was statistically not significantly different, although the median for the high grade 

































4.3.2.2 Correlation of tumour stage with αvβ6 
expression 
 
The classical method to analyse the stage of the tumour is the TNM method of 
classification. T stands for primary tumour, N stands for regional lymph nodes, M 
stands for distant metastasis. The Beatson Institute data set had clinical follow up 
data associated with the T stage 2 and 3 for all patients. The T stage of classification 
can be divided into various sub-stages, Tx, T0, T1, T2, T3 and T4. Each stage 





















Figure 73: Correlation of αvβ6 expression and T stage classification of PDAC 
tumours in patient samples. Mann-Whitney test p= 0.205. 
 
The data in Figure 73 showed that there was no significant correlation between αvβ6 
expression and the T stage 2 (n= 13) (blue) where tumours are limited to the 
pancreas, (2 centimetres or less in the greatest dimension) versus T stage 3 (n= 105) 
(pink), where tumours extend beyond the pancreas but without involvement of the 
coeliac axis or superior mesentery using Mann-Whitney test p= 0.205. The median 
score suggested that the level of expression of αvβ6 was not significantly different 
between the different stages but a slight increase in median β6 expression was 

































4.3.2.3  Correlation of differentiation status with αvβ6 
expression 
 
It is characteristic for pancreatic ductal adenocarcinomas to have glandular 
structures embedded in an extremely desmoplastic stroma. The extent of changes in 
PDAC morphology from the typical glandular duct-like structures to a more squamoid 
or spindle cell like cellular architecture are indicators of PDAC differentiation. There 
are variations in the levels of differentiation in PDACs and they behave differently 
depending on the stage of differentiation. The well differentiated PDACs consist of 
large duct-like structures in tubular or cribriform patterns embedded in a 
desmoplastic stroma. They retain more epithelial cell-like features. Moderately 
differentiated PDACs comprise a combination of medium sized incomplete duct-like 
structures and tubular structures in a desmoplastic stroma. Poorly differentiated 
PDACs are less common and consist of tiny irregular glands with almost no duct-like 
structures. They also tend to lose their epithelial cell-like phenotype (WHO 























Figure 74: Correlation of αvβ6 expression and cellular differentiation of PDAC 
































The data in Figure 74 showed that there was no significant correlation between αvβ6 
expression and differentiation status of human pancreatic cancer in the samples 
tested using the Kruskal-Wallis test (p= 0.768). This test can be used as an 
alternative to the one-way independent-samples ANOVA to compare between 
groups. The p value represents differentiation status compared across all the groups. 
The median expression of αvβ6 was found to be lower in both the well differentiated 
(n=7), well to moderate differentiated (n=12) compared to the moderately 
differentiated tumours (n=65). This is contrary to what was expected considering well 
differentiated tumours retain more epithelial cell-like features and αvβ6 is an 
epithelial specific integrin. The moderate to poorly differentiated tumours (n=13) and 
the poorly differentiated tumours (n=21) expressed more β6 than the well 
differentiated tumours in this particular data set.  
 
4.3.2.4  Correlation of αvβ6 expression with lymph node 
positivity 
 
One of the major routes of dissemination in pancreatic cancer is lymph node 
metastasis. The lymph node ratio (number of lymph nodes containing tumour cells 
compared to the number of lymph nodes examined in total) is considered to be a 
strong prognostic marker in pancreatic cancer [264]. A high lymph node ratio means 
significantly reduced survival in PDAC patients who have undergone surgical 
















Figure 75: Correlation of αvβ6 expression and lymph node positivity in PDAC 



















































The data in Figure 75 showed that there was no significant correlation between αvβ6 
expression and lymph node positivity in PDAC patients using the Mann-Whitney test 
(p= 0.883). The box and whisker plot with lymph node positivity (n=94) (pink) tended 
to show a marginally higher median score of αvβ6 expression compared to the plot 






















Figure 76: Correlation of αvβ6 expression and lymph node ratio in PDAC 
patient samples. Mann-Whitney test p= 0.857. n=24 for 0 lymph node ratio, 
n=60 for <25%, n=24 for 25-50% and n=10 for >10% lymph node ratio. 
 
The data in Figure 76 show that there was no significant correlation between αvβ6 
expression and lymph node ratio in the PDAC patients in this data set using the 
Mann-Whitney test (p= 0.857). High lymph node ratio is a poor prognostic marker in 
pancreatic cancer and although there was no significant difference in αvβ6 
expression between patients with lymph node positivity, the median score for αvβ6 
expression was highest for patients with a lymph node ratio of >50% (n=10) (pink) 



















































4.3.2.5 Correlation of αvβ6 expression with perineural 
invasion 
 
Perineural invasion is a characteristic feature of pancreatic cancer. The cancer cells 
invade the surrounding nerves and metastasise. It is believed that more aggressive 
tumours tend to spread to the nerves causing significant back pain to patients. The 
infiltration accounts for local recurrence following surgical resection, usually involving 




















Figure 77: Correlation of αvβ6 expression and perineural invasion in PDAC 
patient samples. Mann-Whitney test p= 0.935.  
 
The data in Figure 77 show that there is no significant correlation between αvβ6 
expression levels and perineural invasion in the PDAC patients analysed using the 
Mann-Whitney test (p= 0.935). n=112 for patients with no perineural invasion and 


















































4.3.2.6  Correlation of αvβ6 expression with vascular 
invasion 
 
Detection of vascular invasion in pancreatic cancer is a very difficult challenge and in 
the absence of evident metastatic disease, the presence of vascular invasion plays 
an important role in determining how resectable the tumour is and what the likely 
success of such resection will be. Recent improvements in imaging techniques allow 





















Figure 78: Correlation of αvβ6 expression and vascular invasion in PDAC 
patient samples. Mann-Whitney test p= 0.907. 
 
The data in Figure 78 show that there is no significant correlation between αvβ6 
expression and vascular invasion in PDAC patients in the data set analysed using 


















































4.3.3 Clinical analysis of PDAC TMAs from the University of 
Verona 
 
Tissue Microarray Cores (TMA) of PDAC patients were stained for αvβ6 expression 
using the monoclonal antibody 62G2 (Biogen) by IHC (section 2.6). There was a total 
of 147 PDAC patients in the data set. Four cores per slide represented each patient 
and the scores of all four cores were averaged to obtain a single score per patient. 
The scores of individual cores were matched to the follow up data and all further 
clinical analyses were performed at Barts Cancer Institute, Queen Mary University of 
London, with help from Mr. Hemant Kocher and Dr. Colan Ho-Yen.  
 
The X-tile software has been developed by Yale University, USA and is a robust and 
increasingly used statistical platform to determine the best “cut point”, while dividing 
patients into subsets based on expression of a potential biomarker It has been 
validated on a number of well established prognostic markers (tumour size, p53 
expression) in breast cancer [266]. Despite the existence of various statistical tests 
for determining the optimal cut point, X-tile provides a more rigorous evaluation by 
dividing a single cohort into “training” and “validation” subsets for estimating the p 
value. It also performs additional Monte Carlo simulations to generate corrected p 
values to assess statistical significance of the data assessed by multiple cut points. 
Monte Carlo simulations try to define a possible input from a probability distribution, 
thus the cut off value generated by the X-tile software is more robust than testing 
multiple cut points and accepting the value and gives the best p value.  
 
The median scores for all patients on the data set based on αvβ6 expression were 
uploaded on to the X-tile software along with the survival data, and a “cut off” median 
score of five was determined by the software. All PDAC patients with a median score 
greater than or equal to five were referred to as high expressers and all patients with 
a median score of less than five were referred to as the low expressers of β6 for the 






















Table 15: Total number of PDAC samples that were available for further clinical 
analysis in the data set from the University of Verona.  
 
There were a total of 149 PDAC cases available for analysis out of which two 
patients had to be removed because of lack of clinical data follow up (Table 15).  
Kaplan-Meier (KM) survival curves were plotted based on integrin β6 subunit 
expression scores for a total of 147 PDAC cases (Figure 79). A logrank test was 


























Figure 79: Kaplan-Meier survival curve of Verona PDAC patients (n=147) based 
on expression levels of αvβ6 (median cut off score used was 5). Logrank test 
p= 0.776.  
 
The red line in the graph represents a group of 124 patients with a median score 
greater than or equal to five and the green line represents 23 patients with a median 
score less than five (Figure 79). A logrank test showed no significant statistical 
difference between the high expressers (red line) of αvβ6 and the low expressers 
(green line) of αvβ6 with a p value of 0.776.  
 
The University of Verona TMA data set had a variety of clinical data in addition to the 
survival data shown in Figure 79.  The grade of tumours, the stage of tumour, sex 
and the age of the patient at the time of surgery, perineural and vascular invasion, 
were some of the other parameters, which were correlated to αvβ6 expression. A 
Spearman’s rho test compares how well the relationship between two variables can 
be described using a function, in this case αvβ6 expression levels (median scores) 
and the various parameters in the clinical follow up data. It also indicates the 
direction of correlation between the X and the Y variable. If Y tends to increase with 
an increase in X, then it is a positive correlation and if Y tends to decrease with an 
increase in X, then it is considered to be a negative correlation. If X and Y are 
perfectly related, then the Spearman correlation coefficient becomes 1. A 
Spearman’s rho test was used to test for significance and work out the relationship 






















between αvβ6 expression levels and various other parameters available for testing 
as part of the follow up clinical analyses.  
 
4.3.3.1 Correlation of tumour stage with αvβ6 
expression 
 
The PDAC patients in the data set were divided into two groups depending on the 
stage of the tumour based on the American Joint Committee on Cancer (AJCC) 
classification. Any patient with a stage greater than or equal to IIB was classified as 
high stage and any patient below the IIB stage was classified as low stage. This was 
done because there is no nodal involvement or metastasis of cancer until stage IIB in 





















Table 16: Table showing the TNM scoring and characterisation of stage in 
PDAC patients according to AJCC. (Table modified from AJCC 7th edition).  
 
Table 16 shows the staging of PDAC patients according to the AJCC system of 
classification. T represents the tumour size, N represents nodal involvement of the 
disease and M represents metastatic spread. A PDAC patient is classified as stage 
IIB regardless of T stage 1, 2 or 3 and if regional lymph node metastatic spread can 
be detected as denoted by N1. N0 means there is no lymph node metastatic spread. 
M0 means there is no distant metastasis, while M1 indicates that there is metastatic 

























Figure 80: Correlation between AJCC stage of Verona PDAC patients in the 
data set with αvβ6 expression. Spearman’s rho test p= <0.01 (**).  
 
The data in Figure 80 showed that there was a significant difference in the 
expression levels of αvβ6 and the stage in PDAC patients in this data set with a p 
value of <0.01 using the Spearman’s rho test. The patients categorised as high stage 
(red) (n=100) had a lower median score for expression of αvβ6 expression compared 
to the patients in the low stage (green) (n=47). A Spearman’s correlation coefficient 
calculated using the SPSS platform revealed that there was a negative correlation of 
-0.299 between αvβ6 expression levels and the stage of PDAC in patients in this 
data set. This means that αvβ6 expression levels were higher in patients with low 
stage PDAC compared to people with high stage disease, where expression levels of 

































4.3.3.2 Correlation of tumour grade with αvβ6 
expression 
 
Patients with a follow up data for the grade of pancreatic cancer at the time of 
diagnosis/surgery were divided in to three groups: grade 1 (low grade), grade 2 
(medium grade) and grade 3 (high grade). This was correlated with expression of β6 
based on the TMA scores. A Spearman’s rho test was used to test for any statistical 
significance between tumour grade and β6 expression levels in PDAC patients in this 























Figure 81: Correlation between tumour grade and αvβ6 expression levels in 
Verona PDAC patients. Spearman’s rho test p= 0.994.   
 
The data in Figure 81 showed no significant correlation between αvβ6 expression 
levels (median scores) and grade of pancreatic ductal adenocarcinoma tumours in 
patients in this data set tested using the Spearman’s rho test (p= 0.994). It should be 
noted that there were only three cases with a grade 1 disease and majority of the 







































4.3.3.3 Correlation of αvβ6 expression with sex of 
PDAC patients 
 
The clinical follow up data included the sex of patients and PDAC is a type of cancer 
where the incidence rates between men and women are similar. αvβ6 expression 






















Figure 82: Correlation between αvβ6 expression levels and gender in Verona 
PDAC patients. Spearman’s rho test p= 0.406.  
 
The graph in Figure 82 showed that there was no significant correlation between 
expression levels of αvβ6 and gender of PDAC patients tested using the Spearman’s 
rho test (p= 0.406).  There is a very slight increase in the median score in females 


































4.3.3.4  Correlation of αvβ6 expression with T stage in 
PDAC 
 
The classical method to analyse the stage of the tumour is the TNM method of 
classification, where T stands for the size of the primary tumour. The University of 
Verona data set had clinical follow up data associated with the T stage 2, 3 and 4 for 
all patients. The T stage of classification can be divided into various sub-stages, Tx, 






















Figure 83: Correlation between αvβ6 expression levels and T stage 
classification in Verona PDAC patients. Spearman’s rho test p= 0.856.   
 
The graph in Figure 83 showed no significant correlation between αvβ6 expression 
levels and T stage of tumours in PDAC patients tested using the Spearman’s rho test 
(p= 0.856). T stage 2 (no colour) had a small number of patients (n= 5), stage 3 (red) 
had the most number of cases (n= 129) and stage 4 (green) had slightly more 
patients compared to stage 2 (n= 13). The median score for αvβ6 expression tended 










































4.3.3.5 Correlation of αvβ6 expression with vascular 
invasion 
 
Vascular invasion in pancreatic cancer is extremely difficult to detect though recent 
improvements in imaging technologies have made it feasible to detect it more easily. 
In the absence of metastatic disease, vascular invasion plays an important role in 





















Figure 84: Correlation of αvβ6 expression levels with vascular invasion in 
Verona PDAC patients. Spearman’s rho test p= 0.075.  
 
The data in Figure 84 show that there was no significant correlation between the 
level of αvβ6 expression and vascular invasion in PDAC patients in this data set 
using the Spearman’s rho test (p= 0.075). The median score of αvβ6 expression in 
patients with vascular invasion (red) tended to be higher than the patients with no 
vascular invasion (green). The Spearman’s test p value of 0.075 was just out of 
significance and perhaps more data points would have shown a significant difference 





























4.3.3.6 Correlation of αvβ6 expression with perineural 
invasion 
 
Perineural invasion is a process in which the pancreatic cancer cells invade the 
surrounding nerves and metastasise. The more aggressive tumours tend to 























Figure 85: Correlation of αvβ6 expression levels with perineural invasion in 
Verona PDAC patients. Spearman’s rho test p= <0.01.   
 
The data in Figure 85 showed that there was a significant difference in correlation 
between the expression level of αvβ6 and perineural invasion in PDAC patients in 
this data set tested using the Spearman’s rho test (p= <0.01). The patients with 
perineural invasion (red) tended to show a higher expression of αvβ6 (higher 
median) compared to the patients with no perineural invasion (green).  A Spearman’s 
correlation coefficient calculated using the SPSS platform revealed that there was a 
positive correlation of 0.221 between β6 expression levels and perineural invasion in 
































αvβ6 has been linked with poor prognosis in many cancers. Bates et al showed that 
there was a significant difference in median overall survival between the αvβ6 low 
expressers (16.5 years) and αvβ6 high expressers (5 years) in colon cancer patients 
[173]. A significant difference in overall survival was observed in cervical cancer 
patients with only 54% of patients with strong αvβ6 expression surviving for 5 years 
compared to 91% who were negative for αvβ6 expression [267]. In lung cancer 
(NSCLC) patients, αvβ6 was shown to be a potential prognostic marker, with >75% 
of αvβ6 weak expressers surviving over 5 years compared with only <50% in the 
strong αvβ6 expressers [204]. It is worth mentioning that the high 5 year survival rate 
in the NSCLC patients in the above study was due to patients being treated at a very 
early stage of the disease. αvβ6 has also been shown to be a prognostic marker in 
breast cancer patients with a significant difference in overall survival between the 
αvβ6 low (10 years) and high (5 years) expressers (in-house data, not published). 
Thus, four different cancers with high αvβ6 expression have been associated with 
poor survival. To date, no study has compared the levels of αvβ6 expression and 
overall survival in PDAC patients.  
 
Through collaboration with the Beatson Institute, Glasgow and the University of 
Verona, Verona, two independent cohorts of PDAC patients were available for the 
purposes of this study. Barts Cancer Institute also has a public domain, pancreatic 
expression database, which provided data on β6 mRNA expression levels. This 
meant I could examine expression of αvβ6 both at the mRNA and protein level in 
independent cohorts of patients.   
 
Bioinformatics studies are often used as a tool to check for expression of genes at 
the mRNA level. It can also be used to identify differential gene expression based on 
expression levels of a gene of interest. Results obtained here have shown that 
ITGB6 is overexpressed in PDAC tumour tissue when compared with normal 
pancreas (Figure 64). Further correlation and analysis using stringent cut offs (high 
threshold ≥8) generated a list of forty genes, which were up regulated and one gene 
which was down regulated as the same time as ITGB6 was overexpressed in PDACs 
(Table 14). Thus, it is a possibility that one or more of these genes was regulated 
directly by ITGB6 or regulated as a result of ITGB6 overexpression. 
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In order to ascertain if any of the genes identified were under the influence of ITGB6 
expression, qPCR analysis was performed on a small subset of genes picked out 
from the list due to their link with pancreatic cancer [253, 254]. As these studies 
occurred late in my project, the data must be considered preliminary. However, these 
results suggested that MMP11 expression is decreased when αvβ6 expression is 
knocked down in Capan1 cells using siRNA (Figure 66). Since very little is known 
about αvβ6 downstream signalling in cancer, the aim was to identify key genes 
relevant to pancreatic cancer using the pancreatic expression database. This list of 
genes generated in this study can potentially provide possible target genes, which 
could be under the influence of αvβ6 or influence αvβ6 activity in PDAC tumour 
tissue. More validation assays have to be performed, which may provide further 
clues to determine the role of αvβ6 in PDAC.  
 
To date no studies have attempted to correlate ITGB6 expression and survival in 
cancer. In this study, using bioinformatics, high mRNA expression levels of ITGB6 
were linked to poor prognosis with a significant difference in mean overall survival in 
PDAC patients (n=292, p= 6.7x10-4). The difference in overall survival was 6 months 
for high expressers compared to 12 months for low expressers. Admittedly, the 
difference in survival is very modest compared with correlation of αvβ6 expression, at 
the protein level, and survival in colon cancer [173]. However, as only about 24% of 
PDAC patients have a one-year relative survival rate (American Cancer Society, 
facts and figures, 2010) after diagnosis and as this falls to about 5%- 6% of patients 
over a period of five years (WHO report, Pancreatic cancer, 2010), a doubling of 
overall survival in this challenging disease is encouraging. Having observed a 
significant difference in survival at the mRNA level, it was critical to check if the same 
could be observed at the protein level.  
 
Since patients with PDAC present at a late stage, it usually is inoperable. Tissue 
samples are often limited to biopsies, thus conducting tissue studies in PDAC is 
challenging. It is usually difficult to obtain statistically significant and robust follow up 
data because of the limited number of patient samples combined with the 
exceptionally poor prognosis of the disease. Tissue microarrays from the Beatson 
institute dataset had a total of 118 PDAC cases and 20 normal cases and the 
University of Verona has a total of 147 PDAC cases and 12 normal cases in their 
data set. The two centres also had valuable follow up clinical data that was collected 
and matched to every patient included in the data set. Analyses for the Beatson 
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Institute data set including statistical analyses was performed at the Beatson 
Institute, as the follow up clinical data were not available to the author in order to 
maintain data security. The follow-up data for the cohort of patient tissue from the 
University of Verona was available and I performed all further analyses. Due to 
restrictions in sharing follow up clinical data between institutes, all further analyses 
for both cohorts had to be presented separately.  
 
As discussed previously, three independent assessors scored the TMAs separately 
and the median of the scores was used to carry out all further clinical analyses. Of 
the 118 PDAC cases stained for αvβ6 in the Beatson data set, 98 cases were 
positive with a median score ≥1 (83%) and out of the 147 in the Verona data set, 144 
were positive for αvβ6 with a median score ≥1 (98%). The control normal pancreas 
samples in both data sets were completely negative for αvβ6. This strong up 
regulation of αvβ6 is typical for many solid epithelial cancers [203] but the very high 
percentage positivity is typical to the PDAC cases (91% if scores from both data sets 
were combined) is higher than any other cancer reported to date but in agreement 
with the original study that reported 100% αvβ6 expression in human PDAC [201]. In 
comparison, only 58% out of 85 cervical cancer patients tested were positive for 
αvβ6 expression [267] and 54% out of the 311 NSCLC cases tested were positive for 
αvβ6 [204]. It came as a surprise that 20 PDAC cases were scored negative for αvβ6 
in the Beatson data set (83%) considering only three cases of PDAC tumours from 
the Verona data set were negative for αvβ6 (98% positive). This could be due to a 
variety of factors including poor tissue preservation and differentiation status of the 
tumours tested. It should be noted that aside from the studies carried out by Sipos et 
al [201], using 34 PDAC cases, this data here are probably the biggest collection of 
PDAC samples that were tested for αvβ6 expression to date. Thus, there exists a 
possibility that more αvβ6 negative PDAC tumours might be identified with an 
increase in the number of PDAC tumours being tested for αvβ6 expression. It should 
be noted that, overall the samples in the Beatson data set did show a weaker αvβ6 
staining compared with the Verona data set suggesting that tissue preservation might 












Figure 86: Low magnification pictures of examples showing a normal pancreas 
core stained for αvβ6 (left), a core stained for αvβ6 (median score 8) from the 
Beatson data set (centre) and a core stained for αvβ6 (median score 8) from 
the Verona data set (right).    
 
Thus, Figure 86 clearly illustrates the difference in the intensity of the staining 
between the two data sets (centre and right), even though staining was performed at 
the same time using the same set of reagents. Care was taken to score both data 
sets independently and this difference in intensity of staining was taken into account 
while scoring the cores.  
 
Having established αvβ6 expression in the TMAs tested, the next logical step was to 
check if there was any relation between αvβ6 expression and overall survival in the 
two independent data sets. Kaplan-Meier survival curves were plotted to relate αvβ6 
expression levels and survival in patients. Surprisingly, neither the Beatson data set 
(Figure 71) nor the Verona data set (Figure 79), plotted separately, showed any 
significant relationship between αvβ6 expression and survival tested using the 
logrank test. This was unexpected considering all the available literature that was 
reported showed αvβ6 as a poor prognostic marker for cancer. In the Beatson data 
set, there was a slight shift of the curve observed in the high expressers of αvβ6, 
indicative of poorer prognosis, but the difference was not significant (p= 0.241).  
However, in the Verona dataset the low expressers of αvβ6 tended have a marginally 
poorer survival rate but this was not significantly different from the high expressers of 
αvβ6 (p= 0.776).  Even though αvβ6 has been shown to be a poor prognostic marker 
in other cancers, the obvious conclusion here is that the expression of αvβ6, at the 
protein level, cannot be used as a prognostic marker in PDAC. 
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This lack of correlation between αvβ6 expression and survival in PDAC patients 
could be attributed to a variety of factors. Incidence rates of PDAC are relatively low 
compared with many other solid cancers like breast or lung cancer. Even though this 
study had 2 separate data sets with 118 and 147 cases, which is a significantly large 
number of cases compared to other PDAC studies published so far, it may still not be 
enough to carry out the rigorous statistical analyses that are required to study patient 
survival based on high and low αvβ6 expression at the protein level. The p values 
obtained suggested that even if the two data sets were to be combined, it would not 
have changed the overall conclusions. Another reason could be the very high 
percentage positivity of αvβ6 in PDAC (91%), combined with the high mortality rate, 
making it difficult to follow patients for a sufficiently long period of time before any 
differences in survival are observed. The majority of patients who have PDAC tend to 
die of the disease within a few weeks or months after diagnosis, making survival 
analysis studies extremely difficult. If compared with other solid cancers such as 
breast cancer, where the incidence rates are higher, only about 30-35% of the 
tumours are positive for αvβ6 and five-year survival rates (85.1%, 2005-2009) 
(Cancer Research UK, 2012) are remarkably better than PDAC (3.8%, 2005-2009) 
(Cancer Research UK, 2012), there is a more even distribution of patients between 
the two cohorts (high and low) divided based on the levels of αvβ6 expression with 
greater follow up time, making it feasible to conduct statistically robust long-term 
survival analysis.  
 
So far, the clinical data generated appear to conflict when comparing αvβ6 
expression levels at the mRNA and the protein level. High expression of mRNA 
encoding the β6 integrin subunit correlates with significant reduction in overall 
survival (p= 6.7x10-4) (Figure 69) but there was no significant difference in overall 
survival observed in analysis of two independent sets of clinical samples for αvβ6 at 
the protein level (Figure 71, Figure 79). Since the mRNA data seem so compelling it 
is possible the data indicate the β6 protein and mRNA are differentially regulated in 
PDAC tissue. Preliminary data from our laboratory suggest that such a regulation 
occurs in oral SCCs. In situ hybridisation for β6 mRNA on OSCCs show non-uniform 
density of expression, with much higher levels at the tumour stroma interface 
(unpublished data). This will be an important issue to examine in future studies. 
Thus, while it remains a speculation that such a mechanism occurs in PDAC, the 
presence of αvβ6 on 91% of PDAC tissue but not in the normal tissue still makes it 
potentially a valuable target for therapy.  
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4.5 Clinical follow up data 
 
Both the Beatson and the Verona data set had clinical follow up data for all the 
patients: grade, stage, age, differentiation status, perineural invasion, vascular 
invasion, lymph node metastasis were some of the parameters correlated with αvβ6 
expression from both data sets.  
 
4.5.1 Beatson data set 
 
118 patients with follow up data were available for further clinical analyses in the 
Beatson data set. None of the parameters analysed showed a significant correlation 
with αvβ6 expression. Follow up data analysed was tested using the Mann-Whitney 
test and even though there was no significant difference observed there was a 
general trend observed in the pattern of αvβ6 expression. Thus, patients with higher 
grade or higher stage of PDAC had a higher median score of αvβ6 expression 
(Figure 72, Figure 73). Patients with greater lymph node metastasis, usually a sign of 
poor prognosis, tended to express higher levels of αvβ6 (Figure 75, Figure 76). 
These results showed that there was a tendency for patients with more severe 
disease to express higher levels of αvβ6 albeit at levels that were not significant in 
this cohort. The analysis shows that moderate and poorly differentiated cancers 
expressed slightly higher levels of αvβ6 when compared to the well differentiated 
cancers, which had a lower median score than expected. This was a surprise as our 
previous observations in the laboratory suggested that αvβ6 is stronger in the more 
epithelial-like tumours. It could be that the total numbers of patients in the well and 
well-moderately differentiated group (n=19) was too small and happened to score 
lower compared to the total numbers in the moderate and poorly differentiated 
tumours (n=99); as such no correlation was observed. There was no trend observed 
between αvβ6 expression levels and perineural or vascular invasion, which are 
markers for poor prognosis in PDAC patients. Even though αvβ6 has been shown to 
be involved in promoting tumour growth and metastasis in other cancers [268], no 
correlation was observed between αvβ6 expression levels and the parameters tested 
in this data set. The presence of a trend in αvβ6 expression in patients with severe 
disease suggests that, perhaps with more samples in this particular data set, some of 
the clinical parameters might become significantly associated with αvβ6 expression.  
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4.5.2 Verona data set 
 
147 patients with clinical follow up data were available for further clinical analyses in 
the Verona data set (Table 15). Follow up data were analysed using the Spearman’s 
rho test. There was a significant negative correlation between αvβ6 expression levels 
and the stage of the PDAC in patients (Figure 80). The low stage tumours (up to 
stage IIA) had higher levels of αvβ6 compared with the high stage tumours (stage IIB 
to stage IV). This was contrary to what was expected and what has been published 
in literature so far about the expression of αvβ6, where it has been associated with 
higher stage colon cancer [173]. The exact reason as to why this inverse correlation 
between αvβ6 expression and stage is observed in PDAC remains unclear but 
perhaps in this data set, the patients in the high stage cohort had poorly 
differentiated tumours leading to the decreased expression of αvβ6. This could not 
be verified because differentiation status for this data set was not available as part of 
the follow up clinical data.  
 
Some of the other parameters listed below as part of the clinical follow up data 
analyses did not show any significant correlation with αvβ6 expression when tested 
using the Spearman’s rho test. The patients were grouped on the basis of grade of 
the tumour (Figure 81), gender of the patients (Figure 82), T-stage (Figure 83) and a 
vascular invasion (Figure 84). It is a possibility that there might be no relationship 
between αvβ6 protein expression and the above mentioned clinical parameters but it 
should be noted that there is also a possibility that with more patients included in the 
study, some of the parameters tested might have shown a significant correlation with 
αvβ6 expression. This was highlighted when patients in the data set were divided 
into two cohorts based on vascular invasion. There was a very clear trend observed, 
where the patients with vascular invasion had high levels of αvβ6 expression 
compared with the low αvβ6 expression in patients with no vascular invasion. The 
data were very nearly significant (p value= 0.07) and may well have been significant 
if there were more patients in the data set (Figure 84). Interestingly, in the current 
breast cancer studies in my laboratory, strong expression of αvβ6 correlated with 
vascular but not lymphoid metastasis (data not published). αvβ6 has been shown to 
promote invasion of tumour cells and just like in other cancers, αvβ6 expression is 
higher in PDAC tumours that invade the surrounding vasculature.  
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There was a significant positive correlation between αvβ6 expression levels and 
perineural invasion in patients (Figure 85). Individuals with perineural invasion had 
higher levels of αvβ6 compared to the patients with no perineural invasion with low 
levels of αvβ6 expression (p value= <0.01). It was no surprise that αvβ6 has been 
shown to correlate with perineural invasion in PDAC patients. It has been shown that 
the more aggressive PDAC tumours tend to invade into the surrounding nerves and 
is usually associated with local recurrence of the disease in patients. It also causes 
severe pain and discomfort to the patient [243]. Even though a significant difference 
in perineural invasion was observed, it has be noted that the perineural invasion data 
from the Beatson data set did not show significant difference. This clearly highlights 
the importance of screening a large cohort of patient material before making any 
conclusions with regard to selecting a potential marker can be made. It will be 
interesting to study the data from the two cohorts of patients in greater detail to try 
and answer some of the questions.   
 
Although a total of 118 patients and 147 patients were included in the analyses 
carried out for the purposes of this study, it is still necessary to expand these 
numbers. A larger number of samples in the study are vital for carrying out robust 
statistical analyses on the follow up data before it is possible to draw definite 
conclusions.  
 
In contrast, high β6 mRNA levels in PDAC tumours is a poor prognostic marker at 
the mRNA level with significant difference in overall survival. The high percentage 
(91%) of PDAC tumours that express αvβ6 and the absence of αvβ6 on normal 
pancreas suggests that αvβ6 can still be used a potential therapeutic target to treat 
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5. Development of in vivo models for screening anti-
αvβ6 therapy 
 
This study has so far examined protein expression of αvβ6 in 118 and 147 PDAC 
patients from two independent cohorts, of which 91% were scored positive for αvβ6. 
Survival analysis on two independent cohorts of patients revealed that there was no 
significant correlation between αvβ6 expression and patient survival. In contrast, 
there was a very strong correlation with ITGB6 gene expression and survival. Thus it 
seems likely that the role of αvβ6 is perhaps more complex than I first considered. 
Regardless of this, since αvβ6 is absent from normal pancreas but expressed by 
most PDAC, it constitutes a possible therapeutic target to treat pancreatic cancer 
patients.  
 
To develop anti-αvβ6 cancer therapy, a xenograft model that most closely replicated 
the human pancreatic cancer had to be generated. In this study novel orthotopic 
xenograft models with CFPac1 and Panc04.03 and a subcutaneous xenograft model 
(CFPac1) with and without co-injected pancreatic stellate cells (PS1) were 
developed. The latter model, with PS1 cells introduced, recapitulated key aspects of 
PDAC and was used for therapeutic antibody studies.  
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5.1. Generation of novel αvβ6 positive orthotopic xenograft 
mouse models  
 
Having established that Panc04.03 and CFPac1 cell lines exhibit human PDAC-like 
features and express αvβ6 in 3D organotypic co-culture models, both cell lines were 
tested in orthotopic xenograft models. Intra-peritoneal laparotomy was performed 
(section 2.10.2) on mice, the pancreas was exposed and injected with two million 
cells per animal. After 6-8 weeks, mice were killed and tumours and neighbouring 



















Figure 87: Orthotopic xenograft of Panc04.03. Cells were grown as an 
orthotopic xenograft in the mouse (CD1nu/nu) pancreas. After 6 weeks growth, 
tumours were harvested and processed to paraffin. Image shows an H&E 
stained section showing tumour cells infiltrating the normal pancreas. (Scale 




















Figure 88: Orthotopic xenograft of CFPac1. Cells were grown as an orthotopic 
xenograft in the mouse (CD1nu/nu) pancreas. After 6 weeks growth, tumours 
were harvested and processed to paraffin. Image shows an H&E stained 
section (10X) showing tumour cells infiltrating the normal pancreas. (Scale bar 
represents 100µm). 
  
Images show typical histology of Panc04.03 (Figure 87) and CFPac1 (Figure 88) 
tumours infiltrating the host pancreas with immune infiltrate and stromal response 
clearly visible. The CFPac1 cell line was particularly good as an orthotopic xenograft 
model with local metastasis observed in the spleen and distant metastasis to the liver 










































Figure 89: Metastasis of CFPac1 to the liver and spleen in an orthotopic 
xenograft model. 10X H&E stained images of distant metastases of the liver 
and local metastases of the spleen observed in CFPac1 orthotopic xenograft 
mouse model harvested six weeks post injection.  CFPac1 tumour cells can 




A total of 10 animals per group were used for generating and validating each of the 
orthotopic models using CFPac1 and Panc04.03 cell lines. All 10 animals in the 
CFPac1 group developed tumours. Two animals had metastasis to the liver (Figure 
89) and four animals had local metastasis to the spleen  (Figure 89) although 
metastases to the lung were not observed in either of the orthotopic models. Seven 
out of the 10 animals in the Panc04.03 group developed tumours. Images depicted 
are representative images and all tumours were harvested at the same time (6 
weeks post injection). Tumour sizes were roughly the same in all animals at 
approximately 7mm length (Figure 90).  
 
 
Figure 90: Panc04.03 and CFPac1 orthotopic xenograft tumours. Tumours were 
excised 6 weeks post injection of two million tumour cells directly into the 
pancreas of CD1nu/nu mice. Images are representative of tumour bearing mice 
from 10 per group. 
 
5.1.1. Expression of αvβ6 in Panc04.03 and CFPac1 orthotopic 
models 
 
Both orthotopic models generated using Panc04.03 and CFPac1 cell lines were 
tested for their retention of αvβ6 expression. The pancreata from all the animals were 
harvested six weeks post injection together with the spleen, liver and lungs. Post 
fixation and processing, the pancreas tissues were stained for αvβ6 using the same 
antibody used for staining the human TMA samples but using a mouse-on mouse 
(M.O.M) immunohistochemistry kit from Vector laboratories, UK. This kit was used in 
order to reduce non-specific binding of the mouse primary antibody to mouse tissue 






































Figure 91: Expression of αvβ6 in CFPac1 (top) and Panc04.03 (bottom) 
orthotopic xenograft models. Pancreases were harvested six weeks post 
injection of 2 million CFPac1 or Panc04.03 cells into the pancreas of CD1nu/nu 
mice. Sections were stained with 62G2 (Biogen) antibody used at 1µg/ml. 
Strong brown membranous staining of αvβ6 was observed in CFPac1 and 
Panc04.03 tumour cells and the normal pancreas, in blue, was negative for 
αvβ6. (Scale bar represents 100µm). 
Normal pancreas Beta 6 positive tumour 
Beta 6 positive tumour 
Normal pancreas 
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There was a strong expression of β6 specific to the epithelial cell membrane in all the 
tumours harvested from the orthotopic xenograft models. Both CFPac1 (Figure 91) 
and Panc04.03 (Figure 91) showed high levels of αvβ6 expression as observed by 
the brown coloured staining. The pattern of staining was very similar to that observed 
in the human TMA samples. Also, as in human tissues, the normal mouse pancreas 
together with the surrounding stroma was negative for αvβ6. There was a very slight 
increase in background staining of the xenograft tumours compared to human tissue 
because of using a mouse antibody on mouse tissue but this was overcome by using 
an M.O.M kit to carry out IHC on the samples.   
 
Thus, two new orthotopic models were successfully generated and both models 
maintained expression of αvβ6. Even though this was perhaps an ideal model to use 
from a physiological point of view, it was not possible to carry out testing of new 
therapeutic agent targeting αvβ6 using these models due to lack of an accurate 
method to monitor tumour growth in the pancreas on a daily basis. An ultrasound 
scanner to measure tumour growth or luciferase tagged tumour cell lines to image 
using an IVIS scanner were the two options available to overcome this issue. The 
latter was more feasible and Panc04.03 and CFPac1 luciferase tagged cell lines 
were generated but too late for use in this study (data not shown). Based on data 
obtained from colleagues who performed PDAC orthotopic experiments using a 
different pancreatic cancer cell line, it was evident that the luciferase tagged cells 
imaged using an IVIS scanner did not provide an accurate read out proportional to 
the tumour size in the pancreas. This was a major set back in terms of using the 
orthotopic models generated for further experiments to test the efficacy of anti-αvβ6 
therapy using function blocking antibodies. A subcutaneous model seemed like the 
most viable option to carry the study forward but this model had to be modified to try 




5.2. Generation of an αvβ6 positive subcutaneous xenograft 
mouse model  
 
Two million CFPac1 cells were injected subcutaneously in 200µl PBS into five 
CD1nu/nu mice. Tumour growth was monitored twice a week and tumours were 
harvested six weeks post injection. Following tissue processing, these tumours were 
stained with 62G2, an anti-αvβ6 antibody to determine expression levels of αvβ6.  
 
CFPac1 cells injected subcutaneously into CD1nu/nu mice grew in approximately six 
weeks to give rise to tumours. Tumour cells frequently showed mitotic morphology 
and the developing masses contained small luminal structures as shown by H&E 
staining. The tumour cells (CFPac1) maintained strong membranous αvβ6 
expression as detected by the brown staining. Higher levels of background staining 
were observed in all subcutaneous xenograft sections that were stained for αvβ6. 
This was probably due to the non-specific binding of the mouse primary antibody 











































Figure 92: αvβ6 expression in a CFPac1 subcutaneous tumour. CD1nu/nu mice 
were injected with 2 million tumour cells subcutaneously and the tumour 
harvested six weeks later. Strong expression of β6 (brown staining) was 
observed in the epithelial cell membrane (arrow). H&E staining showed the 
presence of luminal structures. The above pictures are representative of 
images obtained from tumours in five animals. (Scale bar represents 50µm). 
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An αvβ6 positive subcutaneous xenograft model was successfully generated but this 
model lacked a key feature, tumour-stroma interactions, which is a very important 
feature of PDAC tumour growth and progression. A xenograft model that more 
closely replicated human pancreatic cancer therefore had to be generated for pre-
clinical validation of anti-αvβ6 therapy. Human PDACs have a very strong 
desmoplastic reaction and usually up to 70% of the tumour is composed of stroma. 
This desmoplastic reaction had to be mimicked in the xenograft model in order to 
make it more physiologically relevant. Pancreatic stellate cells (PS1) isolated and 
immortalised from human pancreatic cancer patients were available in-house. This 
cell line was characterised by colleagues, who have shown that the ratio of the 
number of stellate cells to cancer cells plays an important role in determining the 
growth and invasion of PDAC cell lines grown in 3D organotypic co-culture models 
(data not published, manuscript submitted). Their data suggested that a ratio of 1:2, 
cancer cells to stellate cells, provided the maximum growth and invasion in the in 
vitro 3D co-culture analysis performed. Thus, before attempting therapeutic 
approaches, I set out to determine whether the incorporation of pancreatic stellate 
cells in the subcutaneous injection resulted in a tumour appearance which more 
closely approached the morphology seen in human pancreatic cancer. 
 
5.3. Development of novel xenograft models incorporating 
pancreatic stellate cells 
 
PS1 cells were co-injected with CFPac1 tumour cells in a 2:1 ratio both into the 
pancreas and subcutaneously in to CD1nu/nu mice. The subcutaneous tumours 
were measured every two days and tumours harvested fifteen days after injection. As 
expected the introduction of the stellate cells increased the rate of growth compared 
to the growth of CFPac1 in the absence of stellate cells (Figure 94). All mice that 
were injected with CFPac1 together with PS1 cells in a 1:2 ratio, had measurable 
tumour volumes from day 3. In contrast, only three of the five mice injected with 
CFPac1 tumour cells alone developed tumours and this was only apparent from day 
11. At day 15, the mean tumour volume of CFPac1/PS1 tumours was 349mm3 







Figure 93: Introduction of PS1 cells into a CFPac1 subcutaneous model 
increases desmoplastic reaction. 1 million CFPac1 tumour cells alone (A) or 1 
million CFPac1 with two million PS1 stellate cells (B) were injected 
subcutaneously into CD1nu/nu mice (n=5 per group). Tumours were harvested 
from mice fifteen days post injection. The black arrows in (B) point to 
increased desmoplastic response observed in the cancer cell and stellate cell 
co-injected subcutaneous xenograft model. The red arrows in (B) point 
towards the fibroblast-like stellate cells (PS1) interspersed in the tumour 






















Figure 94: Accelerated growth of CFPac1/PS1 (1:2 ratio) subcutaneous 
tumours compared to CFPac1 cells alone.  1 million CFPac1 and 2 million PS1 
cells were co-injected subcutaneously into the CD1nu/nu mice and tumour 
growth compared to that of CFPac1 cells alone (n=5 per group). Data show the 
























It was observed that the introduction of the stellate cells with the cancer cells 
stimulated a desmoplastic response similar to that which has been observed in 
human PDAC (Figure 93). The stellate cells could be seen in the surrounding tumour 
stroma (shown by red arrows). This increased desmoplastic response was not 
observed in the CFPac1 cells alone subcutaneous model generated previously 
(Figure 92- top). The addition of the stellate cells into the subcutaneous model also 
significantly increased the rate of tumour growth (Figure 94). This was a significant 
step towards achieving a more physiologically relevant subcutaneous model. A 
similar response was also observed in the orthotopic model (Figure 95) but this 
model is, of course, more technically demanding and places greater stress on the 
























Figure 95: Introduction of PS1 cells into a CFPac1 orthotopic model increases 
desmoplastic reaction. 1 million CFPac1 tumour cells alone (A) or 1 million 
CFPac1 with two million PS1 stellate cells (B) were injected orthotopically into 
the pancreas of CD1nu/nu mice (n=5 per group). Tumours were harvested from 
mice six weeks post injection. The black arrows in (B) point to increased 
desmoplastic response observed in the cancer cell and stellate cell co-injected 
orthotopic xenograft model. The red arrows in (B) point towards the fibroblast-
like stellate cells (PS1) interspersed in the tumour stroma. The above pictures 
are representative images and scale bar represents 100µm.  
 
In order to determine that αvβ6 expression was retained in the modified 
subcutaneous model (CFPac1/PS1) tumour sections were stained for αvβ6. Figure 
96 shows CFPac1 cells expressed αvβ6 strongly on the cell membrane. A strong 
desmoplastic response also was observed, which is typical of the human disease. 
Multiple tumour sections from all animals in the CFPac1/PS1 cohort were observed 
by two independent pathologists (Dr. Colan Ho-Yen and Prof. Louise Jones), who 





















Figure 96: Expression of αvβ6 in a CFPac1/PS1 subcutaneous tumour. 
Tumours were harvested fifteen days post injection and stained for αvβ6. 
Arrows point towards β6 staining (brown) on the cell membrane of CFPac1 
cells. Note also the marked stromal response in between islands of tumour 
cells. The above picture is representative of tumour sections from five animals 
per group. (Scale bar - 100µm). 
  
 234 
5.3.1. Direct comparison of CFPac1/PS1 subcutaneous model 
with CFPac1/PS1 orthotopic model  
 
In the absence of a genetically modified spontaneous mouse model for pancreatic 
cancer, it was important to validate the modified subcutaneous xenograft model 
against the orthotopic model, the latter seeming most likely to represent the more 
physiologically relevant and comparable model to the human disease. H&E stained 
sections showed that the CFPac1/PS1 subcutaneous model had an increased 
desmoplastic response compared to the injection of CFPac1 cells on their own 
(Figure 93) and certainly these tumours looked morphologically similar to the 
CFPac1/PS1 orthotopic xenograft model (Figure 93 compared with Figure 95). This 
was considered to be promising and more experiments were carried out to validate 
the new modified subcutaneous model further. 
 
5.3.1.1. Desmoplastic response in CFPac1/PS1 
xenografts.  
 
PDAC disease is typified by the presence of an intense desmoplastic stroma. This 
stromal response has been attributed largely to the presence of the activated 
pancreatic stellate cells in the stroma surrounding the tumour [86]. It has also been 
shown that orthotopic models for pancreatic cancer where tumour cells and stellate 
cells have been co-injected tend to replicate the desmoplastic reaction seen in 
humans making them suitable models to study PDAC growth and progression [77]. 
The modified subcutaneous xenograft model tumours were stained for collagen using 
Sirius red dye, which binds specifically to the helical structure on fibrillar collagen 
(type 1-4). Therefore it was used as a measure to compare total collagen deposition 



















Figure 97: Increased collagen deposition in CFPac1/PS1 orthotopic and 
subcutaneous xenograft models. Representative images show total levels of 
collagen deposition using Sirius red staining on tumour sections from CFPac1 
cells alone or tumours produced by CFPac1 cells in combination with PS1 
cells in an orthotopic model (A and B) and subcutaneous model (C and D) 
(Scale bar - 100µm).  
 
There was no difference observed in terms of total collagen deposition between the 
CFPac1/PS1 orthotopic and CFPac1/PS1 subcutaneous xenograft models when 
stained with Sirius red (Figure 97). The red colour of the dye was observed where 
there was collagen deposition and the addition of the stellate cells into the 
subcutaneous model significantly increased the desmoplastic response observed as 
seen in Figure 97D compared to the CFPac1 alone when injected subcutaneously 
Figure 97C. This increase in collagen deposition was also observed in the orthotopic 
model upon addition of PS1 cells (Figure 97B compared with Figure 97A). The 
CFPac1 alone subcutaneous model still had some collagen deposition; presumably 
as a result of the host stromal response but the level of collagen deposition was 
dramatically lower than that when PS1 cells were incorporated. All sections from the 
different models were stained at the same time using the same procedure. This 
suggested that the modified subcutaneous model with CFPac1/PS1 was as good as 
the CFPac1/PS1 orthotopic model in terms of laying down a desmoplastic stroma 
thereby mimicking human disease.  
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5.3.1.2. Tumour vascularity in the xenograft models 
 
Poor vascularity is a common feature in human PDAC and one of the major reasons 
why chemotherapeutic agents do not reach the tumour. This poor vascularity is also 
observed in the genetically modified mouse model (KPC), widely used in pancreatic 
cancer research and considered the gold standard to recapitulate human disease. In 
contrast, transplanted tumours, either orthotopic or subcutaneous have been shown 
to be highly vascularised thereby not replicating the physiological scenario observed 
in human PDAC [269]. Tumour vascularity therefore was investigated in both the 
tumour models generated previously to determine if these novel xenograft models 


















Figure 98: Decreased tumour vascularity in CFPac1/PS1 orthotopic and 
subcutaneous xenograft models. Representative images show blood vessels, 
identified by being stained for endomucin, on tumour sections from CFPac1 
alone or in combination with PS1 cells in an orthotopic model (A and B) and 
subcutaneous model (C and D) (Scale bar - 100µm).  
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The tumours harvested from CFPac1 and CFPac1/PS1 orthotopic xenograft models 
were stained for blood vessels using a rat anti-endomucin antibody; endomucin is a 
blood vessel marker specifically expressed on the endothelial cells. It was clearly 
apparent from visual inspection that the addition of the PS1 stellate cells with the 
CFPac1 cells significantly reduced the number of blood vessels in both the 
subcutaneous and orthotopic tumour models (Figure 99). The numbers of blood 
vessels were quantified by counting the number of endomucin positive blood vessels 
in four high power fields per tumour sample. There was a significant reduction in the 
number of blood vessels in the CFPac1/PS1 orthotopic model compared to the 
CFPac1 orthotopic model (p= <0.01). The tumours in both cohorts were harvested at 
the same time and the counting was done blind to avoid any element of bias in the 
analysis (Figure 99A). Similarly, there was a significant reduction in the number of 
endomucin positive blood vessels in the CFPac1/PS1 subcutaneous tumours 
compared with the CFPac1 tumour cells alone (p= <0.03). The number of blood 
vessels was quantified using the Ariol microscope, which uses automated software to 
analyse the number of blood vessels and express it relative to the area of the tumour 
(Figure 99B). The blood vessels around the edge of the tumour were not included for 

































Figure 99: Quantification of blood vessels in CFPac1 and CFPac1/PS1 
orthotopic and xenograft tumour models. Blood vessels were stained for 
endomucin. A) Four high power fields per tumour sample (n=3 per group) were 
used to quantify the number of endomucin positive blood vessels in the 
orthotopic models. B) Ariol scanning microscope was used for quantifying the 
number of endomucin positive blood vessels and expressed relative to area of 
the tumour sample (n=3 per group). Student’s t-test p= <0.01 (orthotopic 






These results suggested that another important aspect of PDAC tumours, 
hypovascularisation, was retained in both the CFPac1/PS1 subcutaneous and 
orthotopic xenograft models. There was a strong and near identical desmoplastic 
response observed in both the subcutaneous and orthotopic models, which could be 
the reason for the significant reduction in vascular density in the tumours. The 
modified subcutaneous model was comparable to the modified orthotopic model in 
terms of the desmoplastic response observed (collagen deposition) and reduced 
vascularity (endomucin quantification) in the tumours. These parameters were 
physiologically relevant and comparable to the published data using the genetically 
modified KPC mouse model [93, 269].  Although the modified subcutaneous model 
may still not be considered the perfect model, in terms of representing human 
disease, this study addressed some of the key issues that arise from using a 
subcutaneous mouse model. 
 
5.4. Anti-αvβ6 targeted therapy in a subcutaneous xenograft 
mouse model of pancreatic cancer 
 
Having established a suitable subcutaneous xenograft model that retained major 
features of human PDAC, a novel human anti-αvβ6 antibody was next tested as a 
potential therapeutic. In a pilot experiment (n=3 mice per arm) 1 million CFPac1 cells 
were co-injected with 2 million PS1 cells subcutaneously into female CD1nu/nu mice. 
Mice were given antibody 264RAD at 10mg/Kg or isotype control at 10mg/Kg once 
tumours reached a size of 100mm3. The animals were treated twice a week and the 
antibodies were administered intra-peritoneally (IP). Tumour volume was assessed 

















Figure 100: Pilot experiment testing the therapeutic efficacy of 264RAD 
antibody against CFPac1/PS1 subcutaneous tumours. CD1nu/nu mice bearing 
subcutaneous CFPac1/PS1 tumours were treated with 264RAD at 10mg/Kg or 
IgG control antibody at 10mg/Kg twice a week. Data represent the mean 
tumour volume and standard deviation of 3 animals per group. Student’s t-test 
p= <0.04. 
 
The preliminary experiment, with only n=3 per group, showed that the anti-β6 therapy 
delayed tumour progression compared to the IgG control antibody treated group. 
There was a significant difference between the two groups at day 13 (p= <0.04) but 
the differences in size did not attain significance in the later stages as the treatment 
progressed (Figure 100). This is likely due to the very small numbers of animals used 
per group and also because the animals in the control group reached the upper limit 
of tumour size under the Home Office regulations and had to be killed before a 
significant difference between the two groups could be observed. The tumours from 
these animals were harvested and processed for further IHC analyses. 
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5.4.1. IHC analysis on tumour tissue 
 
Effective antibody therapy in humans requires biomarkers to prove that the 
therapeutic is causing real biological change. Expression of αvβ6, Ki67, phospho 
ERK and caspase3 levels were thus analysed in 264RAD and IgG treated tumours.  
 
5.4.1.1. Expression levels of αvβ6 on tumours 
 
It has been shown that when tumours are treated with 264RAD, they lose expression 
of αvβ6 [233]. Since the tumours were treated with the anti-αvβ6 blocking antibody 













Figure 101: αvβ6 expression in 264RAD and IgG treated CFPac1/PS1 
subcutaneous tumours. Representative images of αvβ6 expression in tumours 
treated with A) 264RAD and B) IgG antibody. Tumours were harvested after 27 
days of treatment (n-3 per group). Brown membranous staining was observed 
on both 264RAD and IgG treated tumours. (Scale bar represents 50µm). 
 
There was no clear observable reduction in the levels of expression of αvβ6 between 
the 264RAD treated and the control IgG treated tumour samples (Figure 101). This 
was not in agreement with the published literature but it could be that the tumours 
were not treated long enough in order to significantly affect levels of expression of 
αvβ6. The high background staining, which made comparison difficult, was because 
of using a mouse primary antibody on mouse tissue despite using the M.O.M kit, 
which aims to reduce background staining. 
  
264RAD treated IgG treated 
A B 
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5.4.1.2. Expression of phospho ERK in 264RAD/IgG 
treated tumours 
 
ERK phosphorylation plays an important role in cellular proliferation, differentiation 
and survival and αvβ6 has been shown to interact directly with the ERK pathway and 
generate survival signals [181]. Since a significant decrease in proliferation was 
anticipated in the tumour sections that were treated with 264RAD compared with the 
IgG control treated antibody, because of the slower growth rate of the tumours, it was 
decided to examine expression levels of phospho ERK at the tissue level between 
the two treatment groups.  
 
Four high power fields per tumour sample were taken at random and the number of 
positive nuclei was counted (Figure 102). There was a significant reduction in the 
expression levels of phospho ERK in the 264RAD treated tumours in comparison 
with the IgG control antibody treated tumour sections (p= <0.0001). These data 
showed the down stream effects of blocking αvβ6 using an αvβ6 function blocking 



























Figure 102: Phospho ERK expression in 264RAD and IgG treated CFPac1/PS1 
subcutaneous tumours. 10X magnification representative images of phospho 
ERK expression in tumours treated with A) 264RAD and B) IgG antibody. 
Tumours were harvested after 27 days of treatment. C) Data show % mean ± 
SEM of phospho ERK positive cells (n-3 per group). Student’s t-test p= 
<0.0001. (Scale bar represents 50µm). 
 
5.4.1.3. Expression of Ki67 in 264RAD/IgG treated 
tumours 
 
Ki67 is a nuclear protein and marker for cellular proliferation. Ki67 is present during 
all phases of the cell cycle but is absent in the resting (G0) phase. Since there was a 
marked decrease in tumour volume in the 264RAD treated tumours compared to the 
control IgG antibody treated animals, the tumour sections were stained for Ki67 to 

























Figure 103: Ki67 expression in 264RAD and IgG treated CFPac1/PS1 
subcutaneous tumours. 10X magnification representative images of Ki67 
expression in tumours treated with A) 264RAD and B) IgG antibody. Tumours 
were harvested after 27 days of treatment. C) Data show % mean ± SEM of Ki67 
positive nuclei (n-3 per group). Student’s t-test p= <0.0001. (Scale bar 
represents 50µm). 
 
Four high power fields per tumour sample were taken at random and the number of 
positive nuclei was counted (Figure 103). There was a significant reduction in the 
expression levels of Ki67 on the 264RAD treated samples in comparison to the IgG 
control antibody treated tumour sections (p= <0.0001). These data confirmed that the 
tumour cells treated with 264RAD αvβ6 blocking antibody were proliferating less 
compared to the IgG control antibody treated tumour cells thus perhaps accounting 
in part for the difference in tumour volumes observed between the two treatment 
groups.  
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5.4.1.4. Expression of activated caspase 3 in 264RAD/IgG treated 
tumours 
 
Activated or cleaved caspase 3 is considered a marker for apoptosis. In general, 
cells positive for activated caspase 3 have undergone or are undergoing apoptosis 
through a caspase dependent pathway. Since there was a substantial difference in 
tumour volume between the 264RAD treated and IgG control antibody treated 
tumours, sections were stained for activated caspase 3 to determine if there was any 















Figure 104: Activated caspase3 expression in 264RAD and IgG treated 
CFPac1/PS1 subcutaneous tumours. Representative images of activated 
caspase 3 expression in tumours treated with A) 264RAD and B) IgG antibody. 
Tumours were harvested after 27 days of treatment. C) Data show % mean ± 
SEM of activated caspase 3 positive cells (n-3 per group). Student’s t-test p= 
<0.0001. (Scale bar represents 50µm). 
















































Four high power fields per tumour sample were taken at random and 200 nuclei per 
field of the number of caspase 3 positive or negative cells (nuclear/cytoplasmic 
brown stain) were counted. There was a significant increase in the expression levels 
of caspase 3 on the 264RAD treated samples in comparison with the IgG control 
antibody treated tumour sections (p= <0.0001). This data confirmed that the tumours 
treated with 264RAD β6 blocking antibody were apoptotic and dying compared with 
the IgG control antibody treated tumours (Figure 104) possibly accounting in part for 
the difference in tumour volumes observed between the two treatment groups. 
 
5.4.2. Targeting αvβ6 in a CFPac1/PS1 xenograft model using 
264RAD and gemcitabine  
 
Having observed a significant difference between the two treatment arms in the pilot 
experiment, it was decided to conduct a larger experiment with more animals per 
group and also include a gemcitabine single agent therapy and 264RAD + 
gemcitabine combination therapy treatment arm. The number of cells injected per 
animal was also halved, as PS1 cells are slow growing.   
 
0.5 million CFPac1 were co-injected with 1 million pancreatic stellate cell line, PS1 
(1:2 ratio) subcutaneously into female CD1nu/nu mice. Tumour growth was 
measured twice weekly and treatment started on an individual basis when tumour 
size reached approximately 100mm3. Mice were randomised to one of four treatment 
















Figure 105: Treatment plan for the 264RAD/gemcitabine therapy of CFPac1/PS1 
xenografts. Animals were randomised and entered into one of the four groups 
when tumours reached 100mm3.  
 
The four treatment arms included the αvβ6 function blocking antibody 264RAD as a 
single agent therapy used at 10mg/Kg final concentration, gemcitabine as a single 
agent (current therapy available for PDAC patients) at 100mg/Kg, a combination arm, 
264RAD used at 10mg/Kg and gemcitabine at 100mg/Kg and a control arm with IgG 
isotype antibody used at 10mg/Kg (Figure 105). The animals were treated twice a 
week and the drugs were administered intra-peritoneally (IP). Each animal in the 
single agent group received 200µl of the drug per injection and the combination 
group received 400µl (200 each of the two drugs) per injection. Therapy was 
continued until 6 weeks (day 42) from the first dose (day 1). There were 9 animals 
per group and tumour volumes were assessed twice a week by bilateral Vernier-
caliper measurement and calculated (taking length to be the longest diameter across 
the tumour and width to be the corresponding perpendicular diameter) using the 


























Figure 106: Treatment of CFPac1/PS1 subcutaneous tumours with 
264RAD/gemcitabine. Mice bearing subcutaneous CFPac1/PS1 tumours were 
treated with 264RAD at 10mg/Kg, gemcitabine at 100mg/Kg, 264RAD (10mg/Kg) 
+ gemcitabine (100mg/Kg) or IgG control antibody at 10mg/Kg twice a week up 
to day 42. Data were log transformed and represent the mean and standard 


































































































































































































































































































































































































264RAD + Gemcitabine 10mg/Kg + 100mg/Kg

















Figure 107: Kaplan-Meier survival curves showing response to the therapy 
administered. Animals in the IgG group were all dead by day 77 after treatment 
started. 8 out of 9 animals survived in both the single agent treatment arms 
whereas all animals were alive at day 105 in the combination group.  
 
There was a significant decrease in tumour growth in all the treatment arms when 
compared to the IgG control antibody treated animals over the six-week treatment 
period (Figure 106). Growth inhibition was calculated from start of treatment based 
on the change in tumour volume. Since the variance in mean tumour volume data 
increases proportionally with volume (and is therefore disproportionate between the 
groups), data were log-transformed to remove any size-dependency. There was 
considerable variation observed in the IgG control antibody treatment arm (Figure 
106) and this was because animals had to be culled as the experiment was in 
progress either due to poor health or the tumour had reached the maximum 
permitted size as per Home Office regulations (Figure 107). Note that by day 56 only 
2 animals in the IgG group survived and they were culled by day 77 (Figure 107). 
There was one animal each from both the single agent therapy arm, which had to be 
culled due to poor health even though their tumour burdens were well within the size 
limit (Figure 107). 
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The 264RAD single agent therapy arm inhibited tumour growth as soon as treatment 
was administered with >50% reduction in tumour growth observed just 9 days after 
treatment commenced when compared to the IgG control antibody treated animals 
(Figure 106). Once treatment stopped at day 32, it was observed that the tumours in 
the 264RAD treated mice started to grow but at a much slower rate than the IgG 
group. In contrast, all animals in the IgG control antibody treated treatment arm were 
dead by day 74 (Figure 106). The gemcitabine single therapy treatment arm 
significantly reduced tumour size over the treatment period when compared to the 
IgG control antibody treated animals. Once therapy had stopped, tumour size seem 
to remain static but the tumour masses started to grow again by day 63. The rate at 
which the tumours were growing was slower than the IgG control arm (Figure 106). 
The combination therapy arm with both 264RAD and gemcitabine reduced tumour 
burden the most effectively of all treatment arms when compared with the IgG control 
antibody treated animals. Once combination therapy stopped, tumour size remained 
static for an additional 49 days since mean tumour size did not increase until day 91. 
Although it appears that tumour re-growth occurs following the end of treatment in all 
treatment arms, the combination therapy arm had the lowest tumour volume at day 
105.   
 
5.4.1. Statistical analyses comparing the four treatment arms 
from day 0 to day 42 
 
Tumour measurements from day 0 to day 42 (end of treatment) were analysed using 
the generalised linear mixed model, which focuses more on the inverse link function 
rather than the link function to model the relationship between the linear predictor 
(time) and the conditional mean (tumour volume). The adjusted p values were 
calculated (Table 17). There was a significant difference in the rate of growth of the 
tumours in the 264RAD single therapy arm from day 6 to day 32 as denoted by the p 
values (***) when compared with the IgG treated animals. There was a significant 
difference in the rate of tumour growth in the gemcitabine single therapy treatment 
arm from day 6 to day 42 when compared with the IgG control antibody treated 
animals as denoted by the p values (***). There was a significant difference in the 
rate of tumour growth in the combination therapy treatment arm from day 2 to day 42 
when compared to the IgG control antibody treated animals as denoted by the p 
values (***). When comparisons were made between the combination therapy 
treatment arm and the gemcitabine single agent therapy arm, there was a significant 
difference in the rate of tumour growth between the two groups from day 9 to day 21 
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and from day 32 to day 42 as denoted by the p values (*). More interestingly, there 
appeared to be a significant difference between the rate at which the tumour was 
growing back when comparing the gemcitabine single agent therapy arm and the 
combination therapy treatment arm. This experiment is still on going and further 























Table 17: Statistical analyses comparing the four treatment arms. Values with 
*/**/*** denote significant statistical difference between two groups at a 
particular time point. Italicised p values are non-significant.  
  
Generalized linear mixed model- adjusted p values (***) denotes significance 












0 0.406 0.497 0.5983 0.1470 0.2407 
2 0.818 0.072 0.0043 ** 0.003 ** 0.1454 
6 0.010 * 0.008 ** 1.35E-05 *** 0.0004 *** 0.1144 
9 0.004 ** 0.0003 *** 2.42E-05 *** 0.0009 *** 0.0136 * 
12 0.0001 *** 2.98E-05 *** 4.46E-06 *** 0.001 ** 0.0577 
15 0.003 ** 9.51E-05 *** 2.30E-07*** 9.86E-06 *** 0.0049 ** 
18 0.001 ** 0.0001 *** 1.85E-06 *** 0.0001 *** 0.011 * 
21 0.015 * 0.0002 *** 2.25E-05 *** 0.0002 *** 0.0108 * 
25 0.003 ** 4.70E-05 *** 8.65E-06 *** 0.0007 *** 0.0811 
28 0.025 * 0.0007 *** 0.0001 *** 0.001 ** 0.0768 
32 0.007 ** 0.0001 *** 5.97E-06 *** 9.94E-05 *** 0.0102 * 
35 0.090 0.0001 *** 0.0003 *** 0.0003 *** 0.0375 * 
39 0.109 0.010 * 0.0002 *** 0.0002 *** 0.0128 * 




Treatment options available to PDAC patients have not improved over the past few 
decades with gemcitabine or a combination of chemotherapeutic drugs with 
gemcitabine and radiotherapy being the only treatment available for patients with 
locally advanced unresectable disease. Only about 20% of patients who present with 
the disease can undergo surgical resection and a further 50%-60% have metastatic 
disease at a stage where palliative care usually is the only option. Currently there are 
18 active clinical trials for pancreatic cancer patients (source: clinical trials.gov, 
2012). Of these, two active trials are investigating potential biomarkers in PDAC 
patients (source: clinical trials.gov, 2012) and one utilises PET imaging to study 
hypoxia in PDAC tumours (source: clinical trials.gov, 2012). There are two active 
trials providing vaccines to PDAC patients to modify the immune system (source: 
clinical trials.gov, 2012) but there are no active trials currently for antibody-mediated 
therapy to treat pancreatic cancer. This could be due in part to the history of poor 
performance by novel antibodies in treating pancreatic cancer or that there are no 
new agents, which are clinically efficient and good enough to enter clinical trials to 
target pancreatic tumour specifically.  
 
As discussed in the previous chapter, even though αvβ6 failed to be a reliable novel 
prognostic marker at the protein level for PDAC, at the mRNA level in a separate 
cohort of 292 patients, individuals expressing high αvβ6 showed significantly poorer 
prognosis compared with the low expressers. The most important piece of 
information from the two data sets that were tested for αvβ6 at the protein level was 
that 91% (median score ≥1) of PDAC patients were tested positive and this is 
dramatically more than what is observed in other cancers studied to date [201, 203, 
204, 267]. Since PDAC patients have very limited treatment options available to them 
and thus developing new treatment options are essential to improve clinical outcome, 
targeting αvβ6 may provide an additional strategy. Integrin αvβ6 is expressed only on 
cancer cells and is absent in normal adult tissues, making it a potential therapeutic 
target for treating PDAC patients. Currently there are no αvβ6 targeting antibodies in 
any active clinical trials to target cancer, although a function-blocking antibody 
against αvβ6 (STX-100), is being used in the clinic to treat patients with pulmonary 
fibrosis (source: clinical trials.gov, 2012). Thus, there remains a clinical opportunity 




5.5.1. Generation of mouse models 
 
Pre-clinical validation of novel therapeutic agents is essential before setting up 
clinical trials. Such experiments also enhance understanding of the kinetics and 
efficacy of the agent. Selection of the correct pre-clinical animal model is extremely 
important because results obtained from these pre-clinical experiments form the 
basis for any further clinical trials conducted in patients. A recent study using the 
KPC model for PDAC used a hedgehog inhibitor (IPI-926) to block hedgehog 
signalling in the surrounding stromal cells. This was targeted to inhibit the anti-
angiogenic functions of the stellate cells to temporarily increase blood supply to the 
pancreatic tumours, before administering gemcitabine to target the cancer more 
efficiently [269]. This combination of inhibitor and gemcitabine showed extremely 
promising results in the KPC mouse model but phase II clinical trails conducted on 
PDAC patients with metastatic cancer showed no significant difference in clinical 
outcome in patients treated with the hedgehog inhibitor/gemcitabine (<6 months 
overall survival) or placebo/gemcitabine (>6 months overall survival) (Infinity 
Pharmaceuticals report, 2012). Thus, choosing the correct animal model and finding 
the optimal treatment strategy, such that it is physiologically relevant to humans, is 
crucial to get novel therapeutics into the clinic. As demonstrated with IPI-926, there is 
still the possibility that humans will not respond in a fashion that mirrors the animal 
model.  
 
I investigated the use of a human anti-αvβ6 function-blocking antibody 264RAD as a 
therapeutic agent, to treat pancreatic cancer in xenograft mouse models, used both 
as a single agent and in combination with gemcitabine, the existing 
chemotherapeutic drug of choice to treat PDAC in humans. 264RAD has been 
validated by in vitro tests performed both in this study and in an independent study, 
which reaffirm that 264RAD can block αvβ6 function in cancer cells specifically [233]. 
Indeed, the independent study also used the 264RAD antibody as a single agent to 
target the xenografts of murine breast and human OSCC cell lines 4T1 and Detroit 
562 respectively, grown in mice [233]. The study showed a significant inhibition of 
tumour growth when the animals were treated with 20mg/Kg of the 264RAD antibody 
compared to a control isotype IgG antibody. The authors of this study also observed 
a decrease in the number of lung metastases from 4T1 tumours in the animals 
treated with the 264RAD antibody compared to the controls. Studies performed by a 
colleague in our laboratory have used 264RAD in combination with Herceptin to treat 
subcutaneous breast cancer xenograft models, with the combination therapy arm 
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performing significantly better than the single agent therapy (data not published). 
These results reaffirmed that αvβ6 is a promising therapeutic target to treat cancer.  
 
Based on the results from the above-mentioned studies, it was decided to test the 
αvβ6 function-blocking antibody on a xenograft mouse model for PDAC. This study 
has used 264RAD at 10mg/Kg (half the concentration used in the published 
literature) or a combination of 264RAD and gemcitabine at 10mg/Kg and 100mg/Kg 
respectively administered to mice twice a week, intraperitoneally (Figure 105). A 
gemcitabine single agent therapy arm was also included in the study to compare how 
effective the αvβ6 function-blocking antibody, as a single agent would be, and also to 
test if there was any synergistic or additive effect when used in combination with 
gemcitabine. Since Astra Zeneca – Medimmune provided the 264RAD and control 
IgG antibody for the purpose of this study; dosage of antibody administered was 
based on their previous data. However, previously published literature has used 
gemcitabine at 100mg/Kg to treat mice twice a week, with a significant difference in 
tumour growth in the treated animals compared to the control [269]. This was used 
as a reference and the same concentration was given to experimental animals in this 
study.  
 
5.5.2. Orthotopic mouse model 
 
Two orthotopic models (Figure 87, Figure 88) were generated as part of this study 
using Panc04.03 and CFPac1 PDAC cell lines. Both cell lines grew successfully in 
vivo, with the CFPac1 model developing both local and distant metastasis (Figure 
89). Both the tumour cell lines grown in mice retained expression of β6 in vivo as 
confirmed by IHC (Figure 91). The surrounding stroma and the normal pancreas was 
negative for αvβ6. In the absence of a genetically engineered mouse model for 
PDAC for this study, the orthotopic xenograft model was the next most 
physiologically relevant model to investigate. Although models were generated and 
tested for expression of αvβ6, it was soon apparent that using them for antibody 
mediated therapy experiments would not be possible. This was partly due to the 
limitations in the technology available to measure tumour growth kinetics daily and 
also due to time and cost restrictions, since orthotopic models took longer to grow 
and required more mice. Therefore, initially we chose to luciferase tag the tumour 
cells to allow tumour growth in the mice to be imaged using the IVIS scanner. 
Unfortunately, further discussion regarding the imaging of orthotopic pancreatic 
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tumours highlighted problems with this technique; colleagues in the laboratory found 
that bioluminescence detected by the IVIS was not proportional to tumour growth and 
thus subtle changes in the tumour size could not accurately be assessed. This was a 
set back in terms of using these models for further therapy experiments and 
subsequently a subcutaneous model was generated for therapeutic experiments. 
While it is accepted that a subcutaneous model for PDAC is not ideal, it does obviate 
the need for laparotomy and thus, presumably, places less stress and discomfort on 
the experimental animals.  
 
5.5.3. Subcutaneous mouse model 
 
Although subcutaneous xenograft models are widely used, they often are not 
considered to be physiologically relevant primarily due to the lack of an appropriate 
tumour-stroma interaction. A αvβ6 positive subcutaneous model was generated 
using the CFPac1 PDAC cell line, (Figure 92). This model was modified by co-
injecting human pancreatic stellate cells, PS1, together with the CFPac1 cells in a 
2:1 ratio respectively. The hypothesis was that by introducing the stellate cells into 
the model it would create a relevant tumour-stroma interaction, thereby making the 
subcutaneous model a closer physiomimetic of pancreatic cancer tissue. Activated 
pancreatic stellate cells form the major component in the tumour stroma and are 
known to be important for PDAC progression in humans [84]. The stromal response 
in PDAC tumours is extremely high, in some cases up to 70%-80% of the tumour is 
composed of stromal cells. Unpublished data obtained from our laboratory 
determined that mixing stellate:cancer cells in a 2:1 ratio generated the optimum 
levels for maximum tumour growth and invasion. Previous studies have co-injected 
stellate cells with cancer cells orthotopically in a 5:1 ratio and shown that the rate of 
tumour growth is accelerated by the presence of the stellate cells [84]. Stellate cells 
have also been shown to induce fibrosis and also stimulate secretion of MMPs 
including MMP9 [270]. This could be one of the mechanisms used by PDAC tumour 
cells to promote tumour invasion. As mentioned previously, αvβ6 has been shown to 
promote OSCC invasion in an MMP9 dependent manner [125]. I have not looked in 
my studies whether a similar mechanism might be operative. However, preliminary 
studies conducted using the pancreatic expression database suggest that MMP11 
(stromelysin 3) may be regulated by αvβ6 in PDAC. This relationship between αvβ6 
and MMP regulation is likely to be a fruitful area to pursue in the future.  
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5.5.4. Comparison and validation of the two modified models 
 
No previous studies have co-injected pancreatic stellate cells (PS1) with CFPac1 cell 
line and compared the subcutaneous and orthotopic models. In fact, I found no 
reports studying CFPac1 cell line in vivo. Co-injecting stellate cells with CFPac1 in 
the modified subcutaneous model invoked a strong desmoplastic response 
compared with the model with the tumour cells alone as confirmed by H&E staining 
(Figure 93). The new xenograft model also retained expression of αvβ6 in the tumour 
cells and the surrounding stromal cells were completely negative (Figure 96).  
 
Two pathologists confirmed, independently, that the modified subcutaneous tumours 
were similar to the human disease, but the model still had to be validated against the 
orthotopic model before being used to carry out any therapy experiments. A modified 
orthotopic model was generated simultaneously with the subcutaneous model using 
the same ratio of PS1 and CFPac1 cells and tumours from both models were 
harvested and stained for collagen deposition. Collagen type I has been shown to be 
one of the major ECM proteins deposited in the highly desmoplastic PDAC tumours 
as a result of the presence of the activated pancreatic stellate cells [86]. The 
presence of PS1 cells dramatically increased expression of collagen compared with 
tumours lacking PS1 cells. Thus, the addition of PS1 cells replicated the fibrotic 
phenotype observed in human PDAC. It was also noted that the fibrosis developed 
was similar in both the orthotopic and subcutaneous models, suggesting that the 
subcutaneous model faithfully reproduced the orthotopic phenotype (Figure 97). 
 
Poor vasculature is another key feature of PDAC in humans. Unlike most tumours, 
the blood supply to the PDAC tumours is significantly lower and this could be due to 
the strong desmoplastic response observed [269]. Recent studies have shown that 
one of the major reasons for the poor response of PDAC patients to 
chemotherapeutic agents is the lack of adequate blood supply to the tumour [269]. 
The same was true in the case of the KPC mouse model where poor vasculature in 
the tumour meant gemcitabine could not reach the tumours. Hedgehog inhibitor (IPI-
926) could temporarily increase blood supply to the tumours by depleting the tumour-
associated stromal cells (reducing the desmoplastic reaction) thus enhancing drug 
delivery to the tumour [269]. Since there was a strong desmoplastic response 
observed in both the modified orthotopic and subcutaneous models generated, the 
sections were stained for a mouse blood vessel marker, endomucin. There was a 
significant decrease in the number of blood vessels in the PS1-containing orthotopic 
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and subcutaneous models when compared with the cancer cell alone model (Figure 
98). Thus, the addition of stellate cells with the cancer cells affected the tumour 
vasculature similarly in both orthotopic and subcutaneous models. This hypo-
angiogenic response could be due to the increased desmoplasia observed as a 
result of the addition of the stellate cells. Importantly, both subcutaneous and 
orthotopic models behaved similarly and were comparable to the KPC mouse model 
and human pancreatic cancer. In conclusion, the co-injection of pancreatic stellate 
cells generated PDAC xenografts that appeared morphologically similar to human 
PDAC tumours, regardless of the site of injection. This highlights the importance of 
pancreatic stellate cells in determining the appearance and growth of PDAC tumours. 
This model also provides an excellent new system for studying the molecular basis of 
how pancreatic stellate cells influence matrix deposition and blood vessel density.  
 
Having established a valid new model I was still concerned that the consequence 
could be a poor response to antibody therapy due to the high desmoplasia and poor 
blood supply. It was decided to go ahead and provide antibody therapy to the 
experimental models bearing subcutaneous CFPac1/PS1 tumours. If response was 
poor then it was planned to consider an approach similar to that adopted by the 
Tuveson group in Cambridge, UK, to perhaps try and modulate the blood supply to 
the tumour to enhance drug delivery.  
 
5.6. Antibody mediated αvβ6 therapy of PDAC 
 
Many novel chemotherapeutic agents used to target PDAC, whether on their own or 
in combination with existing chemo/radiotherapy, have brought about no or at best 
only a modest, improvement in the overall survival of patients. A list of some of the 
antibodies or small molecule inhibitors used in clinical trials so far to treat PDAC is 





















Table 18: Monoclonal antibodies or small molecule inhibitors used in clinical 
trials to treat PDAC patients as a single agent or in combination with 
gemcitabine. 
A monoclonal antibody targeting αvβ6 (264RAD) used as a single agent or in 
combination with existing chemotherapy was hypothesised to be a novel therapeutic 
option for PDAC patients. Validating this in the pre-clinical model was crucial and the 
modified subcutaneous CFPac1/PS1 xenograft mouse model was used to test this.  
 
The 264RAD single agent therapy arm started to show a significant difference in 
tumour volume when compared to the IgG control therapy arm from day 10 (Table 
17). 
It should be noted that the rates of tumour growth in the 264RAD treated tumours 
were slower and the single agent therapy arm showed a significant reduction in 
tumour volume during the whole course of the treatment up to day 42 when 
compared with the control IgG treatment arm (Figure 106). Following the end of 
treatment, tumour recurrence was observed in all animals treated with 264RAD but 
at a much slower rate in comparison with the control IgG treatment arm as shown in 
Figure 106. In fact, by day 56 there were only two animals left in the control IgG 
treatment arm (Figure 107) either because the tumour volume reached the maximum 
Therapeutic 
agent 















































in survival.  
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allowed Home Office limit or the tumours were starting to ulcerate. This shows that 
the treatment with 264RAD alone was sufficient to reduce the rate of growth of the 
tumours thus preventing it from progressing. This effect on reduction in rate of 
tumour growth was similar to the that observed in previously published data where 
264RAD has been used as a single agent at 20mg/Kg to target αvβ6 to prevent the 
growth and metastasis of 4T1 tumours in an orthotopic xenograft mouse model [233]. 
This data confirmed that the antibody was reaching the target αvβ6 positive tumour 
cells and blocking the functional role of αvβ6 in the modified subcutaneous PDAC 
xenograft model.   
 
The gemcitabine single agent therapy arm also showed a significant effect on tumour 
volume when compared with the IgG control from day 6 (Table 17). The growth of the 
tumour was significantly inhibited by gemcitabine; in fact it was better than the 
264RAD single agent treatment arm. Tumour volumes continued to fall until the 
treatment was stopped and tumour recurrence was slower when compared with the 
264RAD single agent treatment arm post treatment (Figure 106). This was not 
entirely surprising because gemcitabine is the best drug available to treat pancreatic 
cancer and PDAC tumour cells. It should also be noted that when the two single 
agents are compared, the molar concentration of gemcitabine used was 10 times 
more than the antibody concentration although its serum half-life is likely to be much 
shorter.  
 
Combination therapies have been used to treat cancer for many years. ABVD 
therapy to treat Hodgkin’s disease is a combination of four chemotherapeutic drugs 
given to patients (doxorubicin, bleomycin, vinblastine and darcarbicine) and work 
best in combination with almost 100% cure rates [271]. Some combination therapies 
have drugs, which work through different mechanisms sometimes in order to target 
and kill the cancer cells or sometimes to alleviate symptoms with some regimens 
showing increased toxicity compared to gemcitabine treatment alone. Gemcitabine is 
used in combination with fluorouracil as therapy given to PDAC patients has 
modestly improved the clinical outcome of patients [216]. Very recently, a 
combination drug regimen consisting of oxaliplatin, irinotecan, fluorouracil and 
leucovorin (FOLFIRINOX) used in combination with gemcitabine have given a 
significant improvement in overall survival (11.1 months) compared with gemcitabine 
treatment alone (6.8 months) in PDAC patients with metastasis [218].  
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The combination of 264RAD and gemcitabine caused a significant reduction in 
tumour volume when compared to the IgG control from day 2 (Table 17). It was 
evident that the combination therapy was working better than either 264RAD or 
gemcitabine mono therapy showing a significant decrease in tumour volume till day 
42. Tumour volumes continued to fall following post treatment and tumour recurrence 
appeared to be significantly slower than both the single agent treatment arms (Figure 
106, Table 17). Even at day 105 (2 months post treatment) the combination therapy 
arm tumour volumes were still very small and the rate of tumour progression was 
very slow. The addition of 264RAD antibody with the gemcitabine seems to have 
made an improvement in the outcome by lowering tumour volumes and greater 
overall survival, which might be indicative of an additive effect. The tumour volumes 
in the combination therapy arm were significantly smaller than the single agent 
therapy arms, 264RAD alone (from day 2) and gemcitabine alone, (from day 15) 
(Table 17). This was similar to the results observed in the breast cancer study, where 
the combination therapy arm of 264RAD and Herceptin performed better than either 
of the single agent therapy arms in a subcutaneous xenograft mouse model (data not 
published).  
 
Even though the above results are in complete agreement with a number of other 
previously published data linking αvβ6 with poor prognosis and cancer progression, it 
was entirely contradictory to a recent study showing that antibody-mediated blockade 
of TGFβ (1D11) or αvβ6 (3G9) promoted pancreatic tumour growth, both in the early 
and late stages of the disease in a genetically modified mouse model [212]. The 
researchers behind this report went on to show that blocking αvβ6 or TGFβ 
attenuated the tumour suppressor role of TGFβ signalling in the tumours resulting in 
an increased rate of tumour growth. These experiments studying the role of αvβ6 
blocking antibody (3G9) and TGFβ blocking antibody (1D11) in early stages of 
cancer, were performed in mice at 5 weeks of age, a point at which the pancreas 
was relatively normal or at the earliest stage of PanIN formation, where αvβ6 
expression levels were very weak (data not published). Moreover, TGFβ has been 
shown to be a tumour suppressor in the early stages of cancer before turning into a 
tumour promoter in the late stages of cancer [272]. Biomarkers that delineate the 
exact switch from a tumour suppressor to tumour promoter are not available. Yet 
another strange observation made was the complete lack of effect on the stromal 
cells when TGFβ function was blocked. TGFβ has been shown to activate fibroblasts 
into myofibroblasts, which in turn promote cancer [273-275]. The authors specifically 
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reported that there were no changes in the surrounding stromal cells, immune cells 
and vasculature as a result of blocking TGFβ function compared with control 
antibody treatment [212]. KRAS/p53lox+ mice with Smad4 deletion where tumours 
arise from cystic neoplasms rather than from PanINs were used at 9 weeks to repeat 
the same study in order to show that blocking αvβ6 or TGFβ in “late stages” of PDAC 
promote pancreatic cancer. The authors also mention that at that age, the animals 
only develop focal PDAC with large parts of the pancreas still normal. I do not think 
this is the right model and from a physiological point of view with relevance to the 
human disease. The experimental design would be similar to starting therapy as 
soon as the patient develops the earliest form of pancreatic cancer or, from a 
xenograft model perspective, it would be similar to starting treatment even before the 
tumours get a chance to develop. It should also be pointed out that none of the mice 
in either the control or the antibody treated groups developed any metastases. 
Nevertheless, it is worth taking on board some of the comments made by the authors 
in terms of the role of αvβ6 in the TGFβ pathway and perhaps performing IHC 
analyses to check for SMAD4 expression in the 264RAD treated tumours and 
compare it to the control antibody treated tumours. It might also be worth screening 
the minority of patients diagnosed at a very early stage of PDAC for SMAD4 
mutations before giving anti-αvβ6 therapy, considering the 50% of patients with 
SMAD4 mutations tend to have a poorer prognosis compared to the wild type 
SMAD4 expressing patients [52].   
 
5.7. IHC analysis of treated tumour samples 
 
The tumours harvested from a pilot experiment, where mice bearing subcutaneous 
tumours (CFPac1/PS1) were treated with 264RAD αvβ6 function-blocking antibody 
or control IgG antibody for 27 days, were stained to check for expression levels of 
αvβ6 (Figure 101). Both 264RAD treated and IgG blocking antibody treated tumours 
expressed αvβ6 and there was no obvious difference in the levels of expression 
between these two groups. This was contrary to what was reported in a recent study 
in an oral SCC model, where bi-weekly treatment with 264RAD seemed to reduce 
expression levels of αvβ6 in the tumours [233]. This might be due to the fact that the 
antibody treatment was carried out for a significantly longer time period (>8 weeks) 
and at double the concentration (20mg/Kg). So there arises the possibility that cells 
that were expressing αvβ6 failed to proliferate in the 264RAD treated tumours at the 
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same rate as the IgG control antibody treated tumours, leading to the significant 
difference in αvβ6 expression levels.   
 
Having observed significant difference in the tumour volumes between the 264RAD 
treated animals and the control IgG treated animals, it was interesting to determine 
how this difference in tumour growth was attained. Caspase 3 is at the convergent 
point of both the intrinsic and extrinsic pathway of apoptosis. Activation of pro-
caspase 3 is indicative of apoptosis and IHC staining on the 264RAD treated and 
control IgG tumour sections revealed a significant increase in levels of activated 
caspase 3 (Figure 104). This suggests that the tumour cells treated with the αvβ6 
blocking antibody 264RAD were dying through apoptosis as compared with the 
control IgG treated antibody. Although Western blotting on cell lysates from CFPac1 
monolayers treated with 264RAD did not show any changes in levels of expression 
of activated caspase 3, these results were in concordance with the cell cycle analysis 
carried out, where 264RAD treatment on CFPac1 cells over 7 days led to a 
significant increase in the sub-G1 population. Increased cell death (apoptosis) also 
explains the differences in tumour volumes observed in the current experiment 
compared to the IgG control treated animals (Figure 106).  
 
IHC staining on treated tumour sections showed that there was a significant 
decrease in proliferation in the αvβ6 function-blocking antibody treated tumours 
compared to the IgG treated tumours as indicated by Ki67 staining (Figure 103). This 
meant that the αvβ6 blocking antibody treated tumours were proliferating less and 
dying more (apoptosis), thereby preventing tumour progression. A similar effect was 
seen in the recently published literature where tumours treated with 264RAD at 
20mg/Kg showed a significant decrease in the levels of Ki67 staining compared to 
the control IgG treated antibody [233]. Anti-integrin targeted therapies to block 
cancer cell proliferation have been published previously. Blocking αvβ3 using a 
specific function-blocking antibody LM609 has been shown to reduce proliferation in 
breast cancer xenograft mouse models, although human trials using this antibody did 
not show any significant difference in overall survival [276].  
 
Reducing proliferation and enhancing apoptosis in the αvβ6 positive tumour cells 
specifically makes αvβ6 an attractive therapeutic target for treatment of PDAC. 
Results obtained so far clearly indicate that 264RAD could be used as a potential 
new therapeutic agent to treat PDAC when used in combination with gemcitabine. 
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Given the strong response observed in the rate of tumour growth as a result of 
treatment with the 264RAD antibody, it was hypothesised that some of the key 
signalling pathways could likely be affected as a result of blockade of αvβ6. 
ERK/MAPK signalling plays an important role in regulating a variety of cellular 
functions including cell proliferation and survival. ERK can control transcriptional 
activity of the cell directly or indirectly through multiple pathways. The cytoplasmic tail 
of the β6 subunit has been shown to bind directly to and activate ERK2 signalling 
pathway in colon cancer [181]. Phosphorylated ERK is an indicator of activation of 
the ERK pathway and IHC staining showed a significant difference in the expression 
levels of phospho ERK between the two treatment groups. 264RAD treated tumours 
had significantly lower levels of phospho ERK compared to the control IgG antibody 
treated tumours (Figure 103). Even though there were no significant differences 
observed in the levels of phospho and total ERK in vitro, a distinct and significant 
difference was observed in vivo. This could be due to multiple factors including 
tumour-stroma interactions or growing cells in a 3D as opposed to plastic 
environment; an environmental change, which can de-regulate signalling pathways. 
A similar effect on levels of phospho ERK expression was also reported in a recently 
published study where breast cancer xenograft models were treated with 264RAD or 
control IgG antibody [233]. The data obtained could mean that some of the 
downstream signalling pathways, which are activated as a result of αvβ6 activity in 
PDAC tumours, were no longer functional, possibly as a result of the blockade of 
αvβ6 by 264RAD antibody. Thus blocking the function of αvβ6 using an αvβ6 
function-blocking antibody, 264RAD, can significantly slow down tumour progression 
by decreasing proliferation of tumour cells, possibly in an ERK/MAPK pathway 
dependent manner, and increase caspase dependent apoptosis in the CFPac1/PS1 
subcutaneous xenograft mouse model for pancreatic cancer. The results from the 
pre-clinical model used in this study suggests that αvβ6 is a potential therapeutic 
target and by using a specific monoclonal antibody, 264RAD, as a potential new 
therapeutic agent in combination with the existing chemotherapeutic agent, 













Pancreatic cancer is often referred to as the “silent killer“ due to the asymptomatic 
nature of the disease in the early stages and the extremely poor prognosis overall. 
Early detection of PDAC still remains a major challenge as it contributes to the 
dismal five-year survival rates. Excluding a small percentage of operable disease, 
there is no long-term effective chemotherapy. Treatment regimens available to PDAC 
patients have not changed over the past decade and although gemcitabine in 
combination with other chemotherapeutic drugs have brought about modest 
improvement in overall survival, therapeutic options are still limited. Thus any 
potential therapeutic target to treat PDAC patients is worth pursing. It was with this in 
mind I investigated the role of integrin αvβ6 in PDAC.  
 
αvβ6 expression in PDAC was tested on two independent cohorts (n=118 and 
n=147) with 91% of patients positive for αvβ6 at varying levels (median score >1). 
Although this data is similar to previously reported expression levels of αvβ6 in 
PDAC, where 100% of cases were positive [201], this high expression level seems 
typical to PDAC. Published literature to date looking at αvβ6 expression have 
reported 54% of NSCLC and 58% of cervical cancer patients positive for αvβ6 
expression and in about 30%-35% of breast cancer patients (data not published). 
High αvβ6 expression, comparable to PDAC, was also observed in head & neck 
cancers, where 80% of patients were positive for αvβ6 [277]. αvβ6 as previously 
mentioned is an epithelial cell specific integrin and is expressed only by the tumour 
tissue (e.g. breast, colon, lung, cervix, ovarian, head & neck and pancreas cancers) 
and is almost entirely absent in normal adult human tissue. There are very few 
molecules that are expressed almost exclusively in tumour tissue and together with 
the fact that 91% of PDAC patients are positive for αvβ6, makes it an attractive 
therapeutic target.  
 
Integrin αvβ6 was hypothesised to be a poor prognostic marker in PDAC patients, 
consistent with the published literature in other cancers including colon [173], lung 
(NSCLC) [204], cervical [267], breast (data not published). However, analysis on two 
independent data sets provided convincing evidence that αvβ6 at the protein level 
was not a marker for prognosis in PDAC patients although bioinformatics studies 
revealed that at the mRNA level, αvβ6 was indeed a marker for poor prognosis. This 
contradictory result was not expected. Interestingly, previous studies conducted on 
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oral squamous cell carcinoma, another cancer where 80% of patients expressed 
αvβ6 [277] did not predict any significant prognostic outcome but showed exactly the 
same contradicting pattern of expression between the mRNA and protein levels. 
However, unpublished data from our laboratory, which used in situ hybridisation 
technique, showed higher expression of αvβ6 mRNA at the invasive front of oral 
squamous cell carcinoma compared with the core of the tumours, despite the protein 
level expression being high in both areas. Thus, while I do not have any data to 
provide an explanation for the difference observed between αvβ6 protein and mRNA 
expression in PDAC samples, it could be similar to the OSCC data. All of the tissue 
studies reported here were conducted on tissue microarrays and there was no way to 
identify if the sections tested for αvβ6 expression were from the leading invasive front 
of the tumour. Thus, in order to investigate whether ITGB6 is also highest at the 
leading edge of PDAC, potentially offering an explanation for the discrepancy 
between protein and mRNA analyses, it would be necessary to examine whole 
sections of PDAC tissues. If resources are made available, this is a possibility worth 
investigating as a priority to test this hypothesis. 
 
Follow up clinical data was available from both the data sets and further analysis 
based on expression levels of αvβ6 did not show any significant correlation between 
αvβ6 and any of the parameters tested in the Beatson data set. However, there was 
a significant negative correlation with tumour stage (AJCC) in PDAC patients 
observed in the Verona data set. Significantly higher αvβ6 expression levels were 
observed in patients with perineural invasion from the same data set. These results 
have to be interpreted with great care as the same parameters tested in the Beatson 
data set did not show any correlation. There could be a variety of possible reasons 
as to why patients from one group showed a correlation and not the other. Patient 
care, treatment regimens, and time of diagnosis could all play an important factor, 
while performing follow up analyses. It could also be down to a ‘chance probability’’ 
that patients in one data set showed a statistically significant correlation with αvβ6 
expression in some of the parameters tested. However, there was a definite trend 
observed in the Beatson data set, where high αvβ6 expression levels were 
associated with increased T-stage, grade, lymph node positivity and lymph node 
ratio, although none of these achieved significance. The ideal situation would be to 
test αvβ6 expression on a larger cohort of PDAC patients from the same centre with 
the same follow up treatment and care before carrying out clinical analyses of this 
nature.  
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With the need for novel targeted treatments, many therapeutic drugs are currently 
being tested in pre-clinical models and a further 18 clinical trials are active for 
pancreatic cancer patients (source: clinicaltrials.gov.uk). Targeting specific molecules 
using antibodies or small molecule inhibitors to treat cancers has been investigated 
previously; for example, Trastuzumab (Herceptin) is currently used in the clinic to 
target the 30% of breast cancer patients that are HER2 positive (Genentech Inc, 
2010). Blocking αvβ3 using an antibody LM609 has been shown to significantly 
decrease breast cancer tumour growth in xenograft mouse models [276]. 
Ibritumomab (Zevalin) is currently in trial to treat follicular B cell non-Hodgkin’s 
lymphoma (NCT01578707, Clinical trials.gov, 2012) patients who are unresponsive 
to rituximab (binds to CD20 antigen) alone. Ibritumomab along with a chelating agent 
tiuxetan, with radioactive Indium111, binds to CD20 antigen present in mature B cells 
and cancer cells but not in B cells in the bone marrow, thereby killing the cells.  
 
Current treatment options available to PDAC patients are restricted to gemcitabine 
alone, or a combination of gemcitabine with other chemotherapeutic drugs (e.g. 
FOLFIRINOX) for patients with locally advanced unresectable metastatic disease 
[218]. Although FOLFIRINOX together with gemcitabine improves overall survival 
significantly, it has been shown to increase toxicity in patients thus compromising 
quality of life. Targeted monoclonal antibody therapies, which can potentially cause 
less discomfort to patients, to treat PDAC have been trialled as a single agent or in 
combination with gemcitabine, such as cetuximab (a monoclonal antibody targeting 
EGFR) [221] and bevacizumab (a monoclonal antibody targeting VEGF) [222], 
although both failed to show any significant difference in overall survival. Erlotinib, a 
small molecule inhibitor targeting EGFR, showed a small but significant increase in 
the overall survival of PDAC patients [219] but is associated with side effects 
including toxicity due to its non-specific nature. Studies published by colleagues in 
our laboratory have shown in in vitro 3D models, that by modifying the stromal 
environment by treatment with all trans retinoic acid (ATRA), PDAC tumour growth 
can be inhibited through modulation of the wnt-β catenin pathway [91]. There is 
therefore an urgent need to continue developing new therapeutic agents that 
specifically target tumour cells or the surrounding stromal cells to treat pancreatic 
cancer patients. 
 
Due to their ability to generate survival, migration, proliferation, invasion and 
induction of proteases, integrins have generally been associated with the promotion 
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of tumour growth. The β6 gene (ITGB6) was identified as one of the genes in a “gene 
signature” essential for survival of lung and pancreatic cancer cell lines that have 
mutated KRAS [207]. Due to its tumour specific expression, αvβ6 makes an ideal 
imaging target. In fact, it has been used to image breast cancer in a pre-clinical 
mouse model using a radiolabelled peptide (In111-DTPA-A20FMDV2), specific to 
αvβ6, using a SPECT/CT scanner [278]. Data showed a 7-10 fold selective retention 
in αvβ6 expressing tumours versus αvβ6 negative tumours. In a separate study, 
BxPC3, a moderate to poorly differentiated αvβ6 positive cell line, was used to image 
αvβ6 in a subcutaneous xenograft model using a radiolabelled peptide (A20FMDV2) 
specific for αvβ6, [(18F)] FBA-A20FMDV2 [235]. It is possible that radio-imaging 
αvβ6 in PDAC could potentially be a non-invasive diagnostic tool for screening PDAC 
in humans. Although it might not become a reality in the near future due to the costs 
involved, a PET/CT scan with the αvβ6 targeted peptide for people in the age group 
most susceptible to develop PDAC could be used as a screening programme to try 
and diagnose pancreatic cancer at an earlier stage (PanIN 2 – PanIN 3) thus, 
potentially identifying individuals at risk destined to develop PDAC. Another 
observation worth commenting on but not discussed in this study, due to very limited 
tissue sample numbers, was the upregulation of expression of αvβ6 as the neoplastic 
cells progressed from PanIN1 (weak/negative) through to PDAC (strong). Similar 
observations were also noted in tissue sections obtained from a transgenic mouse 
model for PDAC. 
 
In vitro analyses were performed on a set of αvβ6 positive and negative cell lines to 
further understand the functional role of αvβ6 in PDAC. In many other cancers αvβ6 
has been shown to be involved with various tumour associated processes including 
proliferation, migration, invasion and survival [125, 207, 210]. These functional 
assays were tested on PDAC cell lines using the αvβ6 function blocking antibodies 
264RAD and 53A.2 (both monoclonal antibodies). Targeting with these antibodies 
significantly decreased cell proliferation in a dose dependent manner in both of the 
αvβ6 positive cell lines tested, Panc04.03 and CFPac1 (Figure 36 and Figure 38). 
Specifically, further cell cycle analysis revealed a G2/M phase block in the 
Panc04.03 cell line and an increase in the sub-G1 phase, indicative of apoptosis, in 
the CFPac1 cell line (Figure 46). Time-lapse video of CFPac1 cells treated with αvβ6 
function blocking antibody also confirmed that there were more dying/dead cells in 
the αvβ6 function blocking antibody treated wells compared to the control antibody 
treated wells and that the antibody did not cause complete detachment of cells from 
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the culture dish (data not shown). This suggests that anoikis may not be the primary 
mechanism of the anti-proliferative effects of the αvβ6 function-blocking antibodies. 
 
In addition, αvβ6 function-blocking antibodies significantly reduced cell migration to 
fibronectin and LAP over a 16hr time period (Figure 53, Figure 55) and invasion over 
72 hours in a panel of αvβ6 positive PDAC cell lines (Figure 57, Figure 58). In order 
to better understand the mechanism through which blocking αvβ6 brings about 
functional changes in cellular behaviour, it would be of interest to examine signalling 
pathways downstream of αvβ6. Very little is known about the pathways that are 
regulated by αvβ6 in vitro. Ahmed et al, have shown that ERK2 binds directly to the 
cytoplasmic tail of the β6 subunit in colon carcinoma cells [181]. Levels of phospho 
ERK were monitored in CFPac1 cell line, even though small changes were observed 
in the levels of ERK phosphorylation at the earlier time points, it was not observed in 
the later time points. This made the results difficult to interpret and no definite 
conclusions could be drawn from that experiment.  
 
The PDAC microenvironment is highly fibrotic and αvβ6 could have an indirect role in 
regulating this through activating the tumour microenvironment via activation of 
TGFβ. It has been established that, like fibroblasts, TGFβ activates stellate cells into 
similar myofibroblast like cells. Since the activated stellate cells have been shown to 
be the principal source of desmoplastic stroma in PDAC, the possibility that αvβ6 
could be a source of activated TGFβ must be considered. It would be interesting to 
monitor TGFβ activity in PDAC cell lines in response to blocking αvβ6 function. This 
hypothesis could be tested in vitro by co-culturing quiescent PS1 cells with αvβ6 
positive and negative PDAC cell lines and observe if they become activated or not. It 
should also be noted that TGFβ can act as both a tumour suppressor and promoter 
and a recent study has shown that blocking TGFβ or αvβ6 in a murine model of 
PDAC actually promoted cancer growth. These results are contrary to most 
published literature linking αvβ6 and cancer. However, further scrutiny of the report 
brings into question the choice of the animal model used and also the timing when 
these studies were conducted in the experimental animals as discussed previously 
(Section 5.5)  
 
Pre-clinical subcutaneous xenograft models were generated and validated against an 
orthotopic model to ensure that they were morphologically similar prior to performing 
αvβ6 targeted antibody mediated therapy experiments. Levels of collagen deposition 
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and tumour vascularity were used as markers to determine if the subcutaneous 
model could be used as a replacement to the orthotopic model (Figure 97). Unlike 
most subcutaneous models used for in vivo studies, the modified subcutaneous 
model used in this study had increased levels of collagen deposition that were 
comparable to those observed in the orthotopic model. The desmoplastic response 
observed was very similar to the human disease.  Pancreatic cancer tumours are 
known to be hypo-vascularised and analysis of the modified subcutaneous tumours 
showed significantly lower number of blood vessels compared with the cancer cell 
alone model. The addition of stellate cells with cancer cells in both the orthotopic and 
subcutaneous models reduced numbers of blood vessels, suggesting that there is a 
dynamic interaction between the tumour cells and the stroma and that the increased 
desmoplasia might be the reason for the poor vasculature, much like in the human 
disease (Figure 98). 
 
It was extremely encouraging that this modified subcutaneous model was 
morphologically relevant to the orthotopic model and in limited aspects comparable 
to the human disease but providing αvβ6 directed therapy to a hypo-vascularised 
tumour was always a concern. Using agents to increase blood supply to the tumours 
might be a potential way to overcome this issue. The Tuveson group has already 
used IPI-926 (smoothened inhibitor) to target hedgehog signalling in the stromal cells 
to enhance drug delivery to the PDAC tumour. Although this particular drug was not 
successful in clinical trials, I feel it is still worth pursuing this and perhaps use other 
drugs, for example verapamil, which could be used to increase blood supply to the 
tumour to enhance drug delivery to the PDAC tumour.      
 
This study did not use any agents to enhance blood supply to the tumour. The 
modified subcutaneous model (CFPac1/PS1) was used to examine the effect of 
blocking αvβ6, either alone or in combination with gemcitabine. There was a 
significant difference in tumour volume when compared with the IgG control arm. 
This was in line with the recently published data using 264RAD antibody, where 
tumour growth of Detroit 562 OSCC cancer cell line and growth and metastasis of 
the 4T1 murine breast cancer cell line was significantly inhibited in an orthotopic 
xenograft mouse model [233]. However, in the current study, the gemcitabine single 
therapy arm out performed the 264RAD single therapy arm, though it should be 
noted that the 264RAD single agent was effective and slowed tumour growth. This 
could be down to using gemcitabine at 100mg/Kg, 10 times more than the dose of 
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the antibody at 10mg/Kg, it was perhaps not that surprising that this effect was 
observed. These data reflected results published on the use of cetuximab in human 
clinical trials as a single agent to treat PDAC, where gemcitabine out performed 
cetuximab and no significant difference in overall survival was observed. However 
the combination of both gemcitabine and 264RAD antibody, significantly inhibited 
CFPac1 tumour growth in comparison with both the gemcitabine and 264RAD single 
agent treatment arms, suggesting an additive effect (Figure 106). Tumour burden 
continued to fall even after 2 months post treatment and results indicate that tumour 
recurrence in the combination treatment therapy arm is slower compared with either 
of the single agent therapy arms (Figure 106). It is important to bear in mind that 
various other monoclonal antibodies (e.g. bevacizumab) used in combination with 
gemcitabine (5.8 months) have not yielded any significant gain in overall survival in 
PDAC patients when compared to gemcitabine alone (5.9 months).  
 
Further analysis on tumour sections treated with 264RAD or control IgG antibody 
revealed that there was a significant up regulation of caspase 3 in the αvβ6 function-
blocking antibody treated tumours compared to the IgG control antibody treated 
tumours, indicative of cell death through apoptosis (Figure 104) This was in contrast 
to the regulation of caspase 3 in cell monolayer cultures treated with αvβ6 function-
blocking antibodies. It is possible that activation of caspase 3 is stronger in vivo. 
There was also a significant down regulation of Ki67, a proliferation marker, in the 
αvβ6 function-blocking antibody treated tumours compared to the IgG control 
antibody treated tumours (Figure 103). Staining for phospho ERK revealed that the 
αvβ6 function-blocking antibody treated tumours expressed significantly lower levels 
of phospho ERK compared to the IgG control antibody treated tumours. This was 
similar to the results reported in a recent study, where a significant reduction in the 
levels of Ki67 in 264RAD antibody treated Detroit 562 oral SCC tumours was 
observed compared with controls [233].  
 
These data imply that blocking the function of αvβ6 with a function-blocking antibody, 
264RAD, results in significantly reduced tumour progression both by reducing 
proliferation of tumour cells in an ERK/MAPK pathway dependent manner and by 
increasing apoptosis in a caspase dependent manner. These results are extremely 
promising and it highlights the fact that by blocking αvβ6 function in combination with 
existing chemotherapeutic drugs given to PDAC patients, such as gemcitabine, 
PDAC tumour progression may be inhibited in humans. These data reaffirm that 
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αvβ6 is a novel therapeutic target and that 264RAD can be used as a novel agent to 
treat pancreatic adenocarcinoma patients.   
 
Future in vivo experiments could be modified to answer several interesting questions 
that arise as a result of this work.  
 
1) Gemcitabine is a chemotherapeutic drug, which is a cytosine nucleotide analogue. 
It is non-specific and can kill normal dividing cells in the body too. In comparison with 
many platinum based drugs, gemcitabine has relatively milder side effects but it can 
still cause discomfort to patients. With the aim of reducing the doses of gemcitabine 
given to patients, the doses of gemcitabine administered in the pre-clinical model 
could be lowered from 100mg/Kg to perhaps 50mg/Kg or even 25mg/Kg when used 
in combination with 264RAD antibody. This would aim to reduce the off target effects 
of gemcitabine and study if differences in tumour progression are still observed.  
 
2) A higher concentration of the αvβ6 function-blocking antibody, as used in the 
published literature [233], would also be worth considering, particularly if an additive 
effect is observed in the combination therapy treatment arm when combined with 
gemcitabine. Preliminary in vitro assays were performed where CFPac1 cells were 
treated with varying doses of gemcitabine combined with αvβ6 function blocking 
antibody at 10µg/ml to test if a decrease in cell proliferation can be observed with 
lower doses of gemcitabine (data not shown).  
 
3) It is important to use other αvβ6-positive cell lines and possibly an αvβ6 positive 
cell line with an inducible stable knock down of β6, and compare results to the 
antibody-mediated therapy experiment. This has to be done in order to confirm that 
the effect seen by the treatment with αvβ6 function-blocking antibody is reproducible 
and not an effect observed only in this particular model.  
 
4) Although never tested in this study, gemcitabine resistance is another key problem 
when it comes to treating patients with PDAC. Most tumours are sensitive to 
gemcitabine but rapidly acquire resistance to it, reducing treatment options to 
palliative care. Some patients acquire resistance much faster than others and there 
are very interesting studies looking at gemcitabine resistance in PDAC patients, even 
though all patients succumb to the disease regardless of sensitivity to gemcitabine 
[279, 280]. Bearing this is mind, another option would be to maintain gemcitabine 
doses at 100mg/Kg but stagger the number of doses over a longer period of time 
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whilst regularly treating with the αvβ6 function-blocking antibody. This might help 
overcome the problem of chemo-resistance to gemcitabine in PDAC tumours.  
 
5) Another option is to treat the KPC mouse model for PDAC with the αvβ6 function-
blocking antibody and observe if tumour progression can be arrested. β6 null mice 
were created many years ago and they do not show any apparent phenotypic 
changes [189]. They have been used to study the effect of radiation on pulmonary 
fibrosis [281]. KPC mice tumour tissues were stained for αvβ6 expression, both 
PanIN 3 and PDAC were positive for αvβ6. So another interesting proposition would 
be to breed β6 null mice with KPC mice with the aim of generating a β6 null KPC 
mice and compare it with the KPC model to study differences in tumour progression.  
 
So in summary, αvβ6 is essential for growth in the PDAC cell lines tested in this 
study. αvβ6 plays an important role in regulating PDAC migration and invasion. 
Targeting αvβ6 using a function-blocking antibody supresses growth of PDAC 
xenograft tumours and when combined with gemcitabine, significantly improves 
therapy when compared with gemcitabine treatment alone in the modified 
subcutaneous xenograft model (CFPac1/PS1) used in this study. Bearing in mind 
that 91% of PDAC patients express αvβ6 at varying levels, it is hoped that these 
effects can be translated into humans and provide a significant beneficial effect in 
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